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Cancer can manifest in many forms and can vary greatly from patient-to-patient. 
It is often treated by giving a cancer patient a drug which will attack the cancer 
cells to prevent them from growing and spreading throughout the body. 
However, these drugs will also attack healthy cells, which gives rise to a long list 
of side-effects of cancer chemotherapies.  
Increasing the selectivity of the drugs, i.e. to promote attack of the cancer cells 
over the healthy cells, allows the patient to receive higher and more effective 
doses while minimising the infliction of harsh side-effects. This can be done 
through the design of prodrugs: drugs that are inactive until they reach the 
desired site of action, whereupon they are activated by a biological process, e.g. 
enzymes, to the active drug. While this can be an effective strategy, the biological 
processes of cancers are very similar to healthy tissues and so there may be some 
prodrug that is activated in healthy tissues that will result in side-effects.  
To overcome these issues, herein is described alternative strategies for prodrug 
activation using electrical and light signals. This allows a prodrug to be given and 
the activation to the active drug to be controlled externally. Therefore, the 






The need to improve selectivity in cancer therapies has driven much research 
into the design and methods of activation of prodrugs. These are primarily reliant 
on biological processes that are present ubiquitously in tissues (healthy and 
cancerous) but with elevated levels in and around cancers. As such many 
therapies still suffer from dose-limiting toxicities from off-target effects.  
Herein are described novel methods of prodrug activation that are reliant on 
physical stimuli — namely electrical and photochemical triggers — to generate 
the active drug species. These methods allow exogenous control over where, 
when and how much prodrug is converted facilitating minimisation of off-target 
effects by increasing the selectivity of the therapy. In conjunction with the 
Implantable Microsystems for Personalised Anti-Cancer Therapies project, it is 
envisioned that these activation systems will be translatable into a device 
implantable and activatable within a tumour. 
In my thesis, prodrug activation systems were developed for Pt(IV) prodrugs that 
use either electrochemical or photochemical approaches to convert bio-inert 
prodrugs into the cytotoxic Pt(II) counterparts. This was accomplished utilising 
a redox mediator or photocatalyst to limit biological interferences and improve 
selectivity towards the Pt species.  
In summary, these prodrug activation systems were brought from the stage of 
discovery to biological evaluation and validation, with significant optimisation of 
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their activation capabilities. The application of these novel prodrug activation 
strategies forms the basis for future research in to the improvement of cancer 
therapies for the benefit of the patient and demonstrates for the first time cancer 
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COX  Cyclooxygenase 
CT  Computerised tomography 
CV  Cyclic voltammetry  
DIPEA  N,N-diisopropylethylamine 
DPV  Differential pulse voltammetry 
FBS  Foetal bovine serum 
FDA  US Food and Drug Administration 
FITC  Fluorescein isothiocyanate 
FRET  Förster resonance energy transfer 
HBTU  Hexafluorophosphate benzotriazole tetramethyl uranium 
HDAC  Histone deacetylase 
HIF-1α Hypoxia-inducible factor 1-alpha 
HPLC  High-performance liquid chromatography 
ICP-OES Inductively-coupled plasma optical emission spectroscopy 
ICP-MS Inductively-coupled plasma mass spectrometry 
LED  Light-emitting diode 
MB  Methylene blue 
MMP  Matrix metalloproteinase 
MRI  Magnetic resonance imaging 
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MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
OxPt  Oxaliplatin 
PBS  Phosphate buffered saline 
PDK  Pyruvate dehydrogenase kinase 




Table of Contents 
LAY SUMMARY I 
ABSTRACT II 
DECLARATION OF AUTHORSHIP IV 
ACKNOWLEDGMENTS V 
ABBREVIATIONS VII 
CHAPTER 1 1 
INTRODUCTION 1 
1. Overview of Cancer Pathophysiology 1 
1.1 Surgery 5 
1.2 Radiotherapy 9 
1.3 Chemotherapy 15 
1.4 Prodrugs 34 
CHAPTER 2 49 
AIMS AND OBJECTIVES 49 
CHAPTER 3 50 
ELECTROCHEMICAL ACTIVATION OF PT(IV) PRODRUGS 50 
3.1 Introduction 50 
3.2 Aims of Chapter 3 54 
3.3 Background 54 
3.4 Discovery and design of Pt(IV) electro-activation system 58 
3.5 Identification of a suitable redox mediator 67 
3.6 Fabrication of discrete redox mediator modified electrodes 75 
3.7 Characterisation of Pt(IV) reduction by the modified electrodes 85 
3.8 In vitro validation of the Pt(IV) prodrug activation systems 100 
Conclusions and Outlook 112 
CHAPTER 4 115 
PHOTO-ACTIVATION OF PT(IV) PRODRUGS WITH SIMULTANEOUS GENERATION OF SINGLET 
OXYGEN 115 
4.1 Introduction 115 
4.2 Aims of Chapter 4 123 
4.3 Background 124 
4.4 Discovery and design of a photocatalysed Pt(IV) prodrug activation system 128 
4.5 Identification of “bio-inert” Pt(IV) prodrugs 129 
4.6 Design, synthesis and optimisation of photosensitisers 135 
4.7 Characterisation of photosensitiser 16 140 
4.8 Fabrication of custom light sources 144 
4.9 Characterisation of photocatalytic Pt(IV) prodrug activation 148 
4.10 Validation of photocatalysed Pt(IV) prodrug activation in cellulo 153 
x 
 
4.11 Extension of application of photocatalytic Pt(IV) prodrug activation 157 
4.12 Elucidation of the mechanism of photocatalytic Pt(IV) prodrug activation 161 
Conclusions and Outlook 167 
CHAPTER 5 172 
EXPERIMENTAL 172 
5.1 General 172 
5.2 Electrochemical measurements 173 
5.3 Small molecule synthesis 173 
5.4 Electrode cleaning and modification 199 
5.5 Fabrication of light sources 201 
5.6 In vitro assays 202 








1. Overview of Cancer Pathophysiology 
 
Cancer is a complex collection of diseases caused by genomic mutations that 
result in aberrant cell behaviour. Gain-of-function mutations that occur in 
oncogenes and loss-of-function mutations that occur in tumour suppressor genes 
have the potential to cause acquired characteristics of cancer cells, which have 
been codified by the ‘hallmarks’ of cancer (Figure 1.1)[1].  
 
Figure 1.1. The hallmarks of cancer: the defining characteristics of which cancers will 
acquire to sustain tumour growth and progression. Image reproduced from reference [1] 
with permissions granted by Elsevier Publishing. 
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Cancerous cells often exhibit unchecked cell growth, division and replicative 
potential. As a result, a neoplasm (or tumour) may form as a mass of 
uncoordinated growth of cancer cells. The tumour microenvironment becomes 
hypoxic and acidic due to the rapidly increasing tumour mass, correlated with 
increasing oxygen consumption and carbon dioxide generation, which may be 
accompanied by a metabolic switch (termed the Warburg effect) from the regular 
oxidative phosphorylation pathways to glycolytic metabolism that produces 
lactate as a by-product[2]. 
Two of the most commonly mutated genes found in cancers are the p53 tumour 
suppressor gene and the Ras oncogene[3-5]. Both have myriad functions in the 
regulation of cellular signalling pathways. The p53 gene products are mainly 
responsible for conserving the integrity of the cell cycle. Over half of all human 
cancers display inactivated forms of p53 by missense mutations, typically in the 
DNA-binding domain. The inactivation of p53 allows cancers cells to bypass cell 
cycle checkpoints as well as to resist growth arrest and apoptotic signals. Certain 
mutations of p53 may not just prevent its regular function but also provide 
mutant isoforms of p53 with oncogenic capabilities[3]. The Ras superfamily of 
proteins have many functions within cellular signalling pathways but like p53 are 
implicated in cell cycle progression, as well as cell proliferation. As they are a 
critical component of a large number of signalling pathways, disruption of regular 
Ras function can have many consequences. The on/off conformations of Ras 
proteins are controlled by guanosine phosphates[5]. When complexed with 
guanosine triphosphate, Ras proteins are considered to be in an ‘on’ state 
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whereas those complexed with GDP are in an ‘off’ state. The structural 
conformation of Ras proteins is dramatically define by which guanosine 
phosphate is bound. Switching between the on and off states is controlled by the 
hydrolysis of GTP bound to the Ras protein to GDP by GTPase activating proteins. 
Oncogenic mutations of Ras occur at key amino acid residues that prevent the 
hydrolysis of GTP, thus disallowing the turning off of the Ras proteins. This drives 
the continual transmission of cell signalling pathways and spurs malignant cell 
growth and proliferation. The symptomatic tumour promoting outcomes of this 
is challenging to treat by chemical means. Blocking Ras-effector interactions 
requires an inhibitor to overcome the abundance of GTP and its high affinity for 
the GTP-binding pocket of Ras proteins[6].  
In adults, angiogenesis – the formation of new vasculature – is a tightly regulated 
and transient process. A number of growth factors are involved in stimulating 
angiogenesis. However, in cancers, there is often ‘always on’ angiogenesis signals 
produced[7]. This is driven by the continuous growth of the tumour and thus, its 
accrescent requirement for nutrients. The vascular endothelial growth factor A 
(VEGF-A) is commonly over-expressed in cancers and has been found to be 
related to oncogene signalling[8] (e.g. hypoxia-inducible factor-1α[9] and 
transforming growth factor-β [10, 11]). 
The ultimate cause of cancer-related death is generally not caused by the primary 
tumour but by secondary tumours caused by metastasis. Metastasis is a process 
in which tumour cells undergo morphological and biochemical changes before 
migration through vasculature or lymphatic systems from the primary source to 
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other organs where they can begin colonisation[12]. This generally proceeds via 
an epithelial-mesenchymal transition (EMT) [13]. Epithelial cells, that are 
typically adherent to basement membranes, become more suited to migration 
and invasion by becoming mesenchyme, with changes in their cell morphology, 
proteome and adherence facilitating their travel through the extra-cellular 
matrix. A key difference that is exhibited by cells undergoing EMT is reduced 
expression of E-cadherin and increased expression of N-cadherin[14]. E-cadherin 
has functions in cell-cell adhesion and reduced levels is correlated to an 
instability in adherens junctions[15]. N-cadherin, a mesenchymal-associated 
marker, promotes interactions with stromal and endothelial cells, which has been 
proposed to enable entry into the vasculature. It is also a trigger for continuous 
activation of the MAPK/ERK signalling pathway, which induces tumour cell 
proliferation and expression of other EMT-related transcription factors[16]. 
The complexity of cancer development, progression and resistance presents 
many difficulties and challenges in the treatment of such diseases.  
Advances in Cancer Therapies 
Over the past 40 years, despite an increasing incidence of cancers, 10-year 
survival rates have doubled: 50% of people diagnosed with cancer will now live 
for 10 years or more[17]. More robust diagnoses at earlier stages and advances 
in therapies provide better treatment outcomes. Treatment for cancer generally 





Cancer surgery is most effective when there are clear boundaries between 
healthy and cancerous tissues, with the intertwining nature of some tumours 
pervading healthy tissues complicating surgeries. Generally, the tumour and the 
surrounding healthy tissue is removed with clear margins to ensure cancerous 
tissue is completely removed. The nearest lymph nodes would also be removed 
in case they contain cancerous cells. Cancers that have undergone metastasis 
(where the primary tumour spreads to secondary sites) typically cannot be 
treated via surgery alone, due to the scope and locations of the secondary 
tumour(s). Chemotherapy or radiotherapy may be used as a neo-adjuvant 
therapy to minimise the size and pervasion of the tumour before surgery, while 
surgery is also limited by the challenges in differentiating cancerous tissue from 
healthy tissue.  
Fluorescence-guided surgery is an emerging technique whereby a fluorescent 
probe that specifically targets cancerous tissue is administered, allowing the 
margins of the tumours to be seen upon illumination with a specific wavelength 
of light[18]. Indocyanine green has seen broad use as a probe for fluorescence-
guided surgery for a range of cancers but while providing sufficient contrasting 
for surgery, ICG is far from ideal[19, 20]. This approved fluorescent probe for 
guided surgery is a “blood pool agent”; meaning that it is slowly excreted allowing 
delayed imaging of the vasculature. This can be used to identify tumours of 
certain types but it does not have any specific targeting towards cancers. 
Optimally, a fluorescent probe would be specifically targeted to cancer and 
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undergo fluorescence turn-on inside the cancer extra-cellular matrix or cells and 
ideally would be quenched until activation to provide maximal contrast. LUM015 
is a probe undergoing clinical testing that is a FRET-based cathepsin protease 
substrate peptide[21]. Upon cleavage by the enzyme cathepsin, which is over-
expressed by tumour cells, and there is a “turn-on” in fluorescence as the 
fluorophore is liberated from the quencher thus allowing visualisation of tumour 
margins (Figure 1.2). LUM015 has shown to be well tolerated by human patients 





Figure 1.2. The structure of LUM015 (top), a fluorescent probe used for visualising the 
margins of tumours to enable surgical resection. It is composed of a quencher (QSY21) 
conjugated to a Cy5 fluorophore through a GGRK peptide, with a 20 kD polyethylene 
glycol chain attached via the C-terminus. Activated LUM015 is seen here with green 
fluorescence generated in a breast cancer tumour sample extracted from a LUM015-
injected patient (bottom, left). The corresponding histology analysis (bottom, right) of 
the same sample to show that the probe has good correlation with the tumour tissue 
(labelled “T”) and the healthy breast tissue (labelled “N”). Images reproduced from 
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reference [21] with permissions granted by The American Association for the 
Advancement of Science. 
Cell-penetrating peptides can also be used for fluorescence-guided surgery, as 
demonstrated by the work of Tsein[25]. Cell-penetrating peptides are typically 
composed primarily of positively charged residues that can be laden (either 
covalently or non-covalently) with a cargo to facilitate the increased uptake of 
the cargo[26, 27]. The mechanisms for how cell-penetrating peptides do this 
varies case-by-case but can occur via endocytosis, passive diffusion or transient 
pore formation[28, 29]. In the latter case, the positively-charged residues form 
strong interactions with the phosphate groups of the phospholipids in the cell 
membrane, distorting its structure and ultimately forming a cylindrical tertiary 
structure through the membrane to form a pore[28].  
Tsein has exploited these features of cell-penetrating peptides to enable their use 
in fluorescence-guided surgery. To afford cancer cell selectivity, the cellular 
association of the cell-penetrating peptide is blocked by the conjugation of a 
negatively charged sequence with an enzyme-cleavable linker[30]. Enzymes that 
are over-expressed by cancer cells, in this case MMP-2 and MMP-9, cleave the 
linker between the cell-penetrating peptide and the inhibitory domain (see 
Figure 1.3). The cell-penetrating peptide, with a fluorescent label, can then 
penetrate into the cancer cells to provide visual guidance of tumour margins. This 
strategy has shown promise in murine xenograft models and benefited surgery 





Figure 1.3. Activatable cell-penetrating peptides, composed of a polycationic domain and 
an inhibitory polyanionic domain with an enzyme-cleavable linker, allow “turn-on” in the 
vicinity of the tumour. The linker is a substrate for MMP-2 and MMP-9; enzymes that are 
over-expressed in many cancers. Upon cleavage of the linker, the cell-penetrating 
domain is then able to enter cells and the fluorescent label (FL) enables fluorescence-
guided surgery. 
Other recent improvements in surgical treatment of cancer include 
intraoperative imaging with CT and MRI. This has led to vast improvements 
particularly for the treatment of neurological tumours, such as glioblastoma[32]. 
1.2 Radiotherapy 
 
Radiotherapy has evolved considerably since the discovery of its therapeutic 
application in the early 1900’s. Pivotal research by Curie and Becquerel in the 
1920’s in to radioactivity improved understanding and accessibility of 
radioactive materials and shortly after, the application of radioactivity to clinical 
radiotherapy for diagnosis and treatment was initiated[33-35]. Since then, 
radiotherapy has become an established and highly effective route for the 
10 
 
treatment of cancer and has undergone significant transformations in tandem 
with technological advances. Today, radiotherapy for cancer is typically given via 
an external beam of high-energy X-rays (rather than using radioactive 
materials)[36, 37]. An X-ray is a type of ionising radiation produced by the 
acceleration of electrons to produce photons with wavelengths around 1 nm. 
These high-energy photons can penetrate deeply into tissues and can induce 
damage to DNA either by directly producing double- and single-strand breaks in 
DNA or indirectly, producing secondary electrons that produce free radicals in 
cells that react with biomolecules. The discovery that the efficacy of radiotherapy 
is directly correlated to the oxygen concentration present in the sample by Gray 
in 1953, provided further insight into the molecular mechanisms of 
radiotherapy[38]. Oxygen is required for the “fixation” of DNA damage i.e. the 
damage is made permanent and irreparable[39]. Therefore, oxygen depletion 
and highly reductive environments in tumours reduces the efficacy of 
radiotherapy by modulating factors required for the fixation of DNA damage: i) 
preventing the formation of reactive oxygen species and ii) preventing the 
cytotoxicity of reactive oxygen species through chemical restitution i.e. reductive 




Figure 1.4. The DNA damage caused by ionised radiation therapy in normoxic conditions 
is more effective due to oxygen-fixation (top). In hypoxic and highly reductive 
environments, commonly present in tumours, the effect of ionising radiation can be 
overcome by reductive or hypoxic environments, preventing the fixation of DNA damage 
(bottom). 
In conjunction with instrumentation, radiotherapy can be given in a highly 
controlled manner. The CyberKnife® technology utilises a robotic arm and a 
three-dimensional rotatable platform to deliver radiotherapy with sub-
millimetre precision (Figure 1.5), monitoring patient breathing rhythms to limit 




Figure 1.5. The components of CyberKnife radiotherapy. The robotic arm allows three-
dimensional movement around the patient on the treatment couch which can also move. 
The “synchrony camera” monitors breathing motions. 
Radiation therapy can also be given via brachytherapy where discrete radiation 
emitters are placed in and around the tumour margins[41]. Typically, a 
radioisotope contained in a capsule (called a “seed”) is inserted with the use of 
imaging-guided applicators. This affords a very accurate placement of the 
capsules and has proven effective particularly for prostate cancer. The low dose 
and range of the emitted radiation limits side effects is an advantage of 
brachytherapy as it causes little damage to surrounding tissue compared to 
external beam radiotherapy. 
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Despite the significant achievements in its development, radiotherapy is still 
hindered by the physiological factors behind many tumours. Monitoring of the 
tumour oxygen levels in situ would enable external beam radiotherapy to be 
more directed and applied to areas more likely to be resistant to therapy. The 
Implantable Microsystems for Personalised Anti-Cancer Therapy (IMPACT) 
project had the aim of delivering a microsystem packaged with sensors that 
would be implanted into a tumour to measure, in real-time, oxygen, pH and cell 
death throughout the course of the therapy e.g. to assess if cell death or apoptosis 
was occurring. 
To do this, known sensing modalities for pH and oxygen were optimised towards 
their miniaturisation and robustness towards biological environments (see 
Figure 1.6). For oxygen sensing, a Clark electrode was used that utilises the 
electrochemical reduction of oxygen on a platinum electrode. The electrodes 
were micro-fabricated with a Nafion membrane as a solid electrolyte which also 
prevented biomolecule interference[42]. Two strategies were employed for pH 
sensing: an ion-sensitive field-effect transistor (ISFET) and a methylene blue-
based sensor. ISFETs detect changes in pH by the relative level of 
protonation/deprotonation of the Si-OH groups of an SiO2 layer by H+ ions. The 
output current is ultimately related to the pH through this mechanism. The 
methylene blue-based sensor exploits the pH-sensitive redox waves of methylene 
blue. As protons are involved in the electrochemical reduction of methylene blue, 
the reduction potential will change proportionally to the concentration of H+ ions 
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in solution, which can be extrapolated from square wave voltammograms and 
thus can measure pH in a robust and rapid manner. 
`  
Figure 1.6. Representation of the sensing mechanisms of ISFETs (top) and Clark 
electrodes (middle) and a picture of a micro-fabricated electrode (bottom). 
In order for the microsystem to detect the occurrence of cell death, biosensors 
were developed using a peptide substrate adhered to an electrode surface with a 
covalently-attached methylene blue as a redox probe[43, 44]. The peptide 
sequence was selected using known cleavage sites for the enzyme of interest. The 
probe was capable of approaching the electrode surface and undergoing 
electrochemical redox reactions which gives characteristic reduction and 
oxidation waves. Upon cleavage of the peptide by a protease, the redox reporter 
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is lost and a reduction in the amplitude of these waves is observed which can then 
be used to measure relative levels of the protease (Figure 1.7). 
 
Figure 1.7. Representation of the sensing mechanism of the protease biosensor. Before 
cleavage of the peptide substrate, the redox reporter is capable of producing a current 
output by participating in redox reactions at the electrode surface (blue line). Following 
peptide cleavage, the signal decrease (green line) is correlated to the levels of protease. 
The research in this thesis details approaches to exploit the implanted microchip 
and its placement within the tumour to allow it to act as a chemotherapeutic 
activator: switching bio-inert prodrugs into active drugs via an externally-
controlled electrical or photochemical signal.  
1.3 Chemotherapy 
 
Cancer chemotherapy has advanced across multiple wide areas of remit. Along 
with the discovery and design of novel small molecule drugs, there has been a 
whole host of innovations with the discovery of new drug targets, new ways to 
hit these targets and new ways to deliver drugs to their targets. Paul Ehrlich 
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coined the term “chemotherapy” in the early 1900’s, during his search for a cure 
by chemical means for syphilis[45]. Ehrlich and Hata discovered, through the first 
iterative drug screening programme, Arsphenamine, an organoarsenic 
compound that possessed anti-microbial properties effective in treating syphilis-
infected patients without killing the patients themselves! This was the first 
“magic bullet” therapy; that a drug could be given that targeted a disease-causing 
area of the body while remaining benignant to healthy areas. However, Ehrlich 
did not believe a “magic bullet” therapy for cancer could be realised, since 
treatment of cancer – composed of cells broadly similar to healthy tissue – is 
vastly different from treating an infection with divergent biology. However, 
significant progress has been made since these beliefs. 
Early chemotherapy exploited key differences between cancerous and healthy 
tissues: namely the increased rate of cell division. Cancer cells are self-sufficient 
in growth signals and have limitless replicative capability allowing unchecked 
growth and division[46]. Chemotherapeutic agents derived from chemical 
warfare agents, such as nitrogen mustards, were thus found to have good 
cytotoxic activity against cancer cells over healthy cells due to their increased 
rates of cell division[47, 48]. Nitrogen mustards are non-specific DNA alkylators; 
forming an aziridinium ion by intramolecular SN2 displacement of the alkyl halide 
by the amine; that is then attacked by the nucleophilic N7 positions of guanine 




Figure 1.8. Mechanism of action of nitrogen mustards: formation of reactive aziridinium 
cycle followed by nucleophilic attack by guanine residues to form cross-linked DNA 
which results in cell death.   
DNA lesions formed by nitrogen mustards (and other DNA alkylators) are 
typically detected by p53, a tumour suppressor protein that induces 
apoptosis[49]. However, over half of human cancers have a loss-of-function 
mutation in p53 expression thereby limiting the cytotoxic effect of nitrogen 
mustards and other DNA alkylators[4, 50]. 
 
1.3.1 Platinum Anti-cancer Therapies 
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Rosenberg is credited with the discovery of cisplatin, another DNA-chelator. 
Rosenberg was studying the effects of an electric field on the growth and division 
of E. coli[51]. There was an observed inhibitory effect on the division of bacteria 
which was postulated to be caused by the electric field generated with platinum 
electrodes; due to the assumed inertness and biocompatibility of platinum. In 
fact, there were degradation reactions occurring at the platinum surface which 
were producing platinate salts. The agents responsible were isolated and among 
them a highly potent anti-cancer agent was found and branded as cisplatin due to 
the arrangement of its ligands: cis-[Pt(NH3)2Cl2] (Figure 1.9). In 1978, cisplatin 
attained FDA approval for the treatment of advanced testicular cancer which 
changed the outlook completely for those with this type of cancer. Prior to the 
clinical testing of cisplatin, 5-fluorouracil was the first-line treatment with a 
success rate of <10%[52]. Treatment with cisplatin saw cure rates rise beyond 
90% for advanced testicular cancer. Later the same year, it was approved for 
advanced bladder and ovarian cancers. Currently, it is approved for 8 distinct 
cancer types and is used in around 40% of all chemotherapy regimens, either as 
a single agent or in combination with other drugs[53, 54].  
 
Figure 1.9. Structures of three FDA-approved platinum anti-cancer therapies: cisplatin, 
oxaliplatin and carboplatin. 
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The first in its class, cisplatin spurred a new frontier in the research of inorganic 
cancer therapies. Despite its extraordinary efficacy in treating cancers, cisplatin 
regimens inflict a harsh side effect profile on patients. The main dose-limiting 
toxicities of cisplatin are nephro-, oto- and gastrointestinal toxicity, among others 
and thus, the therapeutic window of cisplatin can be very narrow[55]. There are 
clinical procedures that aim to alleviate some of the dose-limiting toxicities of 
cisplatin, for example, hyper-hydration before and after cisplatin infusions limits 
nephrotoxicity. There are ongoing clinical trials for adjuvant otoprotective drugs 
but so far these have failed to provide much benefit in preventing hearing 
damage[56]. Anti-oxidant and deactivators of cisplatin applied locally or 
systemically have been examined, such as sodium thiosulfate, N-acetylcysteine 
and aspirin (Figure 1.10). These have not been successful in the clinic and 
currently there is no FDA-approved otoprotective therapy for use with cisplatin. 
Research on gastroprotective agents is in a similar state; with no FDA-approved 
agents [57].  
 




Elevated 5-hydroxytyptamine (serotonin) is implicated in the gastrotoxic effects 
of cisplatin[55]. As such, there is potential overlap for use of anti-psychotics 
which block serotonin receptors. Olanzapine is a serotonin antagonist/inverse 
agonist that lessened the severity and frequency of emesis in cisplatin-treated 
patients and is undergoing further clinical testing[58].  
Improvements on cisplatin have been sought. Structure-activity relationships of 
cisplatin derivatives, modifying the two key sections of the pharmacophore: the 
am(m)ine non-leaving ligands and the anionic leaving ligands. These handles 
have allowed tuning of the properties of cisplatin derivatives to afford two 2nd 
generation platinum anti-cancer therapies: oxaliplatin and carboplatin. The 1,2-
diaminocyclohexane ligand of oxaliplatin reduced nephrotoxicity and 
myelosuppression and provided routes of treatment for cancers where resistance 
was emergent or cisplatin was not effective, such as colorectal cancer[59, 60]. 
Due to its high risk of nephrotoxicity, cisplatin dosing must be preceded and 
followed by hyper-hydration to minimise kidney damage, whereas oxaliplatin 
does not require this procedure.  Before the discovery of oxaliplatin, the front-
line treatment for advanced colorectal cancer was 5-fluorouracil with a success 
rate of around 10-15%[61]. A combination therapy including 5-fluorouracil and 
oxaliplatin (FOLFOX) was found to have synergistic interactions and greatly 
improved the benefit of each therapeutic agent alone with a success rate of 50-
78%. [62, 63]. The pharmacokinetics of the synergism of oxaliplatin and 5-
fluorouracil is thought to occur through more than one mechanism. One of these 
is the possibility that oxaliplatin inhibits or induces the down-regulation of 
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dihydropyrimidine dehydrogenase, an enzyme involved in the metabolic 
inactivation of 5-fluorouracil[64]. Another is the fact that oxaliplatin can inhibit 
thymidylate synthase, which is a target of 5-fluorouracil, however it is unclear 
whether or how this causes the synergistic effect between the two drugs[65]. 
Likewise, 5-fluorouracil induces the up-regulation of the ABCC family of genes 
which can, through up-regulation of efflux transporters, reduce the glutathione 
cellular concentration (a species implicated in the detoxification of Pt therapies) 
thus decreasing oxaliplatin degradative metabolism[66]. 
Classically, Pt anti-cancer agents undergo aquation of the leaving ligands, to 
afford a potent electrophile, which can then react with DNA nucleobases; 
principally the nucleophilic N7 position of guanine residues (Figure 1.11)[67]. 
The aquation of the two chloride leaving ligands of cisplatin occurs due to the 
change in chloride concentration which in the blood is around 100 mM compared 
to the intracellular cytoplasm of 3-5 mM. Increased intracellular chloride 
concentrations have even been implicated as a mechanism of resistance to 
cisplatin, as it can prevent the active aquated species from being formed. The type 
of DNA lesions that can occur by binding of cisplatin are primarily intrastrand 1,2 
guanine-guanine crosslinks with lower levels of intrastrand 1,2 adenine-guanine 




Figure 1.11. The main cellular mechanism of cisplatin: upon entry to the cell, cisplatin 
undergoes aquation, due to the lower chloride concentration inside cells, to form a highly 
reactive species that binds to DNA.  
Although it is the major contributing factor to cell death, DNA chelation is not the 
only mechanism through which cisplatin damages cells. The highly reactive 
aquated electrophilic platinum complex is also reactive towards thiols and other 
naturally occurring nucleophiles found in biological systems. Oxidative stress 
caused by damage elicited by cisplatin on mitochondria can also be responsible 
for the onset of apoptosis[69]. The membrane potential in mitochondria 
decreases upon treatment with cisplatin which results in inhibited glycolysis 
pathways which prevents ATP generation and accumulation of glucose in 
cells[70, 71]. This effect was likely to be caused by the formation of reactive 
oxygen species in mitochondria, leading to down-regulation of glycolysis-
regulated genes such as HIF1α. Gene regulation through microRNA (miRNA) 
modulation by cisplatin has also been identified as another mechanism of action. 
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One function of miRNAs is post-transcriptional gene regulation at the RNA level. 
After a gene is transcribed, a messenger RNA (mRNA) relays the signal for 
translation by ribosomes in the cytoplasm. miRNA can bind and inhibit mRNA 
from reaching the ribosome or induce degradation of the mRNA, thus altering 
ultimate protein expression. Cisplatin has been shown to interact with key 
miRNAs that can regulate apoptosis pathways such as BCL2 and the E2F family 
of genes[72, 73]. 
The ability of oxaliplatin to be used for cancers which have developed resistance 
to cisplatin or where cisplatin is not effective outright suggests divergent 
mechanisms of action are responsible. The dicarboxylate leaving ligands of 
oxaliplatin are thought to undergo a similar method of activation to the chloro 
leaving ligands of cisplatin. The dicarboxylate ligands are labile towards aquation 
and substitution with chloride. As a result of this, oxaliplatin IV infusions must be 
formulated differently than cisplatin[74]. Cisplatin is formulated in sodium 
chloride (typically 0.9%) solution whereas oxaliplatin must be formulated in a 
5% dextrose carrier to prevent premature ligand substitution and complex 
degradation. Oxaliplatin, upon administration into a patient, can therefore 
undergo several possible ligand substitution pathways with intermediates of 
varying reactivity[75]. After oxaliplatin infusion in human patients, the dichloro 
and the monochloro-monoaqua complex can be identified in the plasma 
ultrafiltrate, suggesting the process of activation of oxaliplatin in vivo follows the 
pathway of i) chloride substitution of one or both of the carboxylate ligands then 
ii) aquation of the chloro ligand (Figure 1.12). Ultimately the mono- and di-aqua 
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complexes are still implicated as the damage-dealing species owing to their high 
reactivity.  
 
Figure 1.12. Proposed ligand substitution reactions occurring in the formation of the 
reactive species (hydrated forms) of oxaliplatin. 
The di-hydrated complex shows increased cytotoxicity if dosed directly in vitro 
as the pre-formed complex, compared to oxaliplatin[76]. Like cisplatin, 
oxaliplatin causes crosslinking of genomic DNA with most occurring at the N7 
position of guanine residues with intra-strand crosslinking as the dominant 
conjugate formed with a small amount of inter-strand crosslinks also being 
formed[77]. Divergent mechanisms of cytotoxicity of oxaliplatin from cisplatin 
may include, as mentioned above, thymidylate synthase inhibition, an enzyme 
responsible for the incorporation of thymidine during DNA synthesis. However, 




There is evidence suggesting that oxaliplatin can engage with the immune system 
to elicit immunogenic effects[78]. Oxaliplatin can prompt the translocation and 
presentation of calreticulin on the cell membrane surface which is a promoter of 
macrophage recruitment[79]. Cisplatin does not affect calreticulin presentation 
and therefore does not stimulate an immunogenic response (or at least, not in 
this manner). It was also shown that pre-treatment of colorectal cancer cells with 
oxaliplatin could induce an anti-cancer immunogenic response when injected 
into a murine model, whereas pre-treated cells with cisplatin did not[79, 80]. 
Yet another difference identified between the mechanisms of oxaliplatin and 
cisplatin concerns ribosomal biogenesis stress. In 2017, seminal work by Lippard 
and Hemann et al claimed that oxaliplatin does not kill cells through the DNA-
damage response but rather through a ribosomal biogenesis stress pathway[81]. 
By comparing the RNA interference profiles of cell-death signalling pathways to 
a reference set of drugs with established discrete mechanisms of action, the 
pathway of cell-death brought on by each investigated drug afforded insight into 
the mechanism of action.  Upon treatment of cells with either cisplatin, 
carboplatin or oxaliplatin, it was found that oxaliplatin’s signature differed from 
that of cisplatin and carboplatin and more closely resembled that of a 
transcription-translation inhibitor. The tumour suppressor protein, p53, was 
found to be upregulated by cisplatin through a Chk2-dependent manner. Chk2 is 
activated in response to double strand breaks, which can occur during the 
attempted repair of cisplatin-DNA adducts[82]. Oxaliplatin also upregulated p53 
but did so in a Chk2-independent manner. From an analysis of the ribosomal RNA 
26 
 
synthesis, it was seen that oxaliplatin shared similar phenotypes with 
Actinomycin D, a drug known to induce ribosomal biogenesis stress[83]. Drug-
induced cell death via ribosomal debilitation proceeds via RPL11-dependent 
inhibition of MDM2, the negative regulator of p53. Oxaliplatin was found to 
greatly increase RPL11 levels whereas cisplatin effected no change. To explain 
the high efficacy of oxaliplatin relative to cisplatin for the treatment of colorectal 
cancer, gene expression was examined and ribosome-associated pathways were 
found to be highly enriched in colorectal cancers where a so-called ‘translation 
addiction’ existed as a factor of tumourigenesis. Other cancers that have 
‘translation addiction’ may also be prime yet undiscovered targets for treatment 
by oxaliplatin.  
1.3.2 Emergence of Resistance to Platinum Therapies 
A major shortcoming of platinum-based anti-cancer therapies is the intrinsic or 
acquired resistance of tumours. The low level of cross-resistance between 
cisplatin and oxaliplatin enables circumvention of cisplatin-resistant cancers to 
be treated with oxaliplatin, where applicable. However, oxaliplatin is not suited 
to the treatment of all cisplatin-resistant cancers. Therefore, there has been a 
large body of research into the mechanisms of resistance of Pt drugs. Generally, 
resistance can be accrued by mechanisms preventing the Pt drug from reaching 
its intended targets or by mechanisms that overcome the cytotoxic effects caused 
by Pt drugs after they have bound to their targets. 
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In the former case, changes in the levels of cellular transmembrane transporters 
can prevent the uptake of Pt species. Cisplatin is thought to enter cells via a 
mixture of passive diffusion and active transport[84, 85]. Several active 
transporters have been implicated in the transport of cisplatin into cells. Of these, 
the family of copper uptake transporters have been identified as playing a major 
role in cellular accumulation of cisplatin and acquired resistance[86]. A study 
identified a copper influx transporter CTR1 as a mediator of cisplatin uptake and 
demonstrated that pre-administration of copper chelators could enhance 
cisplatin uptake in a murine model[87]. In another study, CTR1 was also shown 
to affect accumulation of carboplatin and oxaliplatin[88]. Knock-out of the CTR1 
protein in mice, increased resistance to cisplatin and carboplatin treatment but 
affected cytotoxicity of oxaliplatin treatment to a lesser degree, suggesting there 
are again different mechanisms that apply to oxaliplatin but not cisplatin or 
carboplatin. The relative expression of CTR1 has been validated as a prognostic 
marker for efficacy of cisplatin and carboplatin treatment in humans[89]. 
Conversely, increased efflux of Pt species can also prevent their cytotoxicity and 
this is largely caused by over-expression of the copper efflux transporters[90, 
91]. 
Glutathione, an endogenous reductant, acts as a detoxifier in the cytoplasm and 
can deactivate Pt drugs and flag them for efflux and metabolism (Figure 
1.13)[92]. Enzymes associated with glutathione biosynthesis and the conjugation 
of the reductant to the Pt species have been shown to be up-regulated in cells 
with acquired resistance to cisplatin[93, 94]. However, there are to date no 
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clinical studies verifying this effect in vivo. Regardless, prodrugs of Pt species 
comprising inhibitors of glutathione have shown potentiating cytotoxic effects 
(vide infra Section 1.4.1). 
 
Figure 1.13. Structure of glutathione and its adduct with cisplatin, marking it for 
metabolism and efflux from the cell. 
DNA damage-mediated cell death is a critical pathway for cisplatin toxicity. DNA 
repair mechanisms, such as nucleotide excision repair and mismatch repair, can 
be modulated to effect resistance in cancer. Nucleotide excision repair involves 
the identification of damaged bases in DNA, followed by incision at either end of 
the lesion, removal of the oligomer containing the damaged base and re-synthesis 
of the strand. The exact biomolecules responsible for the excision are known to 
be the heterodimer, ERCC1/XPF. The under- or over-expression of this dimer 
corresponds to heightened sensitivity or resistance, respectively, of cells towards 
cisplatin[95, 96]. Resistance to oxaliplatin has also been demonstrated to follow 
some of the mechanisms employed to resist cisplatin, such as increased 
expression of ERCC1/XPF and efflux transporters[97, 98]. However, in light of the 
dissimilarity that oxaliplatin elicits its cytotoxic effects relative to cisplatin it will 
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be of interest if ribosomal-associated pathways are modulated to effect 
resistance.  
1.3.3 Targeting and selectivity strategies 
Despite its less severe side effect profile than cisplatin, oxaliplatin is not a 
targeted therapy and does have off-target toxicities caused by eliciting effects in 
non-cancerous tissues. There have been a number strategies employed in 
attempts to target Pt therapies to cancers.  
Glucose Transport Targeting 
Cancers generally have greatly enhanced glucose uptake relative to normal 
cells[99]. A metabolic switch can occur in some cancers, the Warburg effect, 
where glycolysis is favoured over oxidative phosphorylation[46]. This may be a 
circumvention for the hypoxic conditions in which tumours often inhabit, as 
unchecked cell division outgrows blood (and thus, oxygen) supply, as glycolysis 
can occur in anaerobia. It may also be a result of down-regulation of 
mitochondrial signalling messengers as an anti-apoptotic measure[100]. The 




Figure 1.14. Structure of glucose transporter-targeted Pt(II) complex. 
Over-expression of glucose transporters on cancer cells can allow preferential 
uptake of glucose-conjugated drugs[101]. Many Pt(II) complexes with 
incorporated sugar-containing ligands have been synthesised and characterised 
for their cancer-killing capabilities, with the sugar moiety comprising the non-
leaving ligands or as part of the leaving ligand[102-104]. Replacement of the 
ammine ligands of cisplatin with 2,3-diamino-2,3-dideoxy-D-glucose afforded a 
Pt(II) complex which was less potent a chemotherapeutic agent than cisplatin but 
allowed higher doses to be given (Figure 1.14) [105]. This complex was 
demonstrated to increase the survival time of tumour-bearing mice 3-fold 
compared to the untreated control. Extension of the leaving ligand of oxaliplatin 
with a linker terminated with a glucose unit was shown to greatly enhance water 
solubility and uptake via active transport by the GLUT1 glucose transporter[106]. 
There was a dramatic increase in the IC50 of these complexes where a GLUT1 
inhibitor was co-incubated in vitro. In addition, the maximum tolerated dose was 
around triple that of oxaliplatin in nude mice providing a higher therapeutic 
index. 
Nanoparticle and Polymeric Delivery Systems 
The discrepancies of Pt-based cancer therapy in bioavailability and targeting 
have spurned development of drug delivery systems. “Re-packaging” of known 
drugs to overcome their limitations (insolubility, non-specific targeting, low 
bioavailability, etc.) can provide a more affordable and efficient means of 
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increasing the utility of these drugs relative to the financial expenditure and time 
required for the discovery of new drug entities. There have been huge 
developments made in the field of drug delivery with a broad scope of 
innovations providing solutions to the range of issues drugs can have[107-109].  
There have been a number of liposomal formulation drugs that have been FDA-
approved in the past two decades[110]. Liposomes are spherical vesicles with an 
aqueous solution core encapsulated with a hydrophobic membrane. The biphasic 
nature of liposomes allows both hydrophilic and hydrophobic molecules to be 
encapsulated effectively. They may also be coated to effect changes in their 
uptake and pharmacokinetics. PEGylation can reduce clearance and increase half-
life, while also preventing phagocytic engulfment[111]. It is a contested issue 
whether PEGylation enables greater tumour accumulation[112, 113]. The so-
called “enhanced permeation and retention effect”, caused by the “leaky” 
vasculature, created in a rapid manner to facilitate a tumour’s rapid growth, may 
facilitate increased tumour accumulation of liposomes[114, 115]. However, the 
enhanced permeation and retention effect has been shown to be an unreliable 
factor in humans[116, 117]. This strategy has been applied to doxorubicin, an 
anthracycline anti-cancer drug, which suffers from a dose-limiting cardiotoxicity. 
Liposomal formulation of doxorubicin limits entry into cells with tight junctions, 
such as cardiac cells, due to the larger size of the particles compared to the 
molecule itself[118].  PEGylation of liposomal doxorubicin also affords longer 




Figure 1.15. Depiction of Lipoplatin: the blue sphere is the cisplatin-containing core in 
Tris-HCl buffer (0.1 M, pH 7.5) which is encased by a lipid bilayer with the PEGylated 
lipid strands protruding outwards.  
Cisplatin in a liposomal formulation can overcome issues with its low 
bioavailability and cell uptake[121]. The protective layer of lipids prevents 
premature reaction of cisplatin with biomolecules and may also be able to 
overcome resistance by bypassing the down-regulated transporters of cisplatin 
and directly fusing with the cell membrane to release its cytotoxic cargo[122]. 
One formulation, Lipoplatin, has been under extensive study for a range of 
cancers (Figure 1.15). Lipoplatin is a PEGylated liposomal formulation with an 
average particle size of 110 nm. Currently, Lipoplatin has been tested clinically 
for treatment of pancreatic, metastatic breast, advanced gastric and inoperable 
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non-small cell lung cancer, as well as head and neck cancer and 
mesothelioma[123-127]. Throughout all of these studies, the therapy was well-
tolerated and did not exhibit such severe nephrotoxicity as cisplatin alone. 
Results have been promising, particularly in pancreatic and non-small cell lung 
cancers. Despite nearly equal response and overall survival compared to 
cisplatin, the much more tolerable toxicity profile of Lipoplatin successfully saw 
it through a non-inferiority Phase III trial for the treatment of non-small cell lung 
cancer[128]. Lipoplatin is also being assessed for orphan drug status for 
pancreatic cancer and is in “registrational” Phase II/III trials currently. 
Micellar formulations of cisplatin also are in clinical testing. Micelles are 
comprised of a hydrophobic core surrounded by a hydrophilic layer. NC-6004, a 
micellar nanoparticle with cisplatin derivative conjugated to poly-glutamate in 
its hydrophobic core with a PEG outer shell, is in Phase III clinical trials for 
pancreatic cancer in a combination therapy with gemcitabine[129]. As with 
Lipoplatin, nephrotoxicity was reduced with the micellar formulation.  
No other nanoparticle delivery systems are in clinical trials however more exotic 
and ambitious nanoparticle drug delivery systems for cisplatin have been 
developed and are in pre-clinical testing stages, including magnetic 
nanoparticles[130], metal-organic frameworks[131] and silica mesoporous 
nanoparticles with a photosensitiser for combined chemotherapy and 





A prodrug is an inactive or protected form of a drug that is activated into the 
parent active drug after administration. It has long been used as a strategy to 
modify the physicochemical properties of drugs that may contribute to 
undesirable pharmacokinetic effects, such as poor absorption or stability in the 
harsh conditions of the stomach and GI tract[133]. Ionisable species, such as free 
amines and carboxylic acids that result in charged molecules at physiological pH 
can hinder absorption of orally administered drugs. Additionally, masking of 
charges increases lipophilicity and improves cell membrane permeability. The 
most common pro-moiety, i.e. masking group, is an ester masking a carboxylic 
acid; accounting for just under half of all marketed prodrugs[134]. Intracellular 
esterases can then hydrolyse the prodrug into its active carboxylic acid form. The 
inverse can also be applied for the delivery of drugs containing a hydroxyl group 
with an ester as a pro-moiety. For example, the prodrug abiraterone acetate, a 
treatment for prostate cancers, utilises a simple acetic acid ester to increase oral 
bioavailability and delay first-pass deactivating metabolism over the parent drug 
with a free hydroxyl (Figure 1.16) [135, 136]. Similarly, the boronic acid-
containing drug, ixazomib, is administered orally as a citric acid boronic ester that 




Figure 1.16. Structures of the cancer prodrugs abiraterone acetate and ixazomib citrate. 
Pro-moieties are highlighted in orange. 
Prodrugs can also be used to increase the selectivity of therapies, by design of a 
pro-moiety that facilitates either uptake or activation at the desired site. For 
instance, enzymes that are upregulated in cancers but not in healthy tissues can 




Figure 1.17. Structures of 5-Fluorouracil, 5’-deoxy-5-fluororidine and Capecitabine. 
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With adept rational prodrug design, a change in administration route may 
become possible. This is desirable as it benefits the patient’s quality of life, as well 
as lessens the burden on healthcare providers as hospital stay times are reduced. 
A prime example of the utility prodrugs can offer is capecitabine, a prodrug of 5-
fluorouracil (Figure 1.17). 5-Fluorouracil has been a mainstay of chemotherapy 
for a wide remit of cancers since its discovery in the 1950’s. However, it suffers 
from a poor pharmacokinetic and metabolic profile, with low oral bioavailability, 
that requires it to be delivered in a continuous intravenous infusion[139]. The 
developmental process of capecitabine began with the discovery of another 5-
fluorouracil prodrug: 5’-deoxy-5-fluorouridine. This prodrug was found to be 
suitable for oral administration but its severe dose-limiting intestinal-related 
toxicities prevented its successful utilisation[140, 141]. The installation of a 
carbamate with a lipophilic tail on 5’-deoxy-5-fluorocytidine increased oral 
absorption and alleviated the dose-limiting toxicities by preventing 5-
fluorouracil from being prematurely formed during the absorption process[142]. 
Capecitabine is a prodrug that requires three stages of activation: i) removal of 
the carbamate by carboxylesterases (located primarily in the liver) ii) conversion 
of the cytidine to uridine by cytidine deaminase (located primarily in the liver 
and some cancer cells) followed by iii) removal of the ribose by thymidine 
phosphorylase to generate the active drug, 5-fluorouracil. Capecitabine is now a 
front-line therapy for a range of cancers. 
1.4.1 Pt(IV) Prodrugs 
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All of the Pt(II) therapies discussed above are administered intravenously. Oral 
administration is not possible because of the highly reactive nature of these 
species. Pt(II) species are square planar low-spin d8 coordination complexes and 
are prone to substitution reactions[143]. This prevents oral administration as the 
complex will undergo reactions before systemic absorption. To circumvent this, 
a prodrug strategy utilising the Pt(IV) oxidation state can be employed. In 
oxidation state IV, the complex takes an octahedral geometry with a low-spin d6 
configuration that is more substitution-inert. In addition, the Pt(IV) complexes 
are six-coordinate and so have two additional handles for functionalisation. The 
Pt(IV) species are considered prodrugs as they require reduction to the 
corresponding Pt(II) complex before they can elicit their cytotoxic effects[144, 
145]. This has led to myriad applications in targeted and multi-functional 
therapies. Pt(IV) prodrugs have been widely investigated as an alternative 
therapy to overcome the extensive side-effects of Pt(II) drugs and to enhance 
cancer cell selectivity, outcomes for treatment and to facilitate the design and 
development of novel delivery systems.  
A prime example of this is the Pt(IV) prodrug “Asplatin” or “Platin-A”[146, 147], 
which consists of cisplatin oxidised to the Pt(IV) oxidation state with one axial 
ligand containing a molecule of aspirin (see Figure 1.18). The design of this 
prodrug allows, upon reduction of the Pt(IV) centre, release of both active 
cisplatin and aspirin to elicit DNA-binding and COX-2 inhibition, respectively 
[147]. COX-2 inhibition by aspirin reduces tumour-associated inflammation, one 
of the “hallmarks” of cancer progression[1, 148, 149]. This prodrug was shown to 
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be an effective agent on prostate cancer cells in vitro. Recently, it has also been 
shown to reduce some of the most severe side-effects of cisplatin treatment, 
namely oto- and neuro-toxicity primarily by reducing inflammation, in a guinea 
pig model[150]. 
 
Figure 1.18. Dual-action Pt(IV) prodrug Platin-A releases a molecule of aspirin along with 
cisplatin upon reduction/activation. IC50 values are for a human prostate cancer cell line, 
PC3, with an incubation time of 72 h.  
The additional axial ligands incorporated following the oxidation of Pt(II) to 
Pt(IV) have also been utilised to potentiate the antineoplastic effects following 
drug activation by the addition of adjuvant therapies as ligands. There are myriad 
examples of this, one such being the addition of a nucleotide excision repair 
(NER) inhibitor as a ligand (Figure 1.19)[151]. Nucleotide excision repair can 
mediate cisplatin cytotoxicity by repair of the DNA lesions caused by DNA-
binding of cisplatin[152, 153]. The inhibitor was capable of binding and blocking 
the XPF-binding site of the ERCC1/XPF dimer with the hypothesis that cisplatin 
damage would not be recognised and repaired thus sensitising cells to cisplatin. 
39 
 
The prodrug exhibited high potency and overcame cisplatin resistance in both 
ovarian and lung cancer cell lines. 
 
Figure 1.19. Dual-action Pt(IV) prodrug which releases a nucleotide excision repair 
inhibitor upon reduction/activation, leading to enhanced cytotoxic effects and helps to 
overcome resistance mechanisms. IC50 values are for A549CisR, a cisplatin-resistant lung 
carcinoma cell line, after 72 h incubation. 
Another example is ethacraplatin, a Pt(IV) prodrug with a glutathione-S-
transferase inhibitor[154]. As mentioned above, glutathione is implicated in the 
detoxification of cisplatin, and glutathione-S-transferase (GST) is an enzyme that 
catalyses the conjugation of the reactive thiol of glutathione to electrophilic 
centres. Ethacrynic acid is a known inhibitor of glutathione-S-transferase and 
was readily incorporated into a Pt(IV) prodrug via the free carboxylate (see 
Figure 1.20). The resultant prodrug not only increased the cytotoxicity compared 
to cisplatin alone, but also potentiated the inhibition of glutathione-S-transferase 
relative to ethacrynic acid alone. The way in which ethacrynic acid binds to the 
enzyme is known to be with the carboxylate directed towards the solvent region 
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and as such it was anticipated that the Pt(IV) prodrug would bind in a similar 
mode, devoid of any Pt-enzyme interactions[155]. X-ray crystallographic studies 
were used to probe the binding and elucidated that the Pt(IV) prodrug was 
docking at a different site than ethacrynic acid alone[156]. Ethacraplatin was 
observed to bind to the dimer interface of glutathione-S-transferase, where it was 
reduced to the Pt(II) complex with release of the two axial ligands, ethacrynic 
acid. The resultant Pt moiety remains bound in the dimer interface. 
 
Figure 1.20. Dual-action Pt(IV) prodrug, ethacraplatin, which releases a glutathione-S-
transferase inhibitor upon reduction to overcome glutathione-mediated resistance to 
cisplatin. IC50 values are for a human breast carcinoma MCF-7 cell line after 24 h 
incubation.  
Taking this “multiple-action” concept further, is an example of two different 
Pt(IV) prodrugs linked to each other by a di-carboxylate ligand with the other 
axial ligand of each Pt centre comprised of a carboxylate anti-cancer drug (one an 





Figure 1.21. Quadruple-action dinuclear Pt(IV) complex. Reduction/activation releases 
two Pt(II) anti-cancer agents with discrete mechanisms of cytotoxicity, an HDAC 
inhibitor and a PDK inhibitor. IC50 values are for human colorectal carcinoma HCT-15 cell 
line after 72 h incubation. 
The reduction of the two Pt(IV) centres releases two cytotoxic Pt(II) species with 
disparate mechanisms of action: cisplatin, that binds to DNA to form cytotoxic lesions 
and Pt56MeSS which is unable to complex DNA as a result of its bidentate nitrogen-donor 
ligand and has been postulated to induce cell cycle arrest through actions in the 
mitochondria[158]. Phenyl butyrate is a known HDAC inhibitor, presumed to de-
condense chromatin to expose DNA to cisplatin and potentiate its cytotoxicity. 
Dichloroacetic acid has been used in a prior Pt(IV) prodrug, Mitaplatin, and may be 
capable of inducing a switching back of cancer cell metabolism to oxidative 
phosphorylation (see section 1) which hinders the tumour capabilities of tolerating 
oxygen-deficient environments[159]. 
Of prominence in the Pt(IV) prodrug field is satraplatin which is currently in 
clinical testing for a range of cancers[160]. The cyclohexamine equatorial ligand 
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and the two acetate axial ligands increase the lipophilicity and, in combination 
with the stability of Pt(IV) complexes, allowed satraplatin to become the first 
orally administered platinum anti-cancer agent. Once activated (via reduction to 
the Pt(II) complex and loss of the acetate axial ligands) the mechanism of action 
is similar to that of cisplatin[161]. In 2009, the results of a large-scale phase III 
clinical trial were published reporting that satraplatin was well-tolerated but did 
not benefit overall survival (relative to cisplatin) in hormone-refractory prostate 
cancer despite delaying pain and disease progression[162]. These results have 
shown that satraplatin may find use in scenarios where use of cisplatin is 
precluded such as renal dysfunction or in the elderly.  
Using the two additional handles for functionalisation of Pt(IV) complexes has 
garnered a lot of interest in the design of multi-functional complexes[163, 164]. 
This is an attractive strategy to overcome issues with Pt therapy, such as side 
effects and resistance, as it prevents the active agents from being administered 
individually which can be complicated by variance in pharmacokinetic and 
distribution factors or each agent. For instance, they can be comprised of 
inhibitors associated with platinum therapy resistance.  
As mentioned previously, modulation of glutathione-associated pathways has 
been linked to cisplatin resistance. Platin-B, is a Pt(IV) cisplatin analog designed 
to allow cisplatin to escape sequestration by glutathione[165]. The axial ligands, 
6-bromohexanoic acid, can bind to the reactive cysteines of glutathione, 
preventing the detoxification of the cisplatin (Figure 1.22). The result was a 
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highly potent Pt(IV) agent that was active in a cisplatin-resistant ovarian cancer 
cell line, with an IC50 of 0.75 µM (almost 20-fold more potent than cisplatin).  
 
Figure 1.22. The reduction of Platin-B yields cisplatin and a glutathione inhibitor, 
preventing the sequestration of cisplatin by glutathione.  
There are a huge number of Pt(IV) prodrugs developed that contain a secondary 
drug that activates upon intracellular reduction of the prodrug, thus anti-
inflammatory drugs have been used to reduce inflammation-associated pro-
tumour effects, such as aspirin[147, 166] and ibuprofen[167]; other cancer 
therapies, for instance, DNA alkylators to potentiate cytotoxic effects, such as 
chlorambucil[168] or HDAC inhibitors such as valproic acid[169, 170]; cell 
organelle-specific targeting motifs for the mitochondrion[171, 172] or for cell 
markers such as integrins[173, 174]. However, to date, no other Pt(IV) prodrugs 
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have been taken through to clinical testing stages and new therapies to replace 
the current Pt drugs remain a challenge at the forefront of cancer research.  
1.4.2 Bio-orthogonal Prodrug Activation 
The work discussed herein investigates methods for prodrug activation that do 
not rely on biological triggers but use physical actuators to generate ‘on-demand’ 
drug release. Related prodrug activation strategies that utilise bio-orthogonal 
chemistry to activate prodrugs, that are independent of metabolic pathways, have 
seen success in improving temporal and spatial selectivity. Bio-orthogonality, as 
first defined by Bertozzi, is the capability of chemical reactions to occur in 
biological milieu without interference or interaction with the biological 
system[175]. The participating moieties of the bio-orthogonal reaction must be 
inert and unreactive towards the biological environment. Examples of bio-
orthogonal reactions include the Staudinger ligation, strain-promoted azide-
alkyne click reactions, and tetrazine-dienophile inverse electron demand Diels-
Alder reactions.  The Staudinger reaction has been used previously as a de-caging 
reaction for doxorubicin that was protected with a 4-azidobebenzyloxy group 
(ACBZ-Dox)[176]. Reduction of the azido group by a phosphine, with release of 
dinitrogen, triggers a self-immolative 1,6-elimination to release the active 
doxorubicin (Figure 1.23). The disadvantages of the Staudinger reaction as a bio-
orthogonal means of prodrug activation lie primarily in the phosphine. Its limited 
stability towards oxidation in air and the resultant phosphine oxide by-product 
of the reaction hinder the Staudinger reaction for use in bio-orthogonal chemistry 




Figure 1.23. The Staudinger reaction is used to reduce the azide of the 4-
azidobenzyloxycarbonyl (ACBZ) group to the amine which triggers an electronic 
cascade, resulting in the release of free doxorubicin (DOX), with carbon dioxide and 
azaquinone methide as by-products. 
The inverse electron Diels-Alder reaction is well-suited for click-to-release 
applications due to its high reaction kinetics that are easily tuneable. Vinyl ethers 
can be used as pro-moieties for hydroxyl groups, such as for the protection of 
duocarmycin derivative, Ve-Dcm [177]. De-caging of phenol triggers a cyclisation 
to form a cytotoxic cyclopropanyl derivative (Cyp-Dcm) that acts as a DNA-
alkylator. It was demonstrated that by incubation of a tetrazine coupling partner, 
the prodrug could be activated for a turn-on cytotoxic effect in A549 human lung 




Scheme 1.1. Vinyl ether-protected duocarmycin derivative is decaged by inverse electron 
demand Diels-Alder reaction, following by a cyclisation reaction to form the active 
cyclopropanyl-containing compound. 
The disadvantages of this system are the difficulty in the synthesis of tetrazines, 
limiting their optimisation, the lack of solubility and instability towards 
hydrolysis that they exhibit in aqueous conditions and the resultant pyridazine 
by-product debarring these reactions from being ‘traceless’. In another 
embodiment, the pyridazine by-product was utilised for a dual-prodrug 
activation strategy. With the identification of a biologically-active pyridazine that 
inhibits the function of oncogenic microRNA-21, in combination with a vinyl 
ether-protected camptothecin (a potent topisomerase I inhibitor) prodrug was 
devised a tetrazine inverse electron demand Diels-Alder reaction that resulted in 
the simultaneous activation of two prodrugs: with the tetrazine as a pro-moiety 
for the pyridazine and the vinyl ether being decaged to generate free 




Scheme 1.2. Dual prodrug-prodrug activation through the use of a bio-active pyridazine, 
masked as a tetrazine and a camptothecin prodrug with a vinyl ether pro-moiety. 
Reaction of the tetrazine with the vinyl ether results in two active drugs being formed 
simultaneously. 
Another method of bio-orthogonal prodrug activation is the use of a 
biocompatible organometallic catalyst to perform the de-caging reaction. This 
moves away from the conventional two-component-ligation methods described 
above and allows the conversion of multiple prodrug molecules to active drug by 
the bio-orthogonal catalyst. Typical heavy metal catalysts (such as Pd and Cu 
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species) are associated with toxicity and instability to air and aqueous conditions. 
However, strategies have evolved to overcome these issues by the identification 
of non-toxic and stable catalysts, as well as formulations that prevent leaching 
and exposure of the free metal such as nanoparticles or resins (see reviews [179-
181]). For example, Pd0 particles can be made by the incorporation of Pd(OAc)2 
into swollen resins which can then be cross-linked to prevent any leaching of Pd 
while retaining its catalytic activity[182].  
 
Scheme 1.3. Catalytic de-caging of a proparygyl-protecting 5-fluorouracil prodrug (Pro-
5-FU) to active drug 5-FU by incubation with Pd0-incorporated resin. 
These Pd particles were shown to exhibit minimal toxicity in human colon and 
pancreatic cancer cells at an effective Pd concentration of ~288 µM and were 
effective at de-caging a prodrug of 5-fluorouracil (Pro-5-FU) for turn-on 
cytotoxicity (Scheme 1.3). Further, these particles were shown to be capable of 
functioning in vivo using a zebrafish embryo model and demonstrated by the 






Aims and Objectives 
 
Platinum-based anti-cancer therapies are a mainstay of cancer treatment and 
Pt(IV) prodrugs have shown promise towards the improvement of the toxicities 
of these therapies. The research described herein investigates alternative 
methods of activating Pt(IV) prodrugs, with the ultimate aim of providing 
spatiotemporal control over the “turn-on” of a variety of cancer therapies.  
The work described firstly explores the use of an electrochemical redox-mediated 
approach to prodrug activation by fabricating discrete devices that are capable of 
reducing and activating Pt(IV) prodrugs upon the application of an electrical 
signal. The second approach involved the development of a photocatalytic Pt(IV) 
reduction system using a photosensitiser which, upon illumination, generated 
both cytotoxic Pt(II) species and singlet oxygen simultaneously. These platforms 
were optimised and characterised in vitro for their reduction capabilities, and 






Electrochemical Activation of Pt(IV) Prodrugs 
 
 
Parts of this chapter are published in: 
Norman, D., González-Fernández, E., Clavadetscher, J., Tucker, L., Staderini, M., 
Mount, A.R., Murray, A. F. and Bradley, M., Chemical Communications, 2018, 54, 
9242-9245. 




The discovery of platinum-based anticancer therapies represents a landmark in 
cancer research therapy and was based on the serendipitous observation by 
Rosenberg that Pt species generated during electrolysis with platinum electrodes 
inhibited division of bacteria[184]. Upon further investigation, Pt(NH3)2Cl2 was 
identified as the agent responsible and spurred the FDA approval of the first Pt-
based anticancer agent in 1978 under the name of cisplatin.  Pt(II) anticancer 
chemotherapies such as cisplatin and the more recent, oxaliplatin and 
carboplatin are now commonplace and considered as work-horses of cancer 
therapy, with 10-20% of all cancer patients being prescribed a Pt-based therapy 
at some stage in their treatment regimen[53]. However, despite the clear benefits 
and efficacy of Pt-based therapies, they are hindered by severe side-effect and off-
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target toxicity profiles. This is largely due to the high reactivity and lack of 
specificity of Pt(II) species. In addition, Pt(II) therapies are required to be 
administered intravenously due to the lack of, or the unpredictability of, 
bioavailability with oral administration.  
In attempts to overcome these issues, the oxidised and more substitution-inert 
Pt(IV) derivatives have been explored as potential next-generation 
therapies[185, 186]. The change from a low-spin d8 configuration to a low-spin 
d6 configuration, with associated change from square planar to octahedral 
geometry, results in a lowered lability of ligands thus increasing stability towards 
biological nucleophiles. The kinetic inertness reduces the amount of Pt that is 
sequestered or detoxified on its approach to the tumour. This has provided 
experimental therapies with reduced toxicities and enabled a switch of the route 
of administration from intravenous to oral (see Chapter 1). 
The difference in bioactivity between the Pt(IV) and Pt(II) oxidation states 
present an opportunity for selective drug activation.  
Previous work has utilised biologically-endogenous reductants (such as ascorbic 
acid and glutathione) to reduce Pt(IV) prodrugs to their active counterparts (see 
Chapter 1). The use of mediators (that are not endogenous) to carry out the 
reduction-activation has not been well-explored, despite its potential to allow 
further control of site-selective and temporal control over prodrug activation. 
Sessler et al reported a macrocyclic metallotexaphyrin that was capable of 
reducing Pt(IV) species and explored its use for this purpose. Texaphyrins are 
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expanded porphyrins with the specific one used here named motexafin which 
was complexed with gadolinium. Motexafin gadolinium (MGd) had previously 
been shown to have a slight preferential accumulation in spontaneous mammary 
tumours in mice and functioned as a radiosensitiser[187].  MGd was explored for 
its use as a “redox catalyst” that could mediate the Pt(IV)-Pt(II) conversion and 
enable site-selectivity through the cancer-targeting motexafin (Scheme 3.1). This 
would thus remove dependence on endogenous reductants, which are ubiquitous 
and are found in healthy and cancerous tissues.  
 
Scheme 3.1. Mediated reduction-activation of a Pt(IV) prodrug by motexafin gadolinium 
(MGd). IC50 values are for a human ovarian carcinoma cell line, A2780 with an incubation 
time of 5 days. 
This work demonstrated the feasibility of a non-endogenous redox mediator as the 
actuator for Pt(IV) prodrug activation. However, the system required a high 
concentration of MGd (1 equivalent relative to Pt(IV) concentration) and a long 
incubation time for the turn-on of cytotoxicity. The catalyst also required reduction back 
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to its active oxidation state, proposed to be via ascorbic acid, therefore is not completely 
non-reliant on biological reductants. This study represents the closest related work to 
the investigations detailed in this chapter. To the best of our knowledge, there is only one 
published report of a prodrug activation system that uses electrochemical signals as an 
actuator[188]. It does so for cyclophosphamide (a nitrogen mustard used in the 
treatment of cancers) and uses an external three-electrode electrochemical cell with the 
effluent pumped to wells containing cells of the murine mammary carcinoma cell line 
EMT6 (Scheme 3.2). 
 
Scheme 3.2. Electrochemical oxidative activation of cyclophosphamide. 
 The oxidative activation of cyclophosphamide (a process conventionally carried out by 
liver enzymes) could be observed by the increase in cytotoxicity after 15 min of 
electrolysis, however required the use of an initial solution at 5 mM concentration. In 
addition, due to the high current density required the electrochemical source was 
required to be kept isolated from the cell media thus preventing translation to in vivo 
applications.    





3.2 Aims of Chapter 3 
 
Pt(IV) prodrugs have shown great promise for the delivery of cytotoxic Pt(II) 
anti-cancer agents overcoming issues with administration, solubility, reactivity 
and off-target toxicities. However, the method of activation for these prodrugs 
are biological and selectivity remains of great concern. The research presented in 
this chapter explores the use of a physical stimulus, namely electron delivery, to 
activate and turn-on Pt(IV) prodrugs. The application of a potential can be easily 
controlled and conceptually could be used from outside of the body enabling both 
spatial and temporal control over activation. 
This was accomplished through the discovery of a redox mediator, capable of 
shuttling electrons from an electrode surface to a Pt(IV) species; reducing it to 
the active Pt(II) species. Immobilisation of the redox mediator on to a 
miniaturised electrodes afforded discrete devices which could be applied in a 
biological setting. The capability of this system to kill cancer cells by mediated 
electrochemical activation was validated on both 2D and 3D cell cultures. 
3.3 Background  
 
In conjunction with the Implantable Microsystems for Personalised Anti-Cancer 
Therapy project, where a device containing miniaturised electrodes for sensing 
local pH and oxygen levels is implanted into a tumour, a drug delivery system was 
envisaged that could use electrons to activate and “turn-on” therapies directly at 
the site where therapy is required. This differs from conventional prodrug 
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applications, where systemic biological stimuli are responsible for activation of 
the prodrug. As cancers are innately endogenous and share many similarities to 
healthy tissue, prodrugs reliant on biological stimuli suffer from selectivity 
issues. Over-expressed enzymatic processes are often exploited to increase the 
selectivity of prodrugs and conventional drugs. However, these enzymes are also 
found in healthy tissues, albeit at lower levels. For example, capecitabine is a 
prodrug of 5-fluorouracil whose primary target is the enzyme, thymidylate 
synthase, that is essential for DNA replication. The relative expression of 
thymidylate synthase has been shown to be 1.47-fold higher in human cancerous 
colorectal tissue samples compared to healthy colorectal tissue[189]. Thymidine 
phosphorylase, the enzyme that catalyses the conversion of an inactive 
intermediate of capecitabine to the active drug 5-fluorouracil, was found to be 5-
fold higher in colorectal cancer tissues than in healthy tissues. This is of benefit 
to the efficacy and tolerability of capecitabine over 5-fluorouracil but regardless 
of the enhanced expression of both these enzymes in cancerous tissues, there will 
inevitably be activation of capecitabine and inhibition of thymidylate synthase 
occurring in healthy cells, albeit at lower levels than in cancerous cells.  
 An electrochemical-based approach to prodrug activation offers an alternative 
to overcome this hurdle. A prodrug may be administered, which is bio-inert, i.e. 
it is non-toxic in its caged state and cannot be activated biologically, but can be 
activated via electron delivery, that could be controlled externally by a healthcare 
professional. This could afford unprecedented control of where, when and how 
much prodrug is converted to active therapy.  
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Pt(IV) species are very much suited for this application, being redox-active with 
the reduction waves for Pt(IV)-Pt(II) occurring at relatively low potentials (less 
than -1 V for the dicarboxylate Pt(IV) species)[190, 191]. The general trend of the 
effect of the axial ligands on the reduction potential (EP) of Pt(IV) complexes is 
seen in Figure 3.1. The addition of two ligands during the oxidation of Pt(II) to 
Pt(IV) also affords a handle for further functionalisation through which the 
biological effect could be modulated.  
 
Figure 3.1. General trend of reduction potentials for Pt(IV) species with am(m)ine carrier 
ligands (N) and either halide or carboxylate leaving ligands (X). EDG = electron-donating 
group, EWG = electron-withdrawing group. The range of reduction potentials shown for 
each is based dependent on the type of equatorial ligands.  
Therefore, a system was envisaged by which a potential could be applied in vivo 
to reduce (and thus activate) the Pt(IV) species. A redox mediator, which acts as 
a shuttle between the electrode surface and the prodrug would afford even 
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greater selectivity, through allowing a lower potential to be applied and thus 




Figure 3.2. Representation of the mechanism of electro-catalytic conversion of Pt(IV) to 
Pt(II). A redox mediator, in the reduced form, can shuttle electrons from the electrode 
surface to the Pt(IV) species, becoming oxidised in the process. The reduced form of the 
redox mediator is then re-generated at the electrode surface. 
Suitable redox mediators for the Pt(IV) reduction were explored. Previous work 
based on the electrochemical sensing of satraplatin (a Pt(IV) species) in complex 
biological media that utilised methylene blue as a redox mediator was used as a 
basis for this study[193]. This overcomes the issue of speciation that arises from 
ICP-MS quantitation where only total Pt content is measured[194]. 
Chronoamperometry is used to sense and measure the satraplatin concentration 
of samples, with higher current output being seen for higher concentrations of 
satraplatin after 20 seconds of applying the potential. The sensor is composed of 
a self-assembled monolayer (SAM) on a gold disk electrode with methylene blue 
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adhered to the electrode surface through a thiol-gold bond and back-filled with 
mercaptohexanol. Leucomethylene blue (LMB, the reduced form of methylene 
blue) is generated by applying a reductive potential (-0.3 V), which in turn can 
reduce satraplatin to its Pt(II) analogue. The current output is thus correlated to 
the levels of oxidised methylene blue formed, from which the satraplatin 
concentration can be calculated. 
As the sensing mechanism utilised the Pt(IV) reduction through a redox cycle 
with methylene blue, I explored the use of this redox mediator as a prodrug 
activator as described below. 
3.4 Discovery and design of Pt(IV) electro-activation system 
 
A small library of cisplatin Pt(IV) analogues were synthesised to examine their 
suitability for reduction with the methylene blue-based redox mediator (Figure 
3.3). Complexes 1-5 exhibited varying reduction potentials, allowing the effect 
between reduction potential of the Pt(IV) substrate and the redox mediator to be 
explored. Oxaliplatin Pt(IV) derivative, 6, was also included in the assessment of 





Figure 3.3. Structures of the small library of Pt(IV) complexes initially synthesised for 
analysis/characterisation with respect to the reduction potential and suitability towards 
electro-activation. 
The purity and absence of undesired species (i.e. undesired mono-substituted complexes 
for compounds 3-6 or the undesired di-substituted for compound 2) was verified by 
HPLC (Figure 3.4). The cisplatin derivatives, due to their polar character, elute much 
earlier than the oxaliplatin derivative 6, hindering their usefulness as test compounds. 
With pure compounds in hand, the compounds were further confirmed by mass 




Figure 3.4. HPLC analyses of Pt(IV) prodrugs 1-6 with absorbance measured at 254 nm. 
Compounds were analysed with the same method, eluting H2O/MeCN each containing 
0.1% formic acid at a gradient of 95% H2O to 5% H2O over 10 minutes (for full spectra, 
see Chapter 5). 
The redox processes of complexes 1, 2, 3, 5 and 6 were measured by cyclic 
voltammetry at 1 mM in PBS (Figure 3.5), with compound 4 discounted due to its 
poor water solubility. The difference in peak reduction potentials (Ered) 
demonstrated the effect the axial ligands can have. The compounds showed the 
general relationship known for the reduction of Pt(IV) compounds; with 






Figure 3.5. Cyclic voltammograms demonstrating the effect of the axial ligands on the 
reduction potential of the Pt(IV) complexes 1 (green line), 2 (purple line), 3 (blue line), 
5 (red line) and 6 (orange line). Complexes were analysed at a concentration of 1 mM in 
PBS with a glassy carbon working electrode and a platinum mesh counter electrode and 
a Ag/AgCl reference electrode with potential swept from 0 to -1.2 V, except for 6 which 
was at 2 mM and potential swept from 0 to -1.05 V. Reverse scan has been omitted for 
clarity. Complex 4 was not soluble in aqueous media. 
It can be seen that the diacetato complex (3) had a less negative reduction 
potential than the mono-succinato complex (5). This is likely to be a result of the 
two acetato ligands having a greater effect on the destabilisation of the Pt(IV) 
complex than a single succinato ligand. 1 required the most negative reduction 
potential, i.e. it is the most difficult to reduce, as its ligand is less bulky and has 
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less electron-withdrawing effects than the others. It has been shown previously 
that steric hindrance of axial and equatorial ligands can destabilise the complex 
and lead to less negative reduction potentials[195]. All values obtained for peak 
reduction potentials were corroborated by values found in literature[191]. The 
reduction processes for each compound were a single two-electron wave, with 
the reduction process and release of the axial ligands irreversible in all of the 
compounds analysed. The absence of a corresponding anodic oxidation peak in 
the cyclic voltammograms showing that the reduction process was irreversible. 
A suitable constant reduction potential was selected from the previous CV 
experiments and applied, and the reaction monitored over time by NMR and LC-
MS. LC-MS analyses showed the disappearance of 3 upon application of a fixed 
potential of −0.65 V (vs. Ag/AgCl) for 30 min, however cisplatin was not 
identifiable by LC-MS. Measurement of the consumption of 3 by electrochemical 
methods was also attempted. Cyclic voltammetry lacked the sensitivity to detect 
changes in low concentrations of 3 but it was found that differential pulse 
voltammetry (DPV) was sensitive enough to detect down to at least 100 μM. 
Differential pulse voltammetry is a technique where the potential is sharply 
applied, held for a set interval time before sharply decreasing back down to the 
step potential. The current is sampled just before the pulse in potential and again 
just before the drop back down to the step potential. The twice-sampling 
operation of DPV lends it increased sensitivity through correction of the non-
Faradaic background current. 
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DPV was employed to analyse the progress of Pt(IV)-Pt(II) conversion at sub-
millimolar concentrations and a standard curve was generated using known 
concentrations of 3 (see Figure 3.6). The increased sensitivity of DPV compared 
to CV is demonstrated in Figure 3.7 where with CV the current begins to plateau 
around 300 μM. The peak reduction currents are correlated to the concentration 
through the relationship: 
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where 𝑖𝑝  is the current of the reduction peak, 𝑛  is number of electrons 
transferred,  𝐹  is the Faraday constant, 𝐴  is the area of the electrode, 𝐷  is the 
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where 𝑅  is the gas constant, 𝑇  is temperature and ∆𝐸  is the pulse 
amplitude.[196] 






Figure 3.6. Differential pulse voltammograms for concentrations of 3 at 1000 µM (blue 
line), 500 µM (orange line), 250 µM (purple line), 100 µM (yellow line) and 10 µM (green 
line) in PBS with a glassy carbon macroelectrode (top) and the standard curve for 
differential pulse voltammetry analysis of 3 (bottom). Solid line is the fit with linear 





Figure 3.7. Standard curve of varying concentrations of 3 as measured by cyclic 
voltammetry. Potential was sweeped from 0 to -1 V with a glassy carbon macroelectrode 
in solutions of 3 and the peak reduction potential was taken for each concentration. 
Potentials are referenced against Ag/AgCl reference electrode. 
However, the reduction potential of 3 was found to overlap with the reduction 
potential of the phosphate species in PBS. Therefore, DPV could not be effectively 
employed for the quantification of Pt(IV) species in PBS. Focus was turned to 
developing NMR as an analytical technique for the rapid and quantitative 
determination of Pt(IV) species in aqueous solutions. 195Pt NMR affords sharp 
peaks over a large chemical shift range (-7000 to 1000 ppm) and as such, very 
small changes in structure can be seen with high resolution. In addition, there are 
clear differences in the range of chemical shift between the IV and II oxidation 
states: roughly 0 to 7500 ppm for Pt(IV) species and -6000 to -1000 ppm for 
Pt(II) species[197]. This method of analysis thus would afford a highly resolved, 
quantitative speciation. However, despite the relatively high natural abundance 
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of 195Pt (33.8%), the minimum concentration for discernible peaks with good 
signal-to-noise ratio was found to be ~8 mM of Pt complex 3 which was deemed 
unsuitable (Figure 3.8).  
 
Figure 3.8. 195Pt NMR spectra of 3, demonstrating the ease of analysis and speciation but 
with limitations in concentrations required for suitable noise/signal ratios. Spectra were 
acquired with 1024 scans in D2O and were post-processed with Whitaker Smoother.  
1H NMR was instead used, due to its high sensitivity allowing low concentrations 
to be analysed. Due to the strong residual H2O solvent signal, presaturation 
acquisition methods were explored to suppress the solvent signal allowing lower 
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limits of detection for the Pt(IV)-Pt(II) conversion. PBS solutions were diluted 2-
fold with D2O to allow solvent-locking and 3-trimethylsilylpropane sulfonic acid 
sodium salt was used as internal standard, due to its good aqueous solubility and 
characteristic trimethylsilyl singlet at ~0 ppm. From Figure 3.9, it can be seen 
that concentrations down to 10 µM of 3 could be clearly measured.  
 
Figure 3.9. Standard curve of varying concentrations of 3 in PBS/D2O with a constant 
internal standard (trimethylsilylpropylsulfonic acid) concentration of 100 µM, as 
analysed by 1H NMR with water suppression. The signal corresponding the protons of 
the axial ligands of 3 (▲) at each concentration were calculated as a percentage of the 
signal of the trimethylsilyl moiety of the internal standard (●). 
3.5 Identification of a suitable redox mediator 
 
Macroelectrodes with a gold working electrode surface were modified by 
creating a ternary self-assembled monolayer (tSAM) with the methylene blue 
derivative (MB-PEG-SH) and backfilled with thiohexanol (Figure 3.10). The 
methylene blue derivative was synthesised by employing solid-phase synthesis 
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techniques (Scheme 3.3). Previous work has shown that backfilling facilitates 
travel of the immobilised redox mediator to the electrode surface, presumably by 
preventing stacking and aggregation of the methylene blue aromatic 
moieties[43]. 
 
Figure 3.10. The ternary self-assembled monolayer composed of methylene blue units 
bound to the gold electrode surface, back-filled with thiohexanol. 
 This method allowed for efficient fabrication of a methylene blue-modified 
electrode (MB-tSAM) with immobilisation of the redox mediator to the electrode 
surface confirmed by CV. The characteristic reversible redox waves were 




Scheme 3.3. Synthesis of methylene blue derivative used for the formation of the MB-
tSAM. The grey bead represents the 2-chlorotrityl chloride linker on a polystyrene resin 
for solid-phase synthesis. The final product was composed of a methylene blue unit 
(blue), an ethylene glycol-based spacer (purple) and a mercaptohexamine moiety as an 
anchor (orange) to allow attachment. 
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With modified electrodes in hand, the capability of the MB-tSAM to reduce Pt(IV) 
species was interrogated. A potential of -0.3 V was applied to the MB-tSAM in a 
solution of Pt complex 3 (200 µM) in PBS and the reaction monitored by 1H NMR 
and LC-ICP-MS. No detectable or significant reduction in the Pt(IV) species was 
observed via NMR analysis. However, LC-ICP-MS showed a slight decrease in the 
levels of Pt(IV) and slight increase in Pt(II) species. It was postulated that 
although the methylene blue was capable of reducing the Pt(IV), this occurred 
too inefficiently to be useful, with the small number of methylene blue molecules 
immobilised on the electrode surface deemed to be a major factor. Thus, further 
methods of methylene blue immobilisation were explored where the methylene 
blue concentration could be increased. Previous studies have shown that 
methylene blue can be electro-polymerised onto an electrode surface and using 
the work of Brett as a basis, electro-polymerisation on the glassy carbon 
electrodes was developed and optimised[198, 199]. The specific mechanism of 
electro-polymerisation of MB remains elusive and may be an outcome of multiple 
different cross-linking varieties (due to sweeping between highly oxidative and 
reductive potentials)[198]. Scheme 3.4 shows two possible methods of cross-





Scheme 3.4. Postulated cross-linking pathways for the electro-polymerisation of 
methylene blue monomers and the possible implicated one-electron oxidation species. 
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Regardless, this method of immobilisation afforded an efficient and reproducible 
route to polymethylene blue-modified electrodes (PMB) with tuneable control 
over the quantity of MB immobilised controlled by the application time and 
concentration of monomer solution. It was found that fifteen CV scans between 
- 0.6 V and +1.2 V at 50 mV.s-1 afforded robust devices, while increasing the 
number of deposition scans or lowering the scan rate yielded devices which 
showed reduced amplitude of methylene blue redox waves, suggesting that the 
approach of the redox mediator to the electrode surface was impeded by over-
polymerisation (Figure 3.11).  
The Pt(IV) reduction capabilities of the PMB electrodes were measured and 
analysed via NMR and LC-ICP-MS. As with the MB-tSAM modified electrodes, little 
conversion was observed. It was postulated that methylene blue was not a 
suitable redox mediator for the Pt(IV) reduction and so a screen of mediators in 
solution (with a 1:2 molar ratio of redox mediator:Pt(IV)) with a potential 





Figure 3.11. Cyclic voltammograms confirming the presence of polymerised methylene 
blue on screen-printed carbon ink electrodes. The optimal conditions were methylene 
blue (1 mM) in aqueous (NH4)2SO4 (0.1 M) with the potential swept from -0.6 V to +1.2 
V at 50 mV.s-1 for fifteen scans (blue line). Increasing the scan rate to 200 mV.s-1 (purple 
line) or 100 mV.s-1 (red line) or increasing the number of scans to thirty yielded devices 
with much lower amplitude of the redox peaks of methylene blue. Potentials are 




Scheme 3.5. Structures of the tested redox mediators 
Redox mediators screened included indigo carmine, methyl viologen, (-)-
riboflavin and hexammineruthenium chloride ([Ru(NH3)6)Cl3]) (Scheme 3.5). 
These redox mediators were selected due to their reduction potential occurring 
at a lower potential than that of the Pt(IV) complexes synthesised.  
Of these, it was found that [Ru(NH3)6Cl3] offered the best performance in 
reducing the Pt(IV) species whereas indigo carmine and methyl viologen gave no 
conversion. Riboflavin gave modest conversion however was discounted due to 
its relatively high reduction potential. A bulk electrolysis experiment consisting 
of 6 (100 µM) and [Ru(NH3)6]Cl3 (50 µM) was subjected to a constant potential 
of -0.4 V and was analysed by HPLC and showed good conversion of 6 to the active 




Figure 3.12. The conversion of 6 (100 µM) over time following the application of -0.4 V 
with and without [Ru(NH3)6]Cl3 (50 µM) in PBS as measured by HPLC at 254 nm: solid 
line and dashed line, respectively. 
3.6 Fabrication of discrete redox mediator modified electrodes 
 
Immobilisation of [Ru(NH3)6)Cl2] onto an electrode surface presented a challenge 
due to the lack of handle for electropolymerisation. Therefore, a novel redox 
mediator, pentaammine(vinylpyridine)ruthenium chloride (Vp-Ru) based on 
[Ru(NH3)6)Cl2] was designed and synthesised with replacement of one ammine 
ligand with a vinylpyridine (Scheme 3.6). The installation of a vinyl moiety would 
theoretically afford the handle required for electropolymerisation. The 
substitution of the chloro ligand for the vinylpyridine was successful (as 





Scheme 3.6. Synthesis of monodentate vinylpyridine pentammine ruthenium complex. 
Instead, direct adsorption of the redox mediator to the electrode surface, utilising 
a polymer support for the redox mediator was explored. Previous work by Unwin 
has shown that Nafion was an effective polymeric support for related redox 
mediators, including Ru(bpy)3Cl2[200]. Nafion is a polymer with a 
tetrafluoroethylene backbone with pendant sulfonates and is used as a proton 
conductor, in fuel cells, as the network of sulfonates allows a proton to be shuttled 
through the polymer[201]. Deposition of Nafion affords a porous structure that 
facilitates the transport of cations but excludes anions and electrons. This 
characteristic was exploited for the immobilisation [Ru(NH3)6)Cl2] to encase the 
redox mediator through electrostatic interactions between the positively charged 
redox mediator and the negatively charged Nafion polymer layer. As the Nafion 
layer excludes anions, it may also benefit the application of devices in biological 
complex systems by providing a blocking effect between potential interferents 
and the redox mediator and electrode surface. The redox mediator was found to 
act as a conduit of electrons from the electrode surface and the Pt(IV) species, 
with the mechanism hypothesised to be a chain of redox mediators shuttling 
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electrons to and from each other forming an electrocatalytic network throughout 
the Nafion volume.  
The method of functionalising Nafion-bound [Ru(NH3)6)Cl3] onto the glassy 
carbon disposable screen-printed electrodes was optimised to afford functional 
modified electrode devices (MED). Thin layer Nafion-coated electrodes were 
made by drop-coating the Nafion solution (5% w/v in water and lower aliphatic 
alcohols) directly onto the working electrode surface and allowing the solvent to 
air-dry. The dried Nafion-coated electrode was then soaked into an aqueous 
solution of the redox mediator (in the oxidised form), rinsed with water to 
remove any non-adherent redox mediator and stored wet (Figure 3.13). The 
modified electrodes were unable to be dried and re-wetted without loss of the 
redox mediator signals. This may be due to changes in the morphology of Nafion 
upon hydration-dehydration cycles preventing the redox mediator from being 
retained its adherence, as has been observed in other studies[202]. During 
fabrication of the electrodes, the oxidised form of the redox mediator, 
[Ru(NH3)6]3+, was used. The reasons for this were two-fold: the increased 
positive charge will facilitate binding and integration of redox mediator into the 
Nafion layer and the oxidised form will need to be reduced electrochemically 
before it can reduce Pt(IV) species, thereby preventing any latent Pt(IV) 
reduction by only incubation of the modified electrode in a solution of 6 (without 




Figure 3.13. Fabrication of the modified screen-printed carbon electrodes. 
Hexaammineruthenium (the redox mediator) is encapsulated, exploiting its positive 
charge, into the negatively charged Nafion polymer layer. 
Successful entrapment of the redox mediator was confirmed by CV analysis in 
PBS with the immobilised [Ru(NH3)6]3+ showing the expected reversible redox 
behaviour. In comparison, the redox mediator in solution, i.e. non-adhered to 
electrode surface, the redox waves were shifted slightly more negatively when it 
was incorporated in Nafion (see Figure 3.14).  
In addition, the redox mediator’s interactions with the electrode surface was 
shown to be diffusion-limited by investigating the changes in peak current in 
response to changing the scan rate of the cyclic voltammetry. There was a linear 
proportional response in peak current (A) to the square root of the scan rate 
(mV.s-1) demonstrating that the current associated with the redox mediator’s 
processes were dependent upon the rate at which the mediator could diffuse to 
and from the electrode surface (“diffusion-limited”), as defined by the Cottrell 
equation: 








where I = peak current (A), n = number of electrons implicit, F = Faraday 
constant, A = area of electrode (cm2),  𝑐𝑗
0  = initial concentration of mediator 
(mol.cm-3), D = diffusion coefficient and t = time (s). Where redox processes fit 
linearly to the plot of I vs t-1/2, there is a diffusion-limited process occurring 
whereas deviations from this suggest other possibilities. Therefore, it can be seen 
that the Nafion entrapment of the redox mediator does not hold the redox 
mediator tightly to the electrode surface, otherwise a “surface-controlled” 
processes would be observed where the peak current would be directly 
proportional to the scan rate. This is further evidence that an electron-shuttle 
network has been formed throughout the Nafion layer, where the redox mediator 
can move freely and transfer electrons from molecule to molecule. 
 
Figure 3.14. Cyclic voltammetry of the modified electrodes showed a dependence of peak 
current on scan rate (left) and plot of √Scan rate against peak current demonstrating the 




The modified electrodes were further characterised in terms of stability and 
leaching. CV analyses were taken at 0 and after 24 h in different biological media 
to assess the capability of the polymeric encapsulation of redox mediator to 
withstand interference from components of complex media.  It can be seen from 
Figure 3.15 that the modified electrode was robust towards interference from 
biomolecules. There was a slight deviation from the expected redox behaviour in 
10% FBS solution, which may be attributed to protein binding on the 
Nafion/electrode surface. Despite this, the characteristic redox waves can still 
clearly be observed. 
 
Figure 3.15. Cyclic voltammograms recorded for modified electrodes in phosphate 
buffered saline, foetal bovine serum, HCT 116 cell lysate before (dashed line) and after 
24 h (solid line) incubation. Potentials are relative to the Ag pseudo-reference. 
It is imperative for biological applications, particularly future in vivo experiments 
that the redox mediator does not leech out of the Nafion membrane. Leeching of 
the redox mediator would disable the Pt(IV) reduction/activation capabilities  of 
the modified electrodes and would also lead to safety concerns. Therefore, the 
total quantity of redox mediator entrapped in the Nafion layer was quantified and 
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the percentage that leached examined. The cytotoxicity of the redox mediator was 
also investigated. 
Determination of the total Ru content of the device was analysed by ICP-OES. The 
carbon ink (to which the Nafion-redox mediator system was adhered to) was 
subjected to digestion by aqueous nitric acid to ensure total degradation (and 
dissolution) of the Nafion-encased redox mediator. As can be seen in Figure 3.16, 
the device fabrication process yielded devices with little deviation between 
electrodes and with an average content of 1.08 ± 0.02 µg (n = 5) of Ru.  
 
Figure 3.16. ICP-OES standard curve for Ru detection at 350 nm with RuCl3 as an external 
standard (left). Samples are decomposed by the inductively-couple plasma to their 
atomic components. The wavelength selected is that at which the excited state 
ruthenium ions and free atoms emit as they decay to lower energy states. Five modified 
electrodes were quantified for their total Ru content by ICP-OES analysis (right). 
While this was the total content of Ru held within the Nafion membrane, it is not 
a measure of the redox-active mediator; that is, the proportion of redox mediator 
that can approach the electrode surface and participate in redox reactions. In 
82 
 
order to do this, the differences in charge density were compared between a 
blank SPCE and a Nafion-modified electrode, when a potential of -0.4 V was 
applied in a solution of KCl (aq., 0.1 M). The average charge for each type of device 
(modified and non-modified) was measured by chronoamperometry over 400 s 
and the difference calculated (n = 3), negating background currents (solvent 
effects and non-Faradaic processes) to allow analysis solely on the effects caused 
by the redox mediator (Figure 3.17). The redox-active proportion of 
encapsulated redox mediator was then calculated by coulometric analysis using 
the equation: 
𝑄 = 𝑛𝐹𝐴𝛤 
where Q = charge in Coloumbs, n = number of electrons involved in the redox 
process, F = Faraday’s constant (C.mol-1), A = geometric area of electrode (m2) 
and Γ = surface coverage or surface concentration (mol.m-2). The surface 
coverage can then be related to the mass of redox mediator (m) that is redox-
active, from the molecular weight of [Ru(NH3)6]3+. The redox-active content of 
the redox mediator was found to be 0.84 µg per device (see above calculation and 




Figure 3.17. Amperometric quantification of redox-active [Ru(NH3)6]Cl3 contained in a 
modified electrode in comparison to the total charge after 400 s of application of -0.4 V 
for non-modified electrode (dashed line) and modified electrode (solid line). 
The leaching of Ru was analysed by ICP-OES. Potential (-0.4 V) was applied with 
modified electrodes submerged in aqueous solution and after 24 h of application 
the electrodes were removed and the Ru content of the solutions quantified. 
Figure 3.18 shows that the leached Ru levels were around 10% of the total 





Figure 3.18. ICP-OES standard curve for Ru detection at 350 nm using RuCl3 as an 
external standard (left) and quantification of the Ru leached from the modified 
electrodes over 24 h (right).  
Despite the minimal leaching, it was necessary to confirm (particularly for 
biological experiments) that this leaching would not cause cell death and would 
not interfere with the cell viability assays. The cytotoxicity of both the reduced 
([Ru(NH3)6]2+) and the oxidised ([Ru(NH3)63+]) form of the redox mediator were 
analysed by an MTT assay (Figure 3.19). These two forms of the redox mediator 
were both well-tolerated by HCT 116 cells (up to 10 µM with no reduction in cell 
viability seen up until this concentration). Increasing the concentration up to 100 
µM showed that high concentrations of the reduced form of the redox mediator 
were cytotoxic. However, assuming the total content of each modified electrode 
leached out into cell-containing media (3.4 mL used for 24-well plate), the 
maximum concentration the cells would be exposed to would only be around 1.19 




Figure 3.19. Cell viability for HCT 116 cells treated with [Ru(NH3)6]Cl2 (grey bars) and 
[Ru(NH3)6]Cl3 (black bars). Cells were treated with 0 μM to 100 μM of the oxidised form 
of the redox mediator, [Ru(NH3)6]Cl3, or the reduced form, [Ru(NH3)6]Cl2, and incubated 
for 72 h (n = 3) to verify that any Ru potentially leached from the device would not have 
any effect on cell viability†. 
3.7 Characterisation of Pt(IV) reduction by the modified electrodes 
 
It had now been confirmed that the modified electrodes could be fabricated with 
desirable properties, namely: good total uptake into the Nafion layer; minimal 
leaching of the redox mediator from the Nafion layer and ability to retain their 
redox properties in biological milieu. With these devices in hand, focus was 
turned to characterising the Pt(IV) reduction profile. The optimal Pt(IV) species 
for electrochemical activation in cellulo was considered initially. Ideally this 
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Pt(IV) species would be bio-inert, i.e. it would not be reduced, activated or 
degraded biologically, and would be non-toxic until activated to the active Pt(II) 
species. Additionally, as the electrode would be positioned outwith cells 
(suspended above cellular monolayers in the cell media) it was also important 
that the chosen Pt(IV) species was not taken up into cells and would be retained 
in the cell media until activation. Cell uptake of molecules can be modulated by 
that molecule’s charged state. For instance, cell membrane penetrant peptides 
are generally mainly composed of cationic residues (Arg, Lys, etc.), as they are 
attracted to the predominantly negatively charged surface charge of cell 
membranes, arising primarily from the head section of phospholipids where 
phosphate moieties are presented (see Chapter 1). Vice versa, negatively charged 
molecules and nanoparticles are subject to reduced cell uptake due to the 
electrostatic repulsion between the negatively charged molecule and the 
negatively charged membrane. These mechanisms are overcome by active 
transport and cell surface channels.  
It was therefore postulated that a negatively charged Pt(IV) species would be 
optimal for electrochemical activation. Previous work by Sessler utilised the 
disuccinato Pt(IV) complex 6 showed remarkable stability towards biological 
reductants. Following synthesis of this Pt(IV) complex (6), the cytotoxicity of this 
compound was analysed on HCT 116 cells by an MTT assay and compared to that 
of the concordant active-drug Pt(II) species, oxaliplatin (OxPt) (Figure 3.20). 
There was good disparity in the toxicity of 6 and the OxPt; desirable for turn-on 




With bio-inert Pt(IV) species 6 identified, the reduction by the modified 
electrodes was characterised. The change from cisplatin-based prodrugs to 
oxaliplatin-based prodrugs afforded compounds with increased hydrophobicity 
and also contained 1H-NMR detectable fragments from the 1,2-
diaminocyclohexane equatorial bidentate ligand which facilitated analysis by 
HPLC and NMR, respectively. 
 
Figure 3.20. Cell viability of HCT 116 cells treated with oxaliplatin (black bars) and the 
Pt(IV) prodrug 6 (grey bars), as analysed by an MTT assay. Cells were treated with 0 μM 
to 100 μM of the Pt(IV) prodrug, 6, or oxaliplatin and incubated for 72 h (n = 3). 
With bio-inert Pt(IV) species 6 identified, the reduction by the modified 
electrodes was characterised. The change from cisplatin-based prodrugs to 
oxaliplatin-based prodrugs afforded compounds with increased hydrophobicity 
and also contained 1H-NMR detectable fragments from the 1,2-
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diaminocyclohexane equatorial bidentate ligand which facilitated analysis by 
HPLC and NMR, respectively.  
The oxidised form of the redox mediator, [Ru(NH3)6]3+, was reduced at the 
electrode surface by applying a potential of -0.4 V to afford [Ru(NH3)6]2+, which 
was able to reduce the Pt(IV) species, becoming re-oxidised in the process and 
closing the electro-catalytic cycle (Figure 3.21).  
 
Figure 3.21. Hexaammineruthenium is a one-electron redox mediator, therefore two 
equivalents are required to reduce the Pt(IV) species to the Pt(II). The reduced form of 
the redox mediator can then be regenerated at the electrode surface. 
Prodrug 6 was found to be relatively stable in 10% FBS at 37 °C (16% degradation 
after 24 h, n = 3) and towards reduction by glutathione and ascorbic acid with 
<10% decrease in Pt(IV) levels after 24 h at 37 °C (Figure 3.22). The decrease in 
the concentration of 6 in 10% FBS is likely due to low levels of bio-activation by 




Figure 3.22. Stability of 6 towards gluthathione (GSH) and ascorbic acid (AsA) in PBS 
(top) and towards 10% FBS (bottom), as measured by HPLC. For the ascorbic 
acid/glutathione assay, a solution of 6 (100 μM) in PBS at 37 °C was treated with AsA or 
GSH to give final concentrations of 1 mM of each reductant. HPLC analysis was carried 
out at each time-point with detection at 254 nm. For testing the stability of 6 in 10% FBS, 
a solution of 6 (100 µM) was used and HPLC analysis carried out as above. 
The ability of the modified electrode to function in biological media was assessed 
in 10% FBS and in HCT 116 cell lysate. As noted above, CV analysis over 24 h 
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showed that the modified electrode retained reversible redox behaviour 
characteristic of the Ru(III)/Ru(II) couple (Figure 3.15) with only incubation in 
cell lysate showing a change in redox processes, attributed to protein binding 
affecting the redox mediator and its interactions within the Nafion layer. Despite 
this, the electro-activation of 6 was not significantly affected in cell lysate and also 
performed well in 10% FBS (Figure 3.23). 
 
Figure 3.23. Reduction of 6 after application of -0.4 V with modified electrode (MED), 
non-modified electrode (NME) and with no potential applied in PBS, 10% FBS and HCT 
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116 cell lysate after 24 h. For each medium, solutions of 6 (100 µM) were made, potential 
was applied with either a modified electrode, non-modified electrode or no potential was 
applied with HPLC analysis after 24 h. 
 
It can be seen that the level of reduction was slightly diminished when the 
solution changed from simple PBS to complex media (FBS or cell lysate) but only 
by around 15-20%. The utilisation of the modified electrode also afforded more 
efficient reduction than application of potential with an unmodified electrode. In 
addition, the reaction where the modified electrode was used was deemed to 
occur much more “cleanly” than with an unmodified electrode (Figure 3.24). LC-
MS analysis of the two reaction solutions in PBS showed stark differences, with 
the unmodified electrode solution containing many Pt species (identified by their 
characteristic isotopic splitting), whereas LC-MS analysis of the reaction with the 




Figure 3.24. A representative example of the differences in Pt species formed by electro-
activation of 6 using a modified electrode (top) and using a non-modified electrode by 
LC-MS analysis (negative mode). Where a modified electrode, both oxaliplatin and the 
prodrug 6 can clearly be seen. The reaction with a non-modified electrode produces 
many undesirable Pt species. 
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Quantification of the generation of OxPt was determined. The oxalate ligand in 
oxaliplatin is not stable towards chloride-containing medium and upon 
displacement of the oxalate ligand by chlorides the UV absorption (facilitating 
HPLC analysis) is lost. This has been well-studied and unlike cisplatin, oxaliplatin 
is administered in chloride-free carrier solutions usually in the form of 5% 
dextrose solution to prevent formation of the active Pt(II) species [(1,2-
diaminocyclohexyl)PtCl2]. This is a disadvantage of OxPt administration as it can 
affect electrolyte balance and trigger hyperglycemia in patients.  
A post-derivatisation analytical method was required that would react with the 
resultant [(DACH)PtCl2] in solution to produce an easily-identifiable conjugate. 
For this purpose, guanosine monophosphate (GMP), was employed. Pt-based 
cancer therapies are known to be thermodynamically-driven to react with 
guanosine bases in DNA as their main DNA-chelation mechanism. This is due to 
the hydrogen-bonding between amine or ammine ligands of the Pt species and 
the carbonyl of the DNA base, expediting the attack of N7 to the Pt centre (Figure 
3.25). This mechanism affords a simple and effective method to visualise Pt(II) 




Figure 3.25. Pre-functionalisation assay for Pt(II) based on the thermodynamically-
favoured preferential binding of cisplatin to guanosine monophosphate which affords a 
UV-active complex that facilitates analysis by HPLC with detection at 254 nm. Both 
chloride ligands can be displaced first by aquation then by nucleophilic attack of the N7 
position of guanosine.  
Addition of excess GMP to the reaction solution with HPLC analysis thus allowing 
the quantification of the Pt(II) species. To analyse that the peaks believed to be 
associated with the GMP adducts of Pt(II) species, the peak was collected by 
preparative HPLC and subjected to LC-MS analysis. The GMP bis-adduct of OxPt 
was found (identified by a m/z of 1031 and supported by the expected isotopic 
splitting pattern). The representative HPLC spectra in Figure 3.26 shows an 
increase in the Pt(II)-GMP2 peak (peak b) over time, with a corresponding 




Figure 3.26. HPLC analysis with detection at 254 nm showing the decrease in Pt(IV) 
prodrug 6 over time, peak (c). (a) = excess GMP (b) = OxPt-guanosine monophosphate 
adduct (c) = 6. Inset shows LC-MS analysis of peak (b) confirming it to be the bis-adduct 
guanosine monophosphate of oxaliplatin. 
Since a sufficient method of analysis had been developed for Pt(II) species, 
quantification was carried out for electro-activation with the modified electrode, 
with a non-modified electrode and with no potential applied (Figure 3.27). It can 
be seen that, despite the non-modified electrode having a conversion of Pt(IV) 
around 20% less than that of the MED, there was a significantly lower yield of the 




Figure 3.27. Quantification of Pt(II) species formed by electro-activation with modified 
electrodes (MED), compared to that with a non-modified electrode (NME) and where no 
potential was applied. After 24 h, the solutions for each condition were incubated with 
excess GMP (final concentration of 1000 µM) at 37 °C for 2 h and subjected to HPLC 
analysis.   
This can be explained by the redox mediator facilitating “cleaner” Pt(IV)-Pt(II) 
conversion to the desired products whereas with the bare electrode surface 
unselective reactions were occurring. The absence of the Nafion exclusion layer 
would allow the approach of many electro-active species that could lead to 




Scheme 3.7. Reaction scheme showing the major reaction of 6 occurring upon application 
of -0.4 V with modified electrodes (top) and one possible side-reaction occurring on the 
non-modified electrodes (bottom).  
The effect of pH on the redox-mediated electrochemical reduction of Pt(IV) 
prodrugs was explored in order to confirm that a mediated mechanism was 
occurring, and not direct reduction at the electrode surface. The redox processes 
of the redox mediator are pH-independent, however the reduction process of 6 
are pH-dependent (Figure 3.28). Therefore, it was postulated that, sufficient pH 
deviation from pH 7 by the electrochemical processes, direct reduction would 




Figure 3.28. The pH-dependency of the reduction potential of 6. The reduction potential 
of 6 (2 mM) was measured by cyclic voltammetry in solutions of varying pH. The dashed 
lines extrapolates the pH required for direct reduction to occur at -0.4 V (the potential 
applied with the modified electrodes). Therefore, for direct reduction to occur at -0.4 V, 
a pH of 2 is required. 
It can be seen that at pH values ≤ 2, it may be possible for direct reduction of 6 to 
occur. The pH of the reaction solution was measured following 24 h of applied 
potential (Table 3.1) and showed that there was a slight decrease in the pH, 
presumably from the acidic axial ligands, but after 24 h the pH increased from 
6.91 to 7.41, with the corresponding reduction potential of 6 altering from -0.79 
to -0.81 V. This provides good evidence that the electrochemical Pt(IV) prodrug 
activation is a mediated reduction process, as opposed to direct reduction. 




Before addition of 6 6.99 ± 0.01 
After addition of 6 6.91 ± 0.04 
After 2 h conversion 6.93 ± 0.05 
After 4 h conversion 6.99 ± 0.02 
After 8 h conversion 7.14 ± 0.06 
After 24 h conversion 7.41 ± 0.06 
 
The small observed increase in pH over time may be explained by reactions 
occurring at the electrode surface unrelated to the Pt(IV) reduction, namely the 
reduction of oxygen (Equation 3.1), a process which consumes protons and 
therefore affects pH. 
 
 




3.8 In vitro validation of the Pt(IV) prodrug activation systems  
 
The capability of the electrochemical Pt(IV) prodrug activation system to 
translate to biological applications was examined. HCT 116 cells, a human colon 
carcinoma cell line, were used for these experiments, as oxaliplatin is an FDA-
approved treatment for colon cancer. It can be seen from Figure 3.20 that the 
largest difference between the cytotoxicity of the active Pt(II) species, OxPt and 
the prodrug 6 occurs at a concentration of 50 µM, therefore this concentration 
was selected for cell experiments. Experiments were designed with three 
controls: untreated cells where no Pt species or electrode was introduced; “-0.4 
V” where only a potential was applied with a modified electrode; “6” where only 
the Pt(IV) prodrug 6 was incubated with cells. The experiments combined the use 
of a MED, with application of potential at -0.4 V and incubation of 6 (50 µM).  
The electro-activation of Pt(IV) prodrugs must occur at the electrode surface and 
cannot be done inside cells. As postulated above, the disuccinato Pt(IV) prodrug 
6 is negatively charged, so should not be taken up into cells which is of benefit to 
the electro-activation process. Prodrug 6 was dissolved in cell media and was 
added to HCT 116 cells grown in a 24-well plate. The modified electrode was then 
suspended above the cells, with the electrodes submerged in the Pt(IV)-
containing cell media, and a potential applied for 1 h at 37 °C and 5% CO2 





Figure 3.29. Set-up of the equipment for electrochemical Pt(IV) prodrug activation in cell 
culture. Modified electrodes were connected to a portable potentiostat, with the 
electrodes’ surfaces submerged in cell media and positioned above a monolayer of cells.  
Cell viability was analysed by an MTT assay. It can be seen from Figure 3.30, that 
each component of the system (potential and prodrug 6) alone had negligible 
cytotoxicity, whereas a stark reduction in cell viability is observed when all 
components of the system were combined (72% total cell death). This trend is 
corroborated by an increase in the intracellular Pt content in cells where 6 was 




Figure 3.30. Cell viability, as measured by an MTT assay (n = 3), showing the increased 
cytotoxic effect caused by the electro-activation of 6, compared to controls. Potential was 
applied for 1 h and cells were incubated for 72 h. The data represent the mean ± S.D. *** 
P<0.001 by one-way ANOVA with Dunnett post-test, compared to the untreated control 
group. Red squares ( ) indicate the intracellular Pt content per million cells for each 
reaction condition, as analysed by ICP-MS (n = 3). 
To further probe the effects of the electrochemical prodrug activation, apoptosis 
onset was quantified by an Annexin-V-FITC conjugate labelling. Upon initiation of 
apoptosis, cells translocate phostidylserine protrusions from the inner face of the 
cell membrane to the outer face. Annexin-V is a protein with high affinity for 
phosphatidylserine, such that fluorescent conjugates allow simple monitoring of 
phosphatidylserine levels and thus quantification of cellular apoptosis. Figure 
3.31 shows HCT 116 cells treated with either the reductive potential or 6 alone 
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and in conjunction and analysed with Annexin-V-FITC, 24 h post-activation. It can 
be seen there are more apoptotic cells where 6 has been activated 
electrochemically.  
 
Figure 3.31. Fluorescent microscopy showing HCT 116 cells with nuclei stained (blue) 
and Annexin-V-FITC (green) showing the presentation of phosphatidylserine residues 
indicating apoptotic onset. (i) untreated, (ii) -0.4 V only, (iii) 6 (50 µM) only, (iv) 6 (50 
µM) and -0.4 V. Contract and brightness have been increased by 40% for all figures from 
raw data. † 
The fluorescence related to apoptotic onset was quantified by flow cytometry 





Figure 3.32. Quantification of apoptotic onset with an Annexin-V-FITC assay, as 
measured by flow cytometry. (i) untreated, (ii) -0.4 V, (iii) 6 (50 µM), (iv) 6 (50 µM) and 
-0.4 V. † 
As alluded to above in regards to platinum binding to GMP and other nucleobases, 
the primary mechanism of action of Pt-based anticancer therapies is through DNA 
alkylation/chelation. There are differences between the mechanisms of cisplatin 
and oxaliplatin, which may account for the discrepancy in the type of cancers the 
two drugs are indicated for and their respective side-effect profile (see Chapter 
1). Carboplatin is believed to exhibit similar mechanistic characteristics to 
cisplatin (and is cross-resistant to cisplatin), albeit with a slower dissociation rate 
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of the leaving ligands (Cl in cisplatin, and cyclobutyldicarboxylic acid bidentate 
ligand in carboplatin). The difference in rates of ligand-dissociation or complex-
aquation in cisplatin and carboplatin is believed to account for the limited off-
target toxicities of carboplatin, whereas cisplatin exhibits a harsh toxicity profile, 
due to its highly reactive and labile chloro leaving ligands. These properties may 
be a double-edged sword with respect to treatment however; despite the reduced 
toxicity of carboplatin in general it is less effective and requires a multiple-fold 
increase in dose given to achieve the same effect as cisplatin. There is evidence 
for different mechanisms of cytotoxicity ascribed to oxaliplatin, other than DNA 
inter- and intra-strand crosslinking. These include immunological stimulation by 
oxaliplatin, by translocation of immunogenic signals on the cell surface[79]; and 
prompting ribosomal biogenesis stress[81]. Regardless of the convolution and 
ambiguity pertaining to the mechanism of action of oxaliplatin, quantification of 
Pt-DNA adducts is still used as a measure of efficacy.  
This was done by extracting the whole-cell DNA content and the Pt content 
determined by ICP-MS. Incubation of 6 alone (without activation) displayed 
much less DNA platination (around 5.5-fold) compared to that of 6 with 
activation at -0.4 V, further showing that electrochemical activation was effective 




Figure 3.33. Quantification of DNA-platination in HCT 116 cells with either incubation of 
6 alone or in combination with potential and modified electrode, as measured by ICP-MS. 
After 24 h of incubation post-activation, cells were lysed and analysed for Pt 
content by ICP-MS (Figure 3.34). There was observed a higher Pt content when 
the prodrug 6 had undergone electrochemical activation; indeed some 9.5-fold 




Figure 3.34. Quantification of whole-cell platinum content in HCT 116 cells with either 
incubation with 6 alone or in combination with potential and a modified electrode, as 
measured by ICP-MS.  
In an effort to validate the safety of the modified electrode, the ruthenium content 
of cells was quantified, to show the proportion of redox mediator that may have 
leached out of the Nafion layer during Pt(IV) prodrug activation. Cells were again 
lysed, pelleted and analysed by ICP-MS (Ru content was 0.20 ± 0.05 ng per 106 
cells which equates to around 0.02% of the total Ru content found in the modified 
electrode). This exemplifies the remarkable stability of the electrostatically-
bound redox mediator. 
While 2D monolayer cell culture is used ubiquitously in cancer research, 
primarily due to its low cost, high reproducibility and high-throughput, it does 
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have caveats that must be addressed. Cells are grown on the flat surface of tissue 
culture plastic. This does not translate to how cells are organised in live 
organisms and does not consider complexities associated with ECM production 
and mechanical stimuli (e.g. stiffness/softness of environment). Cells grown in a 
2D monolayer can present with contrasting characteristics to their counterparts 
in vivo: levels of gene expression can be different[203, 204], there are minimal 
nutrient and oxygen gradients[205] and there may be less barriers toward drug 
resistance and penetration (as a result of the lack of ECM production and altered 
morphology)[204, 206]. The tumour microenvironment plays a critical role in 
drug resistance and penetration and so a lack of tumour microenvironment (as 
in 2D cell culture) may be related to “false efficacy”. The flattened morphology of 
cells grown in 2D may also contribute to this. There are multiple ways to mimic a 
neoplastic environment in 3D cell culture. Scaffolds can be used that hold and 
allow cell-binding in attempts to mimic ECM or stimulate ECM production[207]. 
A range of hydrogels and moulds/inserts for cell culture are now commercially 
available, however these are often expensive and require highly optimised 
conditions to facilitate reproducibility. Non-scaffold-based methods are generally 
low-cost and more easily reproducible. Generation of cellular aggregates, termed 
cell spheroids, can be accomplished by the hanging drop method, where cells are 
suspended in a drop of media, hanging from a well plate lid by surface 
tension[208]. The cells aggregate and ultimately form a multi-cellular tumour 
spheroids which display characteristics comparable to in vivo tumours. They 
have similar ECM-cell and cell-cell interactions, ECM production, drug resistance 
profiles and can exhibit hypoxia and necrosis[209-211]. To further validate the 
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redox-mediated Pt(IV) prodrug activation, tumour spheroids were grown and 
subjected to the Pt(IV) prodrug electro-activation process. 
Spheroids were generated from HCT 116 cells by the hanging drop method[212, 
213]. On day 5 of culture, spheroids were transferred from the hanging drop to 
an agarose-coated 24-well plate and treated with 6 followed by electro-activation 
at -0.4 V for 1 h. Cell viability was measured (CellTiter Glo 3D Cell Viability kit) 
after 3 days incubation which showed no decrease in cell viability in spheroids 
treated only with 6 (Figure 3.35). A 50% decrease in spheroid-cell viability was 
observed when 6 was activated electrochemically. 
 
Figure 3.35. Cell viability of HCT 116 MCTS treated with 6 (50 µM) and -0.4 V applied for 
1 h, and incubated for 72 h (CellTiter Glo 3D assay, n = 3). The data represent the mean 
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± S.D. *** P<0.001 by one-way ANOVA with Dunnett post-test, compared to the 
untreated control group. † 
 The live and dead cells were also identified visually with a live/dead assay and 
imaged by fluorescent microscopy. This assay uses a green-fluorescent calcein-
AM to indicate intracellular esterase activity and a red-fluorescent ethidium 
homodimer-1 to indicate loss of plasma membrane integrity. Figure 3.36 shows 
there was an increased number of dead cells (those without an intact plasma 
membrane) where all of the components of the electrochemical prodrug 
activation system are combined, compared to controls. The size of the spheroids 
is also an indicator of their health. It can be seen that the largest diameter of the 





Figure 3.36. Live (i, green) and dead (ii, red) staining of HCT 116 spheroids and merged 
images (iii). The electro-activation of 6 was carried out for 1 h and spheroids were 
incubated at 37 °C for 72 h before staining and imaging. † 
The apoptotic onset caused by electro-activation of 6 in HCT 116 spheroids was 
explored by an Annexin-V luciferase fusion proteins assay. This assay contains 
two different Annexin-V fusion proteins: each with a truncated non-functional 
luciferase attached. Upon translocation of phosphatidylserine to the outer leaflet 
of cell membranes, the Annexin-V units bind and, in close proximity, afford a 
functional luciferase.  This allows real-time monitoring of the onset of apoptosis 
by measurement of luminescence. As can be seen in Figure 3.37, the apoptotic 
onset only occurs at its highest level where all components of the electrochemical 
prodrug activation system are utilised. Collectively, these data demonstrate the 
applicability for electrochemical mediation to switch-on cancer prodrugs, with 




Figure 3.37. Real-time monitoring of the onset of apoptosis in HCT 116 cells caused by 
the electro-activation of 6 for 1 h. Cells were incubated with a RealTime-Glo™ Annexin V 
Apoptosis assay with luminescence increase monitored at different time points. The data 
represents the mean ± S.D, n = 3. 
 
Conclusions and Outlook 
 
An electrochemical Pt(IV) prodrug activation system has been developed and its 
functionality validated in biological settings. The activation was done via a 
mediated approach so as to utilise a relatively low potential, thereby reducing 
biological interferences. To our knowledge, this is the first prodrug activation 
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system that uses electrical signals as an actuator for prodrug activation, instead 
of enzymatic or other biological processes or other physical stimuli, such as light.  
This system was developed with an implantable sensor/activator in mind, which 
could be placed at the site of the tumour. In vitro assessment of the redox-
mediated Pt(IV) prodrug activation system demonstrated the capability of the 
system to use electrons delivered by an applied potential as a prodrug activation 
strategy. Translation towards in vivo applications will require further 
miniaturisation of the modified electrodes to facilitate implantation. Different 
approaches to implantation will also need to be explored, as the location and the 
number of implanted electrodes will be critical to the efficacy of the prodrug 
activation system. Devices should be implanted adjacent to a blood supply to 
maximise exposure to the incoming Pt(IV) prodrug. The device in its current state 
may need “re-engineering” in order to be effective in vivo i.e. a flat-surfaced 
electrode may not be the ideal format for this application. An electrode that could 
be implanted in a similar way to a stent, a tube inserted into vasculature to hold 
the vessel open, may be of great benefit as it would facilitate contact with the 
prodrug and would maximise the surface area of the electrode. Such electrode-
stents are currently under development for chronic recording of neural 
activity[214] and have potential for overlap in applications. 
The immobilisation of the redox mediator should also be further explored. While 
the electrostatic encapsulation of the mediator in Nafion showed good stability 
and retention. Modification of the ligands of hexaammineruthenium could afford 
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a handle for covalent attachment of the mediator to the electrode surface to 
prevent leaching of the mediator in vivo. 
In order to effectively use this prodrug activation system to deliver 
chemotherapeutics, the effect of the route of administration of the Pt(IV) prodrug 
will also need to be investigated. Oral administration may lead to variable uptake 
and affect the quantity of Pt(II) generated by the device. However, it is 
theoretically possible that the Pt(IV)-Pt(II) conversion can be monitored and 
quantified in real-time by measuring the charge generated. Immediate in situ 
information regarding the doses of Pt(II) being formed could be a step towards 
personalised anti-cancer treatment. In addition, the spatial selectivity achieved 
by stereotactic implantation of the device could greatly benefit patients’ quality 






Photo-activation of Pt(IV) prodrugs with 




Light has proven to be a useful tool in photodynamic therapy (PDT) affording 
spatial control of therapy either alone or in combination with photosensitisers — 
molecules that absorb light in order to reach excited states that can facilitate 
energy transfer. PDT was used by the ancient Chinese, Indian and Egyptian 
civilisations to treat diseases[215, 216] but the first modern light therapies, 
developed by Finsen, drove PDT into popularity in medicine and as an active area 
of research. Finsen used red light as a treatment for smallpox, spurred by the 
observation that a Middle Ages treatment involved surrounding patients 
suffering from smallpox with red-coloured objects, the so-called “Red 
Treatment”[217]. Through fusion of anecdote and science, Finsen demonstrated 
that red light can speed up healing of smallpox-related scarring[218], and in 
addition, he found that UV light was cytotoxic to Lupus vulgaris infections of the 
skin, a bacterium associated with tuberculosis[219].  
Light therapy is now commonplace for a variety of diseases, particularly those 
that are readily optically accessible, such as acne and psoriasis[220-223]. 
Hyperbilirubinemia, a disorder commonly seen in new-borns manifesting as 
elevated levels of bilirubin that can deposit in the brain causing neurological 
disorders, can be treated with blue light[224, 225]. Since bilirubin absorbs across 
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the blue region of the electromagnetic spectrum and light therapy causes the 
photo-decomposition to products that are more easily metabolised and excreted, 
blue light therapy normalises bilirubin levels and alleviates symptoms (Scheme 
4.1). 
 
Scheme 4.1. Blue-light therapy leading to photo-degradation of bilirubin through photo-
induced isomerism, oxidation and cycloaddition to Z-lumirubin. 
PDT for cancer and tumour ablation has become an actively researched area, used 
primarily for skin melanomas and other optically accessible cancers[226, 227]. 
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Here, a general mechanism of treatment is used: administration of a 
photosensitiser (PS) followed by irradiation of light of appropriate wavelength at 
the site of the tumour or cancer-affected area. 
The PS exists in its ground singlet state with two electrons of opposing spin and 
upon absorption of a photon of appropriate quantum energy, one electron is 
elevated to an excited state (see Figure 4.1). The decay of this excited electron 
back to the ground state can occur, in the process releasing the excess energy as 
either heat or fluorescence. Alternatively, inter-system crossing can occur: the 
excited electron undergoes a change of spin and a triplet excited state is formed 
with two electrons of parallel spin. The triplet excited state has a long enough 
lifetime that it can react with other triplet state species, such as ground-state 
oxygen in a triplet-triplet annihilation process to give singlet oxygen (named 
Type II reactions) or can participate in single-electron transfer reactions that 
generate reactive oxygen species, such as superoxide and hydroxyl radicals (Type 
I reactions). The reactive oxygen species formed are highly reactive and elicit 




Figure 4.1. Jablonski diagram of the processes involved in photodynamic therapy. 
Absorption of a photon by the ground singlet state (S0) of the photosensitiser allows an 
excited singlet state (S1) to be reached. The energy of the excited electron can be emitted 
via radiative decay (i.e. heat or fluorescence) or inter-system crossing can occur to reach 
a triplet excited state (T1). Triplet-triplet annihilation is an energy transfer process and 
forms singlet oxygen. Electron transfer reactions produce radicals such as superoxide 
(O2-·), hydrogen peroxide and hydroxyl radicals (HO·). Both processes regenerate the 
ground singlet state of the photosensitiser. 
Development of novel photosensitisers can facilitate increased cancer selectivity, 
limitation of side effects, increased yield of singlet oxygen generation and 
extension of the wavelength of light required, enabling deeper tissue 
penetration[228]. Limitations arise for PDT in that light is highly scattered by 
skin and deeper tissues[229]. The ‘therapeutic window’ lies within the 
wavelengths of 650 to 1200 nm, where tissue penetration is at its highest, 
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however, the higher the wavelength of light, the less energy it has to initiate 
photochemical reactions.  
The photodynamic reactions discussed within this chapter were designed in view 
of an implantable device with mounted LEDs for illumination with placement of 
a light source directly at the site of the tumour potentially enabling the benefit of 
lower (and thus higher energy) wavelengths of light to be used more effectively. 
A related concept to this has been demonstrated by the use of a fibre optic to 
deliver light internally through a 22 gauge needle, allowing light of 365 nm to be 
utilised in the activation of a photo-caged doxorubicin prodrug at the site of a 
tumour[230]. 
Tris(2,2’-bipyridyl)ruthenium(II) ([Ru(bpy)3]2+) and its derivatives have been 
utilised for a wide range of applications in medicine, as photosensitisers or DNA-
intercalators for cancer and bacterial infection treatment, and in diagnostic 
sensors; as well as in energy production and storage as an electron transfer agent, 
and in organic synthesis as a photocatalyst. The excited state species of 
[Ru(bpy)3]2+-based photocatalysts can form either highly oxidative 
([Ru(bpy)3]3+) or reductive ([Ru(bpy)3]+) intermediates through the use of 




Figure 4.2. Energy level diagram of [Ru(bpy)3]2+ absorbing blue light to excite an electron 
from ground state (t2g) to an elevated energy level (π*) in a metal-ligand charge transfer 
(MLCT). The excited-state photosensitiser can then undergo reactions with electron 
acceptors (A) or with electron donors (D). Electrons acceptors include nitroaromatics, 
viologens and persulfate ions whereas electrons donors typically used are triaklylamines 
or ascorbic acid.  
The dichotomous nature of [Ru(bpy)3]2+, allows highly reductive or highly 
oxidative species to be formed and has given rise to a large host of photo-
synthetic reactions in which it has been utilised as a photocatalyst: reductive 
dehalogenations[231]; nitro- and azido-aromatic reduction to amines[232, 233]; 
oxidation of benzylic alcohols to aldehydes[234] and oxidative aromatic 




























Aside from its synthetic and energy applications, [Ru(bpy)3]2+ or related 
polypyridyl complexes have been utilised as photosensitisers for treating 
bacterial infections and cancer. To address the growing resistance of microbials 
to contemporary antibiotics, research has been focused on PDT to kill microbial 
infections, as it acts via mechanisms that are discrete from conventional 
antibiotic mechanisms of action and would be resilient towards resistance due to 
the nature of singlet oxygen generation i.e. there are few protein-ligand 
interactions that could be easily modified, as seen in most drug resistance 
emergences. Thus, ruthenium polypyridyl-based photosensitisers have shown 
promise as PDT agents for antibiotic-resistant strains of bacteria. Gu 
demonstrated the efficacy of a ruthenium polypyridyl photosensitiser in killing 
methicillin-resistant Staphylococcus aureus (MRSA) and showed 100% 
reduction in cell viability of planktonic and biofilm forms of MSRA[236]. In the 
same vein, Ligle demonstrated the efficacy of another Ru(II) photosensitiser 
(TLD1433), utilising a Type I (oxygen-independent) photo-process, allowing the 
efficient killing of MRSA cultures under normoxic and hypoxic conditions[237]. 
TLD1433 has also shown promise as an anti-cancer photosensitiser and is 
currently in Phase II clinical trials for bladder cancer[238]. 
In cancer, ruthenium has seen a huge surge in popularity, in the wake of the 
success of platinum-based cancer therapies and there are ruthenium-based 
anticancer agents currently in clinical trials. Of note are NAMI-A, KP-1019 and 
NKP-1339, all of which are in the Ru(III) oxidation state (Scheme 4.2). NAMI-A 
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was found to have low cytotoxicity in cancer cell lines (often 1000-fold less than 
cisplatin) but has the unusual ability to inhibit formation of metastases[239]. 
 
Scheme 4.2. Structures of ruthenium anti-cancer drugs in clinical trials: NAMI-A, KP-1019 
and NKP-1339. NAMI-A is under investigation in non-small cell lung cancer in 
combination with gemcitabine. Clinical testing has recently focused attention more to 
NKP-1339 rather than KP-1019 due to its increased water solubility. NKP-1339 has 
successfully completed a phase I dose-escalation study in advanced solid tumours. 
While the mechanism of this remains elusive, it has been postulated that NAMI-A 
binds to actin-type proteins on cell surfaces, reducing the mobility of cells 
undergoing endothelial-mesenchymal transitions, a hallmark of metastatic 
cancer cells[240, 241]. KP-1019, on the other hand, displays cytotoxic effects in a 
similar manner to cisplatin, with DNA-binding thought to be a main mechanism 
of action[242]. However, KP-1019 was active in murine cisplatin-resistant 
primary colorectal tumours[243] therefore either a different DNA-binding mode 
is responsible for overcoming Pt-resistance or there are other mechanisms of 
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action at work. KP-1019 was found to be well-tolerated by patients during clinical 
investigation. In phase I trials, the maximum tolerated dose could not be reached, 
however this is also a factor of the limited solubility resulting in high infusion 
volumes required[244]. Recently, clinical investigation has focused on the 
sodium salt analogue, NKP-1339, which has higher water solubility[245]. The 
theory that NAMI-A, KP-1019 and NKP-1339, similar to Pt(IV) prodrugs, require 
reduction from Ru3+ to Ru2+ intracellularly to elicit its effects has been proposed. 
However, this has been subject to controversy with reports both supporting and 
opposing this theory of activation[244, 246-248].  
In this chapter, a Pt(IV) prodrug activation platform was designed and validated, 
in a similar manner to Chapter 3 but instead of electron delivery via an applied 
potential, the use of photochemical reactions to activate/reduce Pt(IV) prodrugs 
into their cytotoxic Pt(II) counterparts while simultaneously generating singlet 
oxygen were explored. 
  
4.2 Aims of Chapter 4 
 
Light has been widely used in prodrug activation, as it can deliver energy in a 
radiative manner through tissue with spatial control. This chapter details the 
design of a light-triggered photocatalytic Pt(IV) activation/reduction system 
whereby a ruthenium-based photosensitiser delivers electrons to a Pt(IV) 
prodrug upon becoming excited by light. The system was further developed in 
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terms of the photosensitiser: improving its absorption wavelength, cellular 
uptake and localisation; the Pt(IV) prodrug was improved with respect to 
intracellular stability to biological reductants and cellular uptake; and the light 
source with bespoke devices fabricated for rapid illumination of well plates with 
control over intensity and bandwidth. The use of a PS that also generates singlet 
oxygen by a discrete mechanism allowed a second route of cytotoxicity to be 
utilised simultaneously with Pt(IV) prodrug activation, with the ability of the 
system to overcome resistance in an ovarian cancer cell line, also explored.  
4.3 Background  
 
With the unique opportunity presented by an implantable microsystem (with a 
mounted LED), it was deemed desirable for selective prodrug activation to design 
a light-triggered system for the turn-on of drugs. There are prior examples of 
some Pt-based light-triggered systems.  
Sadler has carried out a number of studies of a range of diazido-Pt(IV) 
compounds which undergoes ligand dissociation and reduction of the Pt centre 
to the II oxidation state, upon irradiation of the complex with light (Scheme 
4.3)[249, 250]. This occurs with release of dinitrogen as a bio-inert by-product 
and affords remarkable light-dark toxicity ratios for a range of Pt(IV) complexes. 
There are disadvantages to this method, however, such as the low wavelength of 
light required may be damaging to surrounding tissues. The high light-sensitivity 
of the Pt(IV) complexes is advantageous for the rapid conversion but also may 
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result in the premature activation (from ambient light) of the complexes causing 
off-target side effects.    
 
Scheme 4.3. Diazido-Pt(IV) complexes can undergo photo-induced reduction to their 
cytotoxic Pt(II) counterparts, with release of nitrogen following illumination at 380 nm. 
Salassa demonstrated the capability of riboflavin to act as a photocatalyst for the 
conversion of disuccinato-Pt(IV) complexes to their Pt(II) counterparts upon 
irradiation with blue light (Scheme 4.4)[251]. Conversion was rapid: almost 
100% reduction of the Pt(IV) species was observed after 5 min irradiation at 460 
nm with a dose of 2.5 mW.cm-1, with 10 mol% of photocatalyst. However, the 
mechanism of the catalytic cycle required a specialised buffer containing N-
morpholinoethanesulfonic acid, as an electron donor, to re-generate the active 
form of the riboflavin catalyst (see Scheme 4.5). The buffer was required in all 





Scheme 4.4. Riboflavin as a photocatalyst for the reduction of disuccinato Pt(IV) 
derivative of cisplatin, in the presence of N-morpholinoethanesulfonic acid. Riboflavin is 
a biocompatible photocatalyst with an absorbance maxima at 460 nm.  
It also shows limited scope of Pt(IV) substrates, requiring two succinate axial 
ligands to facilitate hydrogen bonding between substrate and catalyst. Riboflavin, 
also known as vitamin B2, as a photocatalyst offers a great advantage in that it is 




Scheme 4.5. The mechanism of the photo-induced Pt(IV) reduction with riboflavin as the 
electron donor. The disuccinato-cisplatin Pt(IV) derivative was shown to complex with 
riboflavin through hydrogen bonding and electrostatic interactions. Upon reduction of 
the Pt(IV) species, the excited triplet state of the oxidised riboflavin was then required 
to obtain electrons from two equivalents of the buffer component (MES) in order to re-
generate the reduced riboflavin and complete the catalytic cycle. The figure is 





4.4 Discovery and design of a photocatalysed Pt(IV) prodrug activation system 
 
From Chapter 3, it was found that a ruthenium redox mediator was optimal for 
Pt(IV) conversion. Therefore, it was a logical step that the highly reductive 
[Ru(bpy)3]2+ photocatalyst would be capable of reducing Pt(IV) substrates. This 
was verified with [Ru(bpy)3]Cl2 (0.5 µM) in PBS using the Pt(IV) complex 3 (250 
µM), with blue light (470 nm) applied using a 20-LED array lamp at 40 mW.cm-1 
over 20 h. In the absence of either light or [Ru(bpy)3]2+, there was no conversion 
(Figure 4.3). However, a combination of light and [Ru(bpy)3]2+ were highly 
efficient at reducing the Pt(IV) substrate, with almost full reduction after 20 h.  
 
Figure 4.3. Initial conversion experiment of Pt(IV) complex 6 (250 µM) with 
photocatalyst [Ru(bpy)3]Cl2 (1 µM), irradiated at 470 nm with the LED-array lamp with 
the conversion analysed by HPLC over time. With light and photocatalyst (red line), 
without light and with photocatalyst (green line), with light and without photocatalyst 
(yellow line), without light and without photocatalyst (blue line). 
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Despite this promising result, there were several facets of optimisation that 
needed to be accomplished. The light intensity of the LED-array lamp was 
relatively high and cannot not be easily replicated in an implantable device. In 
addition, the disuccinato-oxaliplatin derivative, although optimal for 
electrochemical activation (as it remained outside the cell), there were no such 
requirements for photochemical activation. The scope of the Pt(IV) substrates 
needed to be explored, while the wavelength of light used would also, ideally, be 
extended to more therapeutically applicable lengths. 
4.5 Identification of “bio-inert” Pt(IV) prodrugs 
 
There are many biomolecules implicated in the endogenous activation/reduction 
of Pt(IV) prodrugs. Small-molecule biological reductants, such as ascorbic acid 
and glutathione, have been shown to reduce some Pt(IV) species, as can proteins, 
such as cytochrome c[252, 253]. The rates at which these biological reductants 
reduce Pt(IV) complexes is highly dependent on the nature of the axial ligands of 
the complex[190, 254]. To identify a Pt(IV) complex that was relatively inert 
towards reduction by biological reductants, an assay was designed whereby each 
Pt(IV) complex was incubated with 100× molar equivalents of sodium ascorbate 
and glutathione. A small library of Pt(IV) complexes (7-13) was synthesised 
(Scheme 4.6) and the ability of each Pt(IV) complex to withstand reduction was 




Scheme 4.6. Synthesis of a Pt(IV) complex library. Oxidation of the Pt(II) complex by 
hydrogen peroxide in either water or acetic acid yielded the symmetric dihydroxy or 
asymmetric hydroxyl/acetyl complexes, respectively. This could then be reacted with the 
anhydride of choice under microwave irradiation for the rapid and facile access to a 
number of symmetric or asymmetric Pt(IV) complexes. 
The library was designed with various axial ligands with asymmetric or 
symmetric complexes synthesised with varying steric bulks and electron-
withdrawing characteristics. The asymmetrical Pt(IV) complexes carrying an 
axial acetate ligand and either tert-butanoate or benzoate axial ligands (9 and 10) 
were stable to reduction by glutathione or ascorbic acid. Symmetrical complexes 
with increased steric bulk, (12 and 13) were, surprisingly, ineffective at 
preventing reduction. The assumed benefit of increased steric hindrance 
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(preventing approach of the reductant) may be outweighed by the destabilising 
effect axial ligands can have on the Pt centre as steric bulk is increased. The 
symmetrical diacetate complex, 7, was also easily reduced. Electron-withdrawing 
axial ligands, such as trifluoroacetate (8 and 11) were unstable towards biological 
reductants. This again may be a factor of the high electron-withdrawing nature of 
trifluoroacetate destabilising the Pt centre. Instability towards reductants and 
hydrolysis has been previously observed with related compounds bearing 
haloacetate axial ligands[255]. 10 was poorly soluble in aqueous solutions and 
was discontinued from further studies, with complex 9 was taken forward into 
further studies.  
 
Figure 4.4. Each member of the Pt(IV) library (15 µm) was subjected to highly reductive 
conditions containing high concentrations of glutathione and sodium ascorbate (each at 
15 mM) in PBS (1×, pH 7.4, 37 °C). The remaining %Pt(IV) was analysed by HPLC to 
identify the “bio-inertness” of the Pt(IV) prodrugs. The Pt(II) species are not observed in 
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HPLC spectra due to the displacement of the UV-absorbent oxalate ligand by chloride-
containing media (see Chapter 3).  
The difference in cytotoxicity of 9 compared to the active drug, oxaliplatin, was 
analysed on HCT116 and SKOV-3-wt cells. Complex 9 was significantly less 
(P<0.0001) cytotoxic compared to oxaliplatin (see Figure 4.5). 
 
Figure 4.5. Dose-response curves for oxaliplatin (red line) and Pt(IV) prodrug 9 (blue 
line) in SKOV-3-wt and HCT 116 cells. The dashed line in each dose-response curve 
indicates the differences in toxicity between the prodrug and the active drug at 20 µM. 
**** P<0.0001 by two-way ANOVA with Dunnett post-test (n = 3) 
The disparity in cytotoxicity between the Pt(IV) prodrug and the Pt(II) active 
drug is of great benefit to this study as it highlights the ability of Pt(IV) prodrugs 
to be bio-inert and non-toxic (increasing the therapeutic dose window) and 
facilitates analysis in cellulo, as cell death will be a stark indicator of the activation 
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of 9. The dashed lines in Figure 4.5 show the selected dose of 9 used for cell 
experiments. 
The emergence of resistance to Pt-based cancer therapies is a constant threat to 
their application and was a focus of this research. The ability of photocatalytic 
Pt(IV) activation to overcome resistance was also explored. In order to do this, a 
cell line was allowed to acquire resistance towards oxaliplatin, by intermittent 
burst doses of oxaliplatin and continuous lower dosing (details of dosing regimen 
are in Chapter 5). SKOV-3 cells are well suited to this purpose as they are innately 
more resistant to Pt-based therapies than most other cancer cell lines. The “wild-
type” SKOV-3 cell lines (naïve to oxaliplatin treatment) were dubbed SKOV-3-wt 
whereas the cell line that was allowed to acquire resistance was named SKOV-3-
OxR. It can be seen from Figure 4.6 that the IC50 of oxaliplatin underwent a 2.8-




Figure 4.6. Dose-response curves for oxaliplatin (red line) and Pt(IV) prodrug 9 (blue 
line) in SKOV-3-OxR cells. The dashed line in each dose-response curve indicates the 
differences in toxicity between the prodrug and the active drug at 20 µM. *** P<0.001 by 
two-way ANOVA with Dunnett post-test (n = 3). 
Cellular uptake of 9 and oxaliplatin was also investigated in the cell lines. It can 
be seen from Table 4.1, that there was a much larger percentage of 9 taken up 
into cells than oxaliplatin, despite the latter having a lower IC50. It is likely that 9 
permeates through the cell membrane more efficiently than oxaliplatin but does 
not undergo reduction and therefore remains in an inactive state, resulting in 
high cellular uptake but lower cytotoxicity, relative to oxaliplatin. Lipophilicity 
may also be a factor in the difference of uptake. 9 is more lipophilic than 
oxaliplatin, which may be of benefit for cell membrane traversal due to the lipidic 
nature of the membrane. However, there are conflicting reports regarding 
whether lipophilicity has a direct relationship with uptake, with some suggestion 
that the two can be poorly correlated[256-258].  
Table 4.1. Cellular uptake of the photosensitiser 16 (1 µM) and the Pt(IV) prodrug 9 (20 
µM) after 4 h incubation, as measured by ICP-MS. The % uptake for each compound was 













275 ± 9 [90 ± 3%] 
 
191 ± 3 [63 ± 1%] 
 







531 ± 20 [14 ± 0.5%] 
 
384 ± 2 [10 ± 0.04%] 
 









161 ± 11 [1 ± 0.9%] 
 
150 ± 5 [1 ± 0.4%] 
 
281 ± 10 [2 ± 0.8%] 
 
 
4.6 Design, synthesis and optimisation of photosensitisers 
 
A new photosensitiser was designed, based on [Ru(bpy)3]2+, with extended 
conjugation in one of the bipyridine ligands via the installation of an indoline 
moiety (Scheme 4.7). This was due to the lack of cell uptake observed with the 
commercial Ru(bpy)3Cl2. 1,3,3-trimethyl-2-methyleneindoline is commonly used 
as a building block in the synthesis of Cy dyes and has high reactivity with 
aldehydes. 4,4’-dimethylbipyridine was oxidised with SeO2 to yield 4-formyl-4’-
methylbipyridine (L-1). Ligand substitution could then be carried out on 
[Ru(bpy)2Cl2] in refluxing ethanol-water mixture to afford the formyl-bearing 
precursor ruthenium complex (L-2) which could then undergo reaction with 
1,3,3-trimethyl-2-methyleneindoline to give the desired compound, following 
counterion exchange to isolate as the hexafluorophosphate salt (Complex 14). 
The ultimate reaction will produce fac- and mer-isomers but were assumed to be 





Scheme 4.7. Synthetic route for photosensitiser 14 
However, complex 14 was found to exhibit rapid degradation to the aldehyde-
containing complex. This may be a result of either singlet oxygen addition over 
the C-C double bond or hydrolysis (Scheme 4.8). Regardless, a series of 
photocatalysts were designed to overcome this issue while further extending the 




Scheme 4.8. Proposed routes of degradation of photosensitiser 14 by either singlet 
oxygen or water addition to form the aldehyde derivative. 
For complex 15, the ligand was synthesised by first mono-brominating the 
benzylic position of 4,4’-dimethylbipyridine to give ligand L-3 (see scheme 4.9). 
This was accomplished by a Wohl-Ziegler reaction, based on prior reports, 
although the solvent, carbon tetrachloride [259], was replaced with chloroform 
with little discernible impact on yield. This could then be derivatised to the 
phosphonate (L-4), enabling a Horner-Wadsworth-Emmons reaction with the 
aldehyde. However, the final step could not be accomplished and only starting 




Scheme 4.9. Synthetic route to photosensitiser 15. 
Complex 16 was synthesised by reaction of 1,3,3-trimethyl-2-methyleneindoline 
with 4-formylphenylboronic acid, followed by Suzuki-Miyaura coupling with 4-
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bromobipyridine to yield the ligand L-6(Scheme 4.10). This ligand was then 
installed onto [Ru(bpy)2Cl2] in the same manner as before, to afford the desired 





Scheme 4.10. Synthetic route to photosensitiser 16. 
4.7 Characterisation of photosensitiser 16 
 
Ruthenium-polypyridyl photosensitisers exhibit characteristic light absorption 
profiles with wavelengths < 300 nm being the ligand-ligand charge transfer 
(LLCT) events where an electron undergoes a π-π* transition[260, 261]. Another 
peak in the blue region corresponds to a metal-ligand charge transfer (MLCT), a 
dπ-π* transition. The absorbance spectra of photosensitiser 16 in PBS was 
recorded and showed similar characteristics to [Ru(bpy)3]Cl2, with the maxima 
at 450 nm corresponding to the MLCT excited state (Figure 4.7). The implications 
of this, in relation to the catalytic cycle for reduction of Pt(IV) substrates, are 
discussed below.  
 
Figure 4.7. Absorbance spectra of 16 (green line) and [Ru(bpy)3]Cl2 (red line) both at 
100 µM in PBS showing the MLCT band at 450 nm.  
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The stability of photosensitiser 16 was evaluated in DMEM supplemented with 
10% FBS by measuring the absorbance at 440 nm (Figure 4.8) and exhibited good 
stability over 24 h. 
 
Figure 4.8. Stability of 16 in DMEM with 10% FBS, as measured by absorbance at 440 nm.  
The ability of PS 16 to generate singlet oxygen was examined and the quantum 
yield of singlet oxygen generation measured in comparison to [Ru(bpy)3]Cl2. 
There exist a host of molecules to probe this, which capture singlet oxygen to 
bring about a spectral change in the probe molecule. However, many suffer from 
poor water solubility, high photo-bleaching or have overlapping absorbances 
with the photosensitisers tested. Therefore, a fluorescent probe, singlet oxygen 
sensor green (SOSG) was utilised. This probe is composed of carboxyfluorescein 
with naphthalene conjugated at the 6’-position that acts as an internal electron 
transfer quencher (see Scheme 4.11). The quenching was inhibited following 





























naphthalene moiety. This afforded an increase in fluorescence of the fluorescein 
moiety in correlation to the amount of singlet oxygen produced. 
 
Scheme 4.11. The mechanism for the fluorescent turn-on probe (SOSG) for the detection 
and quantification of singlet oxygen. Singlet oxygen undergoes a Diels-Alder reaction 
with the anthracene moiety. The resultant endoperoxide is fluorescent, providing a 
quantitative measure of singlet oxygen levels.  
The fold-increase of fluorescence (λex = 504 nm, λem = 525 nm) was plotted for 
both photosensitisers and the quantum yield of singlet oxygen generation (Φ) 
was calculated by the equation: 





where 𝛷𝑆𝑇𝐷  is the quantum yield of Ru(bpy)3Cl2; 𝑘𝟏𝟔  is the rate of increase in 
fluorescence of SOSG by 16 and 𝑘𝑆𝑇𝐷  is the rate of increase in fluorescence of 
SOSG by Ru(bpy)3Cl2. The quantum yield of Ru(bpy)3Cl2 from the literature was 
0.86[262] and the calculated quantum yield of singlet oxygen generation for 16 




Figure 4.9. Quantum yield of singlet oxygen generation by 16 and Ru(bpy)3Cl2, as 
measured by an SOSG assay (where 1 µM of each PS with 5 µM of SOSG in MeOH were 
irradiated with light (λ = 470 nm)) and the increase of the singlet oxygen-activated 
fluorescence probe analysed over time (λex = 504 nm, λem = 525 nm). 
Cellular uptake of photosensitiser 16 was determined in HCT 116 and SKOV-3-wt 
cells (Table 4.1) and was found to be taken up well into cells via live-cell confocal 
microscopy. Cells were co-stained with Hoechst nuclei blue dye and with 
Mitotracker Green (green mitochondrial stain) and Figure 4.10 shows a 
significant overlap of the fluorescence of the PS 16 with Mitotracker Green, 
suggesting co-localisation of the photosensitiser in the mitochondria. Interaction 
with the mitochondrial membrane is often observed for organic cations and the 
localisation of the PS 16 may be driven by the positively charged indoline-




Figure 4.10. Live-cell confocal microscopy with stained SKOV-3-wt cells. i) Hoechst nuclei 
stain in blue; ii) Mitotracker Green, mitochondrial stain, in green; iii) photosensitiser 16 
in red and; iv) merged image. The yellow-orange colouring of the merged image 
demonstrates the overlap between the green mitochondrial stain and the 
photosensitiser in red, indicating co-localisation. 
4.8 Fabrication of custom light sources 
 
Before investigating the photocatalytic reduction reactions, focus was turned to 
the light source used. As stated above, an LED-array lamp was used, however the 
intensity of light is unattainable for implanted devices and the viewing angle of 
the light is not suited for even distribution over a well plate, introducing bias 
towards the centre of the well plate.  
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For illumination experiments in a well plate format, a bespoke light source was 
required. To ensure illumination occurred evenly throughout the well plate, a 
device was designed and fabricated which allowed positioning of a single LED 
above each well in a black well plate to prevent scattering to adjacent wells (Plate 
A). 96 LEDs with a dominant emission wavelength of 470 nm and a 15° viewing 
angle were surface-mounted onto a breadboard, in a matrix format to allow each 
LED to enter its respective well, forming a lid for the well plate (see Figure 4.11). 
 
Figure 4.11. Plate A: LEDs were arranged in nine parallel circuits with a constant-current 
LED driver resistor (output current of 20 mA) and a 48 V power supply.  
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The LEDs were connected in nine parallel circuits, filling nine of the twelve 
columns of the 96-well plate. The intensity of illumination of the LEDs is 
correlated to the current in the circuit. The forward voltage supplied to the LED 
has a non-linear relationship with current[265]. As such, small deviations in 
voltage will drastically affect the forward current, and thus the LED’s brightness. 
In order to overcome this, LEDs are driven in conjunction with modulators of 
current that supply a constant current to the LED (e.g. resistors) and take the 
forward voltage as a fixed value. This results in a more reliably stable brightness 
of the LEDs than if they were “voltage-driven”. To ensure intensity was equivalent 
throughout the circuit, the current was modulated in each parallel circuit by an 
LED driver; maintaining a constant current driven by the power source. The 
compatibility of the fabricated LED well plate for cell-based assays was explored 
with HCT 116 cells. Cells were illuminated for 1 h or kept in the dark and 
incubated for 48 h, before measuring cell viability by an MTT assay. It was found 
that cells that had been illuminated underwent cell death as a result of the light 
source, due to the proximity of the LEDs to the cells.  
Another design for the LED well plate (Plate B) was conceived whereby an LED 
strip was formed into a coil between two well plate covers with equivalent 
spacing between each turn of the coil (Figure 4.12). This allowed a transparent 
well plate to be inserted into the coil, providing a simple and rapid mode of 
illumination. Cell viability after 1 h of illumination of HCT 116 cells showed a 20% 
reduction in cell viability. This was deemed acceptable as illumination in the cell 




Figure 4.12. Design of Plate B with dimensions of the well plate covers used and the 
spacing between each coil of the LED strip (top) which allowed simple insertion of a well 
plate inside for illumination. The illumination of cells was carried out in a temperature- 
and atmosphere-controlled chamber at 37 °C with 5% CO2 (bottom). 
The intensity and uniformity of incident light over the LED well plate was 
measured by a photodiode (1 cm2 sensing area) throughout the well plate giving 
an average of 0.5 ± 0.04 mW.cm-1.  
The light intensity per well for the two setups was calculated as outlined below. 
For Plate A, a single LED in each well had a luminous intensity of 11 candela (with 
15° viewing angle and 20 mA forward current). Candela (cd) can be converted to 
watt by the following equation: 
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𝑐𝑑 =  
1
683
 𝑤𝑎𝑡𝑡 𝑝𝑒𝑟 𝑠𝑡𝑒𝑟𝑎𝑑𝑖𝑎𝑛 
where a steradian is the unit of solid angle in a three-dimensional space (i.e. the 
cone of illumination by the LED). Therefore the intensity per well of Plate A can 
be calculated in watts: 
𝑟 𝑜𝑓 𝑤𝑒𝑙𝑙 = 3.2 𝑚𝑚 
𝑠𝑜𝑙𝑖𝑑 𝑎𝑛𝑔𝑙𝑒 = 𝑟2 = 11.56 𝑠𝑡𝑒𝑟𝑎𝑑𝑖𝑎𝑛𝑠 




𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 = 187 𝑚𝑊 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 
For Plate B, the intensity per well can be extrapolated from the photodiode 
measurement: 
𝐷𝑖𝑎𝑚𝑒𝑡𝑒𝑟 𝑜𝑓 𝑤𝑒𝑙𝑙 = 6.4 𝑚𝑚 
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑃𝑙𝑎𝑡𝑒 𝐵 = 0.5 𝑚𝑊. 𝑐𝑚−1 




𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 = 0.32 𝑚𝑊 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 
Comparison shows there is a large difference (580-fold) in intensity of 
illumination between the two formats. Plate B was utilised in further experiments 
involving illumination. 




The photocatalytic reduction of the Pt(IV) substrate 9 (50 µM) by photocatalyst 
16 (1 µM) was confirmed in PBS, with light delivered using the setup Plate B, with 
a clear reduction in concentration of 9 measured by HPLC (Figure 4.13.) To 
visualise the oxaliplatin content, post-derivatisation with GMP was again utilised 
(as in Chapter 3) forming a UV-active adduct. It is clear that only where light and 
the photocatalyst are used in combination was there any increase in the 
oxaliplatin concentration (Figure 4.13). Controls with either photocatalyst or 




Figure 4.13. HPLC characterisation of the reduction of Pt(IV) complex 9 (50 µM) by 
photosensitiser 16 (1 µM) (top). HPLC analysis over time showing the decrease of 9 
(middle) and the analysis following 60 min irradiation time and incubation with GMP (1 
mM) at 37 °C for 4 h (bottom) showing the formation of Pt(II) species only in the 
presence of Pt(IV) prodrug 9, photosentisiter 16 and illumination of light (red line). No 
Pt(II) species were detected for the conditions: with Pt(IV) complex 9 and PS 16 but in 
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the absence of illumination (orange line); with Pt(IV) complex 9 but without PS 16 and 
illumination (black line); or with Pt(IV) complex 9 and illumination but without PS 16 
(green line).      
In order to provide absolute quantification of the generated oxaliplatin, a 
calibration line was produced from known concentrations of oxaliplatin reacted 
with GMP and subjected to HPLC analysis (Figure 4.14).  
 
Figure 4.14. Calibration line of the area under the curve (AUC) of known concentrations 
of oxaliplatin incubated with GMP (1 mM) at 37 °C for 4 h before HPLC analysis. For the 
reaction with light and photocatalyst combined, the area under the curve was calculated 
as 1421 mAU.min-1, which corresponds to a concentration of 43 µM of oxaliplatin 
generated (86% yield).  
To further demonstrate the robustness of the photocatalytic conversion of the 
Pt(IV) prodrug 9, reaction solutions were analysed by 1H NMR (Figure 4.15). 
Here, the concentration of 9 used was increased to 100 µM to facilitate analysis 
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with the PS (16) concentration remaining at 1 µM. Again, there was an observed 
efficient and clean conversion of 9 into OxPt.  
 
Figure 4.15. NMR analysis over time of the irradiated reaction mixture showing the 
decrease in Pt(IV) along with an increase in the intensity of the Pt(II) resonance. The 
figure shows the protons (Ha and Hb) that were used to monitor the decrease and 
increase of the Pt(IV) and Pt(II) species, respectively (upper). The resultant NMR spectra 
show clearly the reduction of 9 (100 µM) to oxaliplatin, photocatalysed by PS 16 (1 µM) 
in D2O (lower). 
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4.10 Validation of photocatalysed Pt(IV) prodrug activation in cellulo 
 
With the photocatalytic reduction system of the Pt(IV) substrates fully 
characterised, attention was turned to demonstrating cytotoxicity turn-on with 
cancer cells. HCT 116 and SKOV-3-wt cells were once again used for this purpose 
and for each cell type, control experiments were run without illumination, with 
or without photosensitiser 16. Concentrations of the photosensitiser and the 
Pt(IV) prodrug were chosen based on in vitro work described above to give 
maximal cytotoxic turn-on effect without an overly-long illumination time. In all 
cases, in the absence of light no cytotoxicity was observed. When cells were 
illuminated in the presence of photosensitiser 16, there was a slight decrease in 
cell viability (36 ± 13% remaining viable for HCT 116 cells and 83 ± 10% 
remaining viable for SKOV-3-wt cells) compared to control experiment, 
presumably due to singlet oxygen generation. When both photosensitiser 16 and 
Pt(IV) prodrug 9 were illuminated, there was a clear turn-on cytotoxic effect: in 
SKOV-3-wt cells, cell viability was reduced to 12 ± 3% , and in HCT 116 cells, 





Figure 4.16. Cell viability, as measured by a CellTitre Glo 2.0 assay using SKOV-3-wt cells 
(left) and HCT 116 cells (right). “Control” represents untreated cells, “(A)” are cells 
incubated only with the PS 16 (1 µM) and “(B)” are cells incubated with 16 (1 µM) and 9 
(20 µM) for 4 h before illumination for 30 minutes followed by incubation in the absence 
of light for 48 h.  
The ability of the photocatalytic Pt(IV) activation system to overcome acquired 
oxaliplatin resistance in SKOV-3 cells was examined. Figure 4.17 demonstrates 
that, despite a slightly reduced cytotoxic effect, the photocatalytic activation of 9 




Figure 4.17. Cell viability, as measured by a CellTitre Glo 2.0 assay using SKOV-3-OxR 
cells. “Control” are untreated cells; “(A)” are cells incubated with 16 (1 µM) and “(B)” are 
cells incubated with 16 (1 µM) and 9 (20 µM).  
As discussed in Chapter 1, DNA platination remains one of the main routes of 
cytotoxicity, despite other mechanisms of action being implicated for oxaliplatin. 
Pt(IV) species have been shown to be unreactive towards DNA whereas Pt(II) 
species are highly-driven to bind. Therefore, the level of platination found in DNA 
can be used as an indicator of the conversion of the inactive Pt(IV) prodrug to the 
active Pt(II) species. For SKOV-3-wt and SKOV-3-OxR cells, 24 h after 
photocatalytic activation of 9, the cells’ DNA was harvested and quantified, with 
the levels of platination measured by ICP-MS. DNA platination levels were higher 
for both cell lines when photosensitiser 16 and the Pt(IV) prodrug 9 were used in 





Figure 4.18. Quantification of the platination levels found in cellular DNA using SKOV-3-
wt cells (left) and SKOV-3-OxR cells (right), as measured by ICP-MS. For each condition, 
cells were incubated for 4 h with the appropriate compounds (OxPt:20 µM; 16:1 µM; 9:20 
µM). This was followed by illumination for 30 minutes then incubation in the absence of 
light for 24 h. The cells were then lysed and the DNA harvested. The Pt content was 
measured by ICP-MS and the DNA concentration measured by NanoDrop spectroscopy.  
It has been demonstrated that the cytotoxic effect of photocatalytic activation of 
9 can transcend acquired oxaliplatin resistance. The reasons for this are likely 
related to cellular uptake. Oxaliplatin may be taken into cells via different 
mechanisms that 9 and so cellular changes in the transport of oxaliplatin, as a 
resistance mechanism, may not affect 9. Photo-activation of 9 following uptake 
into cells, allows relatively high levels of oxaliplatin to be formed in situ 
intracellularly. As shown above in Table 4.1, the uptake of 9 did not differ greatly 
between SKOV-3-wt and SKOV-3-OxR cells. Another factor contributing to the cell 
death in SKOV-3-OxR cell lines was increased sensitivity to singlet oxygen, as in 
experiments where just the photosensitiser was used. The localisation of the 
photosensitiser in the mitochondrion of the cell may play a role in overcoming 
the resistance mechanisms of SKOV-3 cells. It was thought possible that the 
conversion of Pt(IV) could occur in the mitochondria, which could change its 
mechanism of action towards binding with the mitochondrion or to 
mitochondrial DNA. To probe this, mitochondrial DNA was harvested from SKOV-
3-wt and SKOV-3-OxR cells following photoactivation of 9, and Pt content 
quantified (Figure 4.19). There was no clear relationship or differences between 




Figure 4.19. Quantification of the platination levels of mitochondrial DNA in left) SKOV-
3-wt cells and right) SKOV-3-OxR cells, as measured by ICP-MS. Cells were incubated 
with either oxaliplatin (20 µM) or 16 (1 µM) and 9 (20 µM) together, which were either 
irradiated for 30 minutes or kept in the dark. The cells were then incubated for 24 h prior 
to lysis, DNA harvesting and analysis by ICP-MS. 
4.11 Extension of application of photocatalytic Pt(IV) prodrug activation 
 
Insight into the scope of the photocatalytic Pt(IV) reduction system was explored 
with respect to the Pt(IV) species capable of being reduced and the 
photosensitisers that could be utilised. As mentioned above, TLD1433 is a 
ruthenium-based photosensitiser that is undergoing clinical testing and has 
shown great promise for photodynamic cancer therapy. It was investigated 
whether TLD1433 could photocatalytically activate Pt(IV) prodrugs. The 
photosensitiser was synthesised using a reported procedure[266]. First, the 
terthiophene-phenanthroline ligand was synthesised via a Radziszewski multi-
component reaction between formyl-bearing terthiophene and 5,6-
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phenanthroline-dione in the presence of ammonium acetate (see Scheme 4.12). 
The bis(4,4’-dimethyl-2,2’-bipyridyl)dichlororuthenium complex was then 
synthesised, using a previously reported protocol[267]. With the desired ligand 
(L-7) and precursor ruthenium complex (L-8) in hand, the reaction between the 
two was carried out with microwave heating to yield TLD1433 which was 




Scheme 4.12. Synthetic route for the photosensitiser TLD1433. 
The reduction capabilities of TLD1433 were first tested with prodrug 9. It was 
observed that TLD1433 was capable of reducing 9 upon illumination with light 
(λ = 470 nm), albeit at a slightly diminished rate than photosensitiser 16. 
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Regardless, the scope of Pt(IV) complexes that TLD1433 was able to reduce was 
explored. Oxaliplatin Pt(IV) derivatives were made with varying axial ligands. A 
cisplatin Pt(IV) derivative was also included, to examine effect of the equatorial 
ligands (Figure 4.20). Between the oxaliplatin Pt(IV) derivatives, the different 
axial ligands exhibited little effect in the reduction by TLD1433. The cisplatin 
Pt(IV) derivative with diacetato axial ligands was more easily reduced than the 
corresponding oxaliplatin Pt(IV) derivative. This finding suggests there is clinical 





Figure 4.20. The scope of Pt(IV) substrates that are able to be reduced photocatalytically 
by PS 16 or TLD1433 (top). Illumination was for 1 h (λ = 470 nm) with each Pt(IV) 
species (50 µM) and the photosensitiser (1 µM) in PBS with analysis by HPLC (n = 3). 
Both 16 and TLD1433 were capable of reducing Pt(IV) species. 




Attempts were made to elucidate the photocatalytic mechanism by which 
photosensitiser 16 reduces 9. To determine if the reactive oxygen species, formed 
by the photosensitiser, were donating electrons to the Pt(IV) species, the 
photocatalytic reduction was carried out with a range of photosensitisers: 
methylene blue, rose bengal, XD-Br and zinc phthalocyanine (ZnPc) (Scheme 
4.13). All three of these photosensitisers generate reactive oxygen species yet 
showed no activity towards the reduction of Pt(IV), upon illumination at their 
respective absorbance maxima. ZnPc is a photosensitiser that has an absorption 
maxima of 684 nm and like [Ru(bpy)3]Cl2, it is a metal-based photosensitiser. 
Regardless of the fact the metal centre of ZnPc is redox-inactive[268], it was 
thought that ligand-related redox processes may have been capable of reducing 





Scheme 4.13. Structures of the photosensitisers used to demonstrate that singlet oxygen 
and other reactive oxygen species were not responsible for the photocatalysed reduction 
of the Pt(IV) complexes. 
The typical mechanistic pathways for reactions photocatalysed by [Ru(bpy)3]Cl2 
follow either an oxidative or reductive pathway to yield the desired reactive 
species that then undergo reduction or oxidation reactions, respectively, to 




Scheme 4.14. The catalytic cycles of oxidative and reductive [Ru(bpy)3]2+ reactions, 
where A is electron acceptor, D is electron donor and S represents the substrate in each 
case. 
In this context, it may be that the initial excited state may have high enough 
reductive potential to directly reduce Pt(IV), which would yield the oxidised 
[Ru(bpy)3]3+ complex in the process. To regenerate the starting catalyst and 
complete the catalytic cycle, reduction of this complex is required, which may 
involve biological reductants such as ascorbic acid. However, the catalytic nature 
was proven in PBS and even D2O without such reductants present. It is possible 
that the carboxylate axial ligand, released during the reduction of the Pt(IV) 
substrate, may be capable of donating an electron to [Ru(bpy)3]3+. A putative 
mechanism representing this is described in Scheme 4.15. It is unclear whether 
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the mechanism of reduction of Pt(IV) substrates by one-electron reductants 
involves the rapid dissociation of the second axial ligand due to the instability of 
a Pt(III) intermediate or another equivalent of reductant takes the Pt(III) 
intermediate to the Pt(II) by donation of another electron[269]. 
 
Scheme 4.15. Proposed mechanism for the photocatalytic Pt(IV) activation. 
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To provide evidence for the proposed mechanism, electrochemical analysis was 
employed. The photocatalytic mechanism was probed in acetonitrile with 
tetrabutylammonium hexafluorophosphate as the supporting electrolyte to 
facilitate analysis at the high reductive potential of the process [Ru(bpy)3]3+ → 
[Ru(bpy)3]2+ which occurs at -1.5 V. This process was analysed by CV with scans 
i) with photosensitiser without irradiation; ii) photosensitiser following addition 
of the Pt(IV) without irradiation of light; iii) photosensitiser and Pt(IV) substrate 
together with irradiation of light and; iv) photosensitiser and Pt(IV) substrate 
after 30 min incubation in the dark subsequent to irradiation (Figure 4.21). 
 
Figure 4.21. Cyclic voltammetry analysis of [Ru(bpy)3]2+ under difference conditions: the 
photosensitiser alone (red line) followed by the addition of the Pt(IV) complex 9 (brown 




It can be seen that during the initial scan with the photosensitiser alone (red line) 
and the upon addition of the Pt(IV) substrate (brown line), there was no 
significant changes in the process. Upon irradiation with light, there was 
observed an increase in total charge of the process, suggesting an increase in the 
concentration of the [Ru(bpy)3]3+ species (green line). Following 30 min of the 
solution in the dark, the process returned to a similar state as the initial scan (blue 
line). This is tentative evidence that there was [Ru(bpy)3]3+ formed throughout 
the photocatalytic reduction of Pt(IV). Further study of this reaction by 
spectroelectrochemical analysis and exploring the limits of Pt(IV) scope may 
shed light on the full mechanistic details occurring.  
Conclusions and Outlook 
 
Photodynamic therapy has emerged as a highly effective cancer therapy, however 
it has a number of drawbacks. Patients may suffer from photosensitivity and be 
required to reside in rooms in absence of any light. There are also concerns over 
whether PDT can completely ablate some cancers, due to the requirement of 
complete dispersion of the photosensitiser throughout the tumour. Photo-
activated chemotherapies in conjunction with singlet oxygen generation can 
provide benefits of high cytotoxic effects controlled spatially by targeted light 
irradiation. As activation is photocatalytic, the same therapeutic effect as 
conventional PDT may be achieved with lower doses of photosensitiser, limiting 
photosensitivity side effects. This method of prodrug activation can afford a 
means of overcoming the off-target toxicities of conventional anti-cancer 
therapies, a problem that is rife in Pt-based therapies. 
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The facility of extension of the therapeutic application of PDT to not only generate 
cytotoxic singlet oxygen, but to also concomitantly activate prodrugs 
simultaneously was explored. The photosensitiser that formed the basis of this 
study, [Ru(bpy)3]Cl2, and its many derivatives constitute a highly studied area of 
photosensitisers and photocatalysts with many applications and purposes, many 
of which could be suitable for use in cells, propagating a new method of prodrug 
activation or in situ drug synthesis. Therefore, the scope and potential divergent 
uses for photocatalysis in cells may be of great impact on the treatment of cancer, 
both in increasing the efficacy of treatments, overcoming resistance and in the 
reduction of off-target toxicities.  
The prodrug activation system detailed here can open up avenues for a whole 
platform of new reactions occurring in cells. There are a host of reactions 
photocatalysed by ruthenium polypyridyl complexes that may be useful in 
prodrug activation. For instance, [Ru(bpy)3]2+ has been reported as an efficient 
photocatalyst for the reduction of azides to amines in the presence of ascorbic 
acid. There are a number of combination therapies which consist of oxaliplatin 
and other anti-cancer agents such as gemcitabine and irinotecan. Simultaneous 
dual-prodrug activation may be able to reduce side effects of these arduous 
regimens by reduction of Pt(IV) prodrugs and/or azides (with a self-immolative 




Scheme 4.16. Combination therapies of oxaliplatin that may benefit from simultaneous 
prodrug activation. Gemcitabine in combination with oxaliplatin is in Phase III clinical 
trials (GEMOX) and irinotecan is used in combination with oxaliplatin in an FDA-
approved combination therapy, FOLFIRINOX. 
It was shown that the addition of the positively charged and lipophilic indoline 
moiety benefitted uptake and localisation of the photosensitiser 16 compared to 
[Ru(bpy)3]2+ in cells. However, this could also be achieved in a more selective and 
targeted manner by the conjugation of peptides or antibodies. Peptide- and 
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antibody-drug conjugates have shown great promise in the delivery of 
therapeutics and could prove a useful addition to this system to promote cancer 
selectivity over healthy tissues or change the localisation to another organelle of 
therapeutic interest (e.g. the nucleus). Future work will be required for further 
optimisation of the system in order to overcome its drawbacks.  
The narrow therapeutic window of the Pt(IV) prodrug and the Pt(II) species 
could be improved through extensive screening of Pt(IV) derivatives. Pt(IV) 
prodrugs that are designed to be inert to biological reduction will be of benefit to 
this application and may be accomplished through deeper exploration of the 
effect on both the axial and carrier ligands on the kinetics of reduction by 
glutathione and ascorbic acid (as well as other endogenous reductants). In 
addition, as the Pt(IV) prodrug and the photosensitiser are two discrete entities, 
pharmacokinetic considerations are complicated (such as dosing and bio-
distribution). Tethering of the prodrug to the photosensitiser should be explored 
however this removes the catalytic aspect of the system and may elicit 
photosensitivity-related adverse effects. The wavelength of light (470 nm) 
required for this system is relatively low and will be subject to extensive 
scattering and, as a result, limited penetration through tissue. The wavelength 
required for the MLCT band of the photosensitiser may be red-shifted by 




The prodrug activation platform described here represents a step forward in 
providing means of delivering platinum-based therapies with a view to limiting 










Reactions involving moisture sensitive reagents were performed under a positive 
pressure of dry nitrogen. Evaporation of solvents was performed at reduced pressure, 
using a Buchi rotary evaporator. All chemicals were purchased from Sigma-Aldrich, 
Fisher Scientific or Fluorochem and used as received. CellTitre Glo was purchased from 
Promega. DNeasy Extraction Kit and the Mitochondrial DNA extraction kit were 
purchased from Qiagen.  1H, 13C, and 195Pt NMR spectra were recorded on a Bruker AVA-
600 (at 600, 150 and 129 MHz, respectively) at 298 K in the solvents indicated. 
Resonances are in parts per million (ppm). Column chromatography was performed on 
silica gel 60-120 mesh. Analytical TLC was carried out using commercially available silica 
gel F254 plates (Merck) and visualized with 254 nm light. Low Resolution Mass Spectra 
(LR-MS) were obtained using an Agilent LCMS 1100 ChemStation with a G1946B 
quadrupole mass detector. High Resolution Mass Spectra (HR-MS) were performed on a 
Bruker 3.0 T Apex II spectrometer. Analytical RP-HPLC was performed using an Agilent 
1100 Chemstation equipped with a Kinetix XB-C18 column (particle size: 100 Å ;pore 
size: 5 µM; dimensions: 50×4.6 mm) eluting with a gradient of 95% water/formic acid 
(0.1%) and 5 % MeCN/formic acid (0.1%) to 95% MeCN/formic acid (0.1%) and 5% 
water/formic acid (0.1%) over 10 minutes or 15 minutes with a flow rate of 1 mL/min. 
Compounds were detected using an evaporative light scattering detector and a multi-
wavelength detector. Semi-preparative RP-HPLC was performed on an Agilent 1100 
system equipped with a Zorbax Eclipse XDB-C18 reverse-phase column (particle size: 5 
Å ;pore size: 80 µM; dimensions: 250×9.4 mm) with a flow rate of 2 mL/min and eluting 
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with a gradient of water/formic acid (0.1%) and MeCN/formic acid (0.1%) of 5 to 95% 
over 15 min. ICP-OES were obtained on a Perkin Elmer Optima 5300 DV ICP-OES. ICP-
MS analyses were carried out with an Agilent 7500ce with a collision cell and an 
integrated LC (Agilent 1200 series) system. UV/Visible measurements were performed 
on a BioTek HT Synergy multi-mode reader.  
5.2 Electrochemical measurements 
 
Electrochemical measurements were performed either with a conventional three-
electrode electrochemical cell driven by a computer-controlled AutoLab PGstat-30 
potentiostat running GPES 4.9 software or with screen-printed electrodes driven by a 
computer-controlled portable Dropsens µStat potentiostat. For conventional cells, 2 mm 
diameter polycrystalline gold or glassy carbon electrodes (IJ Cambria, UK) were used as 
the working electrode with a platinum wire counter electrode with potentials referenced 
against a Ag/AgCl reference electrode. The screen-printed electrodes utilise a platinum 
counter electrode and a Ag pseudo-reference electrode. 




Compound 1 was synthesised according to a reported procedure[270]. Cisplatin (1.00 
g, 3.4 mmol) was added to a solution of H2O2 (30%, 6 mL0 in deionised H2O (50 mL) 
and was left to react at rt for 24 h in the absence of light. The mixture was heated to 50 
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°C for 5 h then concentrated under reduced pressure to ~5 mL. The concentrated 
mixture was then left at 4 °C during which a precipitate was formed that was collected 
by centrifugation and washed with cold H2O (10 mL) then diethyl ether (10 mL). The 
product (yellow powder) was dried in a vacuum oven at 37 °C for 24 h. Yield: 800 mg 
(70.1%); purity: 98% (HPLC). 1H NMR (600 MHZ, d6-DMSO) δ 7.07 (m, 3H), 5.61 (m, 





Compound 2 was synthesised according to a reported procedure[147]. Compound 1 
(142 mg, 0.42 mmol) was added to DMF (60 mL) followed by acetylsalicylic anhydride 
(175 mg, 0.3 mmol). The reaction mixture was heated to 65 °C for 48 h (additional 
acetylsalicylic anhydride was added during this time: 144 mg at 12 h and 218 mg at 20 
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h). The solvent was removed in vacuo and the crude suspended in acetonitrile (1 mL). 
The product was precipitated by addition of diethyl ether then isolated by 
centrifugation followed by washing with fresh diethyl ether (x3). The product (yellow 
powder) was dried in a vacuum oven at 37 °C for 24 h. Yield: 31 mg (15%). 1H NMR 
(600 MHZ, D2O) δ 7.81 (d, 1H), 7.59 (t, 1H), 7.39 (t, 1H), 7.15 (d, 1H), 2.61 (s, 3H). 13C 
NMR (150 MHZ, D2O) δ 171.6, 155.1, 150.1, 130.7, 128.1, 123.3, 120.4, 119.2, 25.5. 
HRMS (+): m/z [M+H]+ calcd: 497.011 found: 496.961.  
 
Cis, cis, trans-(diammine)(dichloro)(diacetato)platinum (3) 
 
Compound 1 (100 mg, 0.3 mmol) was added to DMF (3 mL) followed by acetic 
anhydride (1.5 mL, 15 mmol). The reaction mixture was heated in a microwave reactor 
to 90 °C for 45 min. The solvent was removed in vacuo and the crude dissolved in the 
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minimum amount of methanol. The product was precipitated by addition to diethyl 
ether (stirring in a Falcon centrifuge tube), then isolated by centrifugation followed by 
washing with fresh diethyl ether (x3). The product (yellow powder) was dried in a 
vacuum oven at 37 °C for 24 h. Yield: 99 mg (79%). 1H NMR (600 MHZ, d6-DMSO) δ 
6.53 (m, 6H), 1.91 (s, 6H). 13C NMR (150 MHZ, d6-DMSO) δ 167.1, 22.7. HRMS (+): m/z 




Compound 1 (100 mg, 0.3 mmol) was added to DMF (20 mL) followed by benzoic 
anhydride (100 mg, 0.4 mmol). The reaction mixture was left to react at rt for 24 h. The 
mixture was concentrated under reduced pressure and the product was precipitated by 
addition to acetone (stirring in a Falcon centrifuge tube), then isolated by 
centrifugation followed by washing with fresh acetone (x3). The product (yellow 
powder) was dried in a vacuum oven at 37 °C for 24 h. Yield: 118 mg (90%). 1H NMR 
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(600 MHZ, d6-DMSO) δ 7.89 (d, 2H, J = 7.52 Hz), 7.49 (t, 1H, J = 7.30 Hz), 7.40 (t, 2H, J 
= 7.16 Hz). 13C NMR (150 MHZ, d6-DMSO) δ 162.2, 135.3, 133.5, 129.1, 123.8. HRMS 
(+): m/z [M+H]+ calcd: 434.105 found: 434.918. 
 
Cis, cis, trans-(diammine)(dichloro)(disuccinato)platinum (5) 
 
Compound 1 (50 mg, 0.15 mmol) was added to DMF (5 mL) followed by succinic 
anhydride (40 mg, 0.4 mmol). The reaction mixture was heated in a microwave reactor 
to 90 °C for 45 min. The solvent was removed in vacuo and the crude dissolved in the 
minimum amount of methanol. The product was precipitated by addition to diethyl 
ether (stirring in a Falcon centrifuge tube), then isolated by centrifugation followed by 
washing with fresh diethyl ether (x3). The product (yellow powder) was dried in a 
vacuum oven at 37 °C for 24 h. Yield: 24 mg (31%). 1H NMR (600 MHZ, d6-DMSO) δ 
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12.04 (br, 2H) 6.49 (m, 6H), 2.50 (m, 4H), 2.40 (m, 4H). 13C NMR (150 MHZ, d6-DMSO) 
δ 174.8, 165.0, 29.3, 24.4. HRMS (+): m/z [M+H]+ calcd: 532.990 found: 534.109. 
 
Cis, cis, trans-[(1R,2R)-1,2-cyclohexanediamine](oxalato)(dihydroxo)platinum 
(OxPt(OH)2) 
 
OxPt(OH)2 was synthesised according to a published procedure[271]. Oxaliplatin (1 g, 
2.5 mmol) was suspended in H2O (12 mL), then H2O2 (30%, 3 mL) is added and the 
reaction stirred at rt for 24 h. The reaction mixture was then heated to 50 °C for 3 h. 
The reaction mixture was cooled to rt, filtered and the solid washed with water. The 
product (white powder) was dried in a vacuum oven at 37 °C for 24 h. Yield: 864 mg 
(80%). 1H NMR (600 MHZ, D2O) δ 2.75-2.85 (m, 2H), 2.17-2.26 (m, 2H), 1.46-1.64 (m, 
2×2H), 1.13-1.26 (m, 2H). 13C NMR (150 MHZ, D2O) δ 182.04, 166.21, 36.91, 34.51, 




Cis, cis, trans-[(1R,2R)-1,2-cyclohexanediamine](oxalato)(acetato)(hydroxo)platinum 
(OxPt(OH)(Ac)) 
 
OxPt(OH)(Ac) was synthesised according to a published procedure[272]. To a 1:1 
mixture of AcOH:H2O (10 mL), was added oxaliplatin (200 mg) followed by H2O2 (30%, 
1 mL) and the reaction mixture stirred at rt for 48 h. Following completion of the 
reaction, the solvents were removed in vacuo and the crude dissolved in the minimum 
amount of methanol. The product was then precipitated by addition to a Falcon tube of 
rapidly stirring diethyl ether and isolated by centrifugation. The product (white 
powder) was dried in a vacuum over at 37 °C for 24 h. Yield: 166 mg (69%). 1H NMR 
(600 MHZ, D2O) δ 2.86 (m, 2H), 2.28 (m, 2H), 2.05 (s, 3H), 1.63 (m, 2H), 1.56 (m, 2H), 
1.24 (m, 2H) . 13C NMR (150 MHZ, D2O) δ 182.04, 166.21, 36.91, 34.51, 30.77, 23.43, 





Cis, cis, trans-[(1R,2R)-1,2-cyclohexanediamine](oxalato)(disuccinato)platinum (6) 
 
OxPt(OH)2 (100 mg, 0.23 mmol) was suspended in DMF (5 mL) in a microwave vial, to 
which succinic anhydride (115 mg, 1.15 mmol) was added. The mixture was heated to 
90 °C with microwave heating for 45 min. Following completion of the reaction, the 
solvent was removed in vacuo and the residue re-dissolved in methanol and the 
solution filtered. The filtrate was then added dropwise to a Falcon tube of rapidly 
stirred diethyl ether (20 mL). The white-coloured precipitate was isolated via 
centrifugation and dried in a vacuum oven at 40 °C for 12 h to afford compound 1. 
Yield: 102 mg (70%). 1H NMR (600 MHZ, D2O) δ 1.20 (m, 2H), 1.46-1.63 (m, 2 × 2H), 
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2.23 (m, 2H), 2.46 (m, 4H), 2.57 (m, 4H), 2.82 (m, 2H). 1H NMR (600 MHZ, DMSO-d6) δ 
1.16 (m, 2H), 1.39 (m, 2H), 1.50 (m, 2H), 2.11 (m, 2H), 2.40 (m, 4H), 2.52 (m, 4H, 
overlapping with DMSO solvent peak), 2.59 (m, 2H), 8.15 (s, 2H), 8.36 (s, 2H) 12.10 (br, 
2H). 13C NMR (150 MHz, DMSO-d6) δ 24.0, 30.1, 31.0, 31.4, 61.3, 163.8, 174.1, 180.1. 
195Pt NMR (108 MHz, DMSO-d6) δ 1617. HRMS (+): m/z [M+H]+ calcd: 632.110 found: 
632.105, [M+Na+] calcd: 654.087 found: 654.087. 
 
(Chloro)pentaammine ruthenium(III) trichloride 
 
(Chloro)pentaammine ruthenium(III) chloride was synthesised according to a 
published procedure[273]. Ruthenium (III) hexaammine trichloride (500 mg, 1.6 
mmol) was refluxed in 6 N HCl for 8 h. The reaction mixture was allowed to cool then 
filtered with washing of cold ethanol. The product (yellow powder) was dried in a 
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vacuum oven at 37 °C for 24 h. Yield: 200 mg (56%). HRMS (+): m/z [M+H]+ calcd: 
221.155 found: 221.161. IR (neat) νmax 3260, 2160, 1623 cm-1 (br). 
(4-vinylpyridine)pentaammineruthenium(III) hexafluorophosphate (Vp-Ru) 
 
(Chloro)pentaammine ruthenium (200 mg, 0.9 mmol) was dissolved in H2O (10 mL), 
followed by AgNO3 (608 mg, 3.6 mmol) and stirred for 30 min at rt. The solution was 
filtered, to remove the AgCl by-product, and to the filtrate was added 4-vinylpyridine 
(410 µL, 3.6 mmol). The reaction mixture was stirred for 24 h at rt, following which, 
saturated aqueous KPF6 was added dropwise to induce precipitation of the product 
(red-brown powder) and dried in a vacuum oven at 37 °C for 24 h. Yield: 21 mg (8%). 
1H NMR (600 MHZ, DMSO-d6) δ 8.57 (dd, 2H, J = 1.62, 4.58 Hz), 7.47 (dd, 2H, J = 1.62, 
4.57 Hz), 4.25 (s, 2H). 13C NMR (150 MHz, DMSO-d6) δ 152.6, 139.4, 134.4, 130.8, 






OxPt(Ac)(OH) (100 mg, 0.21 mmol) was suspended in DMF (2 mL) in a microwave 
tube to which trifluoroacetic anhydride (70 µL, 0.506 mmol) were added. Reaction was 
carried out under microwave heating at 80 °C for 45 min. Following completion of 
reaction the solvent was removed under reduced pressure and the residue re-dissolved 
in the minimum amount of methanol. Precipitation of the compound was accomplished 
by adding dropwise to rapidly stirred diethyl ether and the compound was isolated by 
centrifugation. The product (yellow powder) was dried in a vacuum over at 37 °C for 
24 h. Yield: 21 mg (8%). 1H NMR (600 MHz, d7-DMF) δ 8.90-9.14 (br, 2×2H), 2.90 (m, 
2H), 2.56 (m, 2H), 2.22 (s, 3H), 1.58-1.84 (m, 2×2H), 1.45 (m, 2H). 13C NMR (150 MHz, 
d7-DMF) δ 161.1, 159.2, 157.6, 152.7, 119.6, 117.2, 115.0, 112.9, 62.1, 30.7, 23.6, 21.9. 








OxPt(Ac)(OH) (100 mg, 0.21 mmol) was suspended in DMF (2 mL) in a microwave 
tube to which trimethylacetic anhydride (103 µL, 0.5 mmol) were added. Reaction was 
carried out under microwave heating at 80 °C for 45 min. Following completion of 
reaction the solvent was removed under reduced pressure and the residue was 
dissolved in DCM and bound to SiO2. Product was purified by column chromatography 
(SiO2) with eluting ethyl acetate:methanol (100:0 – 90:10). The product (white 
powder) was dried in a vacuum over at 37 °C for 24 h. Yield: 102 mg (87%). 1H NMR 
(500 MHz, d7-DMF) δ 1.23 (s, 9H), 1.47 (m, 2H), 1.69-1.85 (m, 2×2H), 2.12 (s, 3H), 2.53 
(m, 2H), 2.94 (m, 1H), 3.11 (m, 1H), 3.267 (s, 1H), 8.60-9.24 (br m, 2×2H). 13C NMR 
(151 MHz, d7-DMF) δ 22.5, 24.1, 27.5, 31.7, 31.8, 40.5, 55.0, 61.7, 62.5, 162.3, 179.7, 
187.5. HRMS (+, ESI) m/z [M+H]+ calcd: 558.1411 found: 558.1404, [M+Na+] calcd: 








OxPt(Ac)(OH) (100 mg, 0.21 mmol) was suspended in DMF (2 mL) in a microwave 
tube to which benzoic anhydride (104 mg, 0.46 mmol) were added. Reaction was 
carried out under microwave heating at 80 °C for 45 min. Following reaction the 
solvent was removed under reduced pressure and the residue re-dissolved in 
methanol. Precipitation of compound was accomplished by adding dropwise to rapidly 
stirred diethyl ether and the compound was isolated by centrifugation. The product 
(white powder) was dried in a vacuum over at 37 °C for 24 h. Yield: 84 mg (69%). 1H 
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NMR (500 MHz, d7-DMF) δ 1.27-1.45 (m, 2×2H), 1.67 (m, 2H), 2.02 (m, 2H), 2.26 (s, 
3H), 7.48 (t, 2H, J = 54 Hz), 7.65 (m, 1H), 7.95 (m, 2H). 13C NMR (151 MHz, d7-DMF) δ 





OxPt(OH)2 (100 mg, 0.23 mmol) was suspended in DMF (2 mL) in a microwave tube to 
which trifluoroacetic anhydride (70 µL, 0.5 mmol) was added. Reaction was carried out 
under microwave heating at 80 °C for 45 min. Following completion of reaction the 
solvent was removed under reduced pressure and the residue re-dissolved in 
methanol. Precipitation of the compound was accomplished by adding dropwise to 
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rapidly stirred diethyl ether at and the compound isolated by centrifugation. The 
product (yellow powder) was dried in a vacuum over at 37 °C for 24 h. Yield: 44 mg 
(30%). 1H NMR (500 MHz, d6-DMSO) δ 1.22-1.38 (m, 2×2H), 1.65 (m, 2H), 2.21 (m, 
2H), 2.78 (m, 2H). 13C NMR (151 MHz, d6-DMSO) δ 22.2, 23.4, 30.7, 61.5, 166.6, 181.4 





OxPt(OH)2 (100 mg, 0.23 mmol) was suspended in DMF (2 mL) in a microwave tube to 
which trimethylacetic anhydride (103 µL, 0.5 mmol) was added. Reaction was carried 
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out under microwave heating at 80 °C for 45 min. Following completion of reaction the 
solvent was removed under reduced pressure and the residue re-dissolved in DCM and 
bound to silica gel (SiO2). Purification of the compound was accomplished by column 
chromatography with eluting ethyl acetate:methanol (85:15). The product (white 
powder) was dried in a vacuum over at 37 °C for 24 h. Yield: 55 mg (43%). 1H NMR 
(500 MHz, d6-DMSO) δ 1.17 (s, 18H), 1.24-1.38 (m, 2×2H), 1.66 (m, 2H), 2.20 (m, 2H), 
2.79 (m, 2H). 13C NMR (151 MHz, d6-DMSO) δ 22.2, 23.4, 30.7, 61.5, 166.6, 181.4 ESI-




L-1 was synthesised according to a published procedure[274]. 4,4’-dimethyl-2,2’-
bipyridine (1 g, 5.4 mmol) and selenium dioxide (0.7 g, 6.36 mmol) were dissolved in 
degassed, anhydrous 1,4-dioxane (50 mL) under N2 atmosphere. The reaction mixture 
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was heated to 105 °C for 24 h. Following completion of the reaction, the mixture was 
filtered hot. The filtrate was concentrated, re-dissolved in ethyl acetate and filtered to 
remove seleniumby-products. To purify the product, the filtrate was extracted with 
Na2CO3 (1M, 2×100 mL). The organic fraction is then shaken with with Na2S2O3 (0.3 M, 
3 × 100 mL) for 5 min at rt, during which the product is converted to the corresponding 
bisulfite and enters the aqueous layer. The aqueous layer was extracted and adjusted to 
pH 10 with Na2CO3 (2 M) and shaken for a further 5 min at rt, to re-form the aldehyde. 
This was then was extracted with CH2Cl2 (4 × 100 mL). The solvent was removed from 
organic layers and and the product (white powder) was dried in a vacuum oven at 37 
°C for 24 h. Yield: 672 mg (62%). 1H NMR (500 MHz, d6-DMSO) δ 10.21 (s, 1H), 8.92 
(d, 1H, J = 4.91 Hz), 8.86 (dd, 1H, J = 0.91, 1.57 Hz), 8.60 (d, 1H, J = 4.90 Hz), 8.31 (m, 
1H), 7.75 (dd, 1H, J = 1.55, 4.90 Hz), 7.22 (ddd, 1H, J = 0.86, 1.74, 5.00 Hz), 2.49 (s, 3H) 
. 13C NMR (151 MHz, d6-DMSO) δ 191.76, 158.34, 154.75, 150.30, 149.21, 142.67, 
125.39, 122.10, 121.39, 120.58, 21.23. HRMS (+, ESI) m/z [M+H]+ calcd: 198.16 
found: 198.61. 
bis(2,2'-bipyridine)(4'-methyl[2,2'-bipyridine]-4-carboxaldehyde)ruthenium(II) 




L-1 (49 mg, 0.24 mmol) and Ru(bpy)2Cl2 (100 mg, 0.21 mmol) were dissolved in 
degassed ethanol/water solution (4:1) in a total volume of 15 mL. The reaction was 
heated in a microwave reactor to 80 °C for 15 min. Upon completion, KNO3 (50 mg, 0.5 
mmol) was added and the reaction mixture stirred at rt for 30 min. Solvents were 
removed in vacuo and the crude re-dissolved in ethanol, which was then filtered. The 
product was purified from the filtrate by column chromatography (SiO2) with eluting 
acetonitrile and H2O (with 0.1% KNO3) with product eluting at 90% acetonitrile. 
Fractions were combined, dried under reduced pressure then re-dissolved in ethanol. 
The solution was filtered and the filtrate concentrated. The concentrated filtrate was 
added dropwise to a rapidly stirring Falcon tube of aqueous saturated KPF6. The 
precipitate was isolated by centrifugation and dried in a vacuum oven for 24 h at 37 °C. 
Yield: 74 mg (39%). 1H NMR (500 MHz, D2O) δ 10.07 (s, 1H), 8.86 (m, 1H), 8.36 (m, 
1H), 8.07 (d, 1H, J = 5.81 Hz), 7.94-8.03 (m, 12H), 7.68 (dd, 1H, J = 5.8, 1.7 Hz), 7.60 (d, 
1H, J = 5.8 Hz), 7.56 (d, 2H, J = 5.7 Hz), 7.40 (dd, 2H, J = 6.1, 1.8 Hz), 2.48 (s, 3H). 13C 
NMR (150 MHz, D2O) δ 192.76, 159.18, 156.96, 156.62, 156.17, 155.67, 153.05, 151.61, 
151.43, 151.32, 151.25, 151.19, 150.69, 150.47, 150.39, 140.99, 137.90, 137.79, 137.46, 
128.65, 128.24, 127.28, 127.12, 125.49, 124.97, 124.83, 124.10, 123.93, 122.26, 120.78, 
88.26, 20.43. HRMS (+, ESI) m/z [M-2PF6]2+ calcd: 306.12 found: 306.44. MALDI-TOF 




A solution of L-2 (250 mg, 0.31 mmol) and 1,3,3-trimethyl-2-methyleneindoline (120 
µL, 0.68 mmol) was made in ethanol/water mixture (9:1) and reacted with microwave 
heating to 80 °C for 30 min. KNO3 (50 mg, 0.5 mmol) was added and the reaction 
mixture stirred at rt for 30 min. Solvents were removed in vacuo and the crude re-
dissolved in ethanol, which was then filtered. The product was purified from the filtrate 
by column chromatography (SiO2) with eluting acetonitrile and H2O (with 0.1% KNO3) 
with product eluting at 90% acetonitrile. Fractions were combined, dried under 
reduced pressure then re-dissolved in ethanol. The solution was filtered and the filtrate 
concentrated. The concentrated filtrate was added dropwise to a rapidly stirring Falcon 
tube of aqueous saturated KPF6. The precipitate was isolated by centrifugation and 
dried in a vacuum oven for 24 h at 37 °C. Yield: 82 mg (25%). 1H NMR (500 MHz, d3-
acetonitrile) δ 8.85 (dd, 1H, J = 1.7, 0.8 Hz), 8.49-8.57 (m, 5H), 8.01-8.14 (m, 5H), 7.70-
7.79 (m, 7H), 7.64-7.68 (m, 2H), 7.59 (d, 1H, J = 5.8 Hz), 7.38-7.46 (m, 4H), 7.32 (ddd, 
1H, J = 5.9, 1.8, 0.7 Hz), 3.93 (s, 3H), 2.69 (s, 3H), 1.55 (s, 6H).  13C NMR (150 MHz, d3-
acetonitrile) δ 164.8, 159.5, 158.6, 157.1, 156.3, 154.5, 153.9, 153.0, 152.2, 149.6, 149.3, 
149.1, 148.2, 147.4, 147.9, 146.7, 145.3, 144.1, 141.4, 132.0, 131.7, 130.0, 129.9, 126.6, 
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126.3, 125.8, 125.2, 123.0, 123.6, 120.1, 115.6, 38.3, 37.2, 28.7, 21.7. HRMS (+, ESI) m/z 
[M+H]+ calcd: 384.01 found: 384.71. 
4-(Bromomethyl)-4'-methyl-2,2'-bipyridine (L-3) 
 
L-3 was synthesised according to a published procedure[259]. 4,4’-dimethyl-2,2’-
bipyridine (2 g, 10.8 mmol) and N-bromosuccinimide (2g, 11.2 mmol) were dissolved 
in CHCl3 (70 mL) under nitrogen atmosphere. Azobisisobutyronitrile (AIBN, 64 mg, 
0.39 mmol) is added and the reaction mixture is heated to reflux (65 °C) for 18 h. The 
reaction mixture was allowed to cool and was washed with H2O. The solvent was 
removed from the organic layers under reduced pressure and re-dissolved in CH2Cl2 
and bound to SiO2. The product was purified by column chromatography 
(CH2Cl2:Acetone, 98:2) and dried in a vacuum oven for 24 h at 37 °C. Yield: 82 mg 
(25%). 1H NMR (500 MHz, d6-acetone) δ 8.66 (d, 1H, J= 4.95 Hz), 8.54 (d, 1H, J = 4.9 
Hz), 8.31 (m, 2H), 7.49 (dd, 1H, J = 1.8, 4.9 Hz), 7.27 (dd, 1H, J = 1.7, 4.9 Hz), 4.72 (s, 
2H), 2.7 (s, 3H). 13C NMR (150 MHz, d6-acetone) δ 154.2, 152.1, 148.2, 146.1, 145.1, 
141.4, 121.4, 121.4, 120.2, 119.8, 33.5, 20.0. HRMS (+, ESI) m/z [M+H]+ calcd: 263.11 





L-4 was synthesised according to a published procedure[275]. A few drops of 
chloroform were added to a solution of 4-(bromomethyl)-4’-methyl-2,2’-bipyridine (1 
g, 3.8 mmol), triethylphosphite (2 mL, 29 mmol) which was then heated to 110 °C for 3 
h. The solution was cooled to room temperature, and triethylphosphite was removed in 
vacuo. The crude was purified by column chromatography (eluting acetone). The 
product (white powder) was dried in a vacuum oven for 24 h at 37 °C. Yield: 1033 mg 
(85%). 1H NMR (500 MHz, d6-acetone) δ 8.59 (d, 1H, J = 5.0 Hz), 8.53 (d, 1H, J = 5.0 
Hz), 8.47 (s, 1H), 8.33 (s, 1H), 7.25 (d, 1H, J = 4.2 Hz), 4.06 (q, 4H, J = 8.4, 7.1 Hz), 3.35 
(d, 2H, J = 22.2 Hz), 2.46 (s, 3H), 1.25 (t, 6H, J = 7.0, 7.0 Hz). 13C NMR (150 MHz, d6-
acetone) δ 158.9, 156.1, 149.4, 147.8, 147.2, 142.3, 141.5, 124.2, 122, 121.3, 62.1, 
61.3,33.7, 32.3, 20.5, 15.4, 14.3. HRMS (+, ESI) m/z [M+H]+ calcd: 321.13 found: 
321.16. 




4-Formylphenylboronic acid (1 g, 6.71 mmol) was dissolved in EtOH/H2O (20 mL, 1:1) 
and 1,3,3-trimethyl-2-methyleneindoline (1.42 mL, 8.05 mmol) was added and the 
mixture was heated to reflux for 15 minutes. Solvent was removed under reduced 
pressure and the crude mixture separated between DCM (50 mL) and aqueous citric acid 
solution (5%, 100 mL). The organic layer was removed and the aqueous layer washed 
twice with DCM (50 mL). Small quantities of acetone were added to break up the 
emulsion. The aqueous layer was dried under vacuum and the crude purified by column 
chromatography (SiO2 normal phase silica, ACN/H2O + 0.5% KNO3). Solvent from 
fractions was removed under reduced pressure and re-dissolved in ethanol then filtered 
to remove excess KNO3 to afford a bright yellow solid Yield: 1.4 g (58%). 1H NMR (500 
MHz, DMSO-d6) δ 1.80 (s, 6H), 4.19 (s, 3H), 7.65 (m, 2H), 7.75 (d, 1H, J = 16Hz), 7.89 (m, 
1H), 7.93 (m, 1H), 7.97 (d, 2H, J = 8 Hz), 8.16 (d, 2H, J = 8 Hz), 8.33 (s, 2H), 8.42 (d, 1H, 
J = 16 Hz). 13C NMR (500 MHz, DMSO-d6) δ 25.7, 35.1, 52.8, 114.1, 115.8, 123.3, 129.4, 
129.6, 130.0, 135.1, 136.2, 142.3, 182.4. HRMS (+, ESI) m/z [M+H]+ calcd: 306.166 
found: 306.166. 




L-5 (719 mg, 1.95 mmol), 4-bromo-2,2-bipyridine (500 mg, 2.14 mmol) and Pd(PPh3)4 
(25 mg, 1 mol%) were combined in degassed acetonitrile (8 mL). Cs2CO3 (591 mg, 4.28 
mmol) was dissolved in H2O (2 mL) and added to the reaction mixture. The reaction 
mixture was then heated to 110 °C with microwave heating for 45 minutes. Following 
completion of the reaction the reaction mixture was filtered. LiCl (212 mg, 5 mmol) was 
added to the filtrate and the solvent removed from the filtrate under vacuum. The 
product was purified by column chromatography (SiO2, normal phase silica, ACN/H2O 
+ 0.5% KNO3). Solvent from fractions was removed under reduced pressure and re-
dissolved in ethanol then filtered to remove excess KNO3 to afford a bright yellow 
powder. Yield: 701 mg (69%). 1H NMR (500 MHz, CD2Cl2) δ 1.88 (s, 6H), 4.37 (s, 3H), 
7.40 (ddd, 1H, J = 1, 5, 7 Hz), 7.63-7.67 (m, 4H), 7.71 (m, 1H), 7.88-7.92 (m, 2H), 7.99 (d, 
2H, J = 8 Hz), 8.21 (d, 2H, J = 8 Hz), 8.31 (d, 1H, J = 16 Hz), 8.52 (d, 1H, J = 8 Hz), 8.74 
(ddd, 1H, J = 1, 2, 5 Hz), 8.79 (m, 2H). 13C NMR (151 MHz, CD2Cl2) δ 156.85, 155.68, 
153.70, 149.92, 147.32, 143.29, 143.16, 141.50, 136.97, 134.71, 134.51, 131.24, 129.65, 
128.17, 124.02, 122.67, 121.42, 121.06, 118.58, 114.90, 113.31, 34.91, 26.25. HRMS (+, 




L-6 (147 mg, 0.31 mmol) and Ru(bpy)2Cl2 (163 mg, 0.34 mmol) were dissolved in 
EtOH/H2O (9:1, 10 mL) and reacted at 80 °C with microwave heating for 30 min. The 
reaction mixture was filtered, LiCl (30 mg, 0.5 mmol) was added to the filtrate and the 
solvents were removed under vacuum. Column purification (C18, 
H2O+0.5%KNO3/ACN) was used to purify the product. Solvent was removed from the 
fractions containing PS-1 and re-dissolved in a minimal amount of acetone and added 
dropwise to a Falcon tube of saturated KPF6 to precipitate the product, which was 
isolated by centrifugation. The precipitate was washed with 1 × sat. KPF6, 3 × ice-cold 
H2O then 3 × ice-cold EtOH before drying in a vacuum oven at 40 °C for 24 hours to afford 
a dark red solid. Yield 62 mg (16%). 1H NMR (500 MHz, Acetone-d6) δ 1.96 (s, 6H), 4.40 
(s, 3H), 7.60 (m, 7H), 7.72 (m, 2H), 7.92 (m, 1H), 7.97-8.02 (m, 3H), 8.09 (m, 7H), 8.22 
(m, 6H), 8.36 (d, 2H, J = 8 Hz), 8.66 (d, 1H, J = 16 Hz), 8.83 (m, 2H), 9.08 (d, 1H, J = 8 
Hz), 9.20 (m, 1H), 13C NMR (151 MHz, Acetone-d6) δ 205.32, 157.98, 157.23, 152.12, 
151.73, 147.78, 143.98, 142.18, 139.75, 138.12, 136.26, 131.07, 130.11, 129.36, 128.22, 
128.02, 127.95, 127.89, 125.04, 124.91, 124.44, 122.89, 121.78, 115.33, 114.34, 52.99, 
34.50, 28.94. HRMS (+, ESI) m/z [M+H]+ calcd: 415.07 found: 415.61. MALDI-TOF m/z 





L-7 was synthesised according to a published procedure[276]. 10-Phenanthroline-5,6-
dione (166.6 mg, 0.8 mmol), ammonium acetate (616 mg, 8 mmol) and 5-formyl-
terthiophene (222 mg, 0.8 mmol) were combined in acetic acid (4 mL) and heated in a 
microwave reactor to 180 °C for 10 minutes. Upon cooling, NH4OH (6 mL) was added 
dropwise to precipitate the product. Product (yellow powder) was filtered and washed 
with water then dried in a vacuum oven at 37 °C for 24 h. Yield: 149 mg (40%). 1H NMR 
(600 MHz, d6-DMSO) δ 9.01 (dd, 2H, J = 4.3, 1.8 Hz), 8.82 (dd, 2H, J = 8.1, 1.8 Hz), 7.83 
(d, 1H, J = 3.8 Hz), 7.80 (dd, 2H, J = 8.1, 4.3 Hz), 7.56 (dd, 1H, J = 5.1, 1.2 Hz), 7.43 (d, 1H,  
J = 3.8 Hz), 7.41 (d, 1H, J = 3.7 Hz), 7.38 (dd, 1H, J = 3.5, 1.1 Hz), 7.32 (d, 1H, J = 3.7 Hz). 
13C NMR (151 MHz, DMSO-d6) δ 148.13, 146.72, 145.45, 144.03, 141.71, 139.64, 137.61, 
136.45, 136.32, 135.23, 133.24, 129.99, 129.06, 128.95, 128.48, 127.29, 127.02, 126.39, 
126.11, 125.78, 125.68, 125.56, 125.50, 124.96, 123.69. LC-MS-ESI m/z [M+H]+ calcd: 
467.77 found: 467.85. 
Bis(4,4’-dimethyl-2,2’-bipyridine)dichlororuthenium dichloride (Ru(dmb)2Cl2, L-8) 
 
L-8 was synthesised according to a published procedure[277]. 4,4-dimethyl-2,2-
bipyridine (700 mg, 3.85 mmol), RuCl3·3H2O (500 mg, 1.91 mmol) and LiCl (550 mg, 12.5 
mmol) were dissolved in DMF (5 mL) and the reaction mixture was refluxed for 7 h. the 
reaction mixture was then allowed to cool, before adding dropwise into a Falcon tube 
containing acetone (12 mL). Precipitation of the product was induced by keeping at 4 °C 
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for 18 h. The resulting precipitate (black-purple) powder was isolated by centrifugation 
and dried in a vacuum oven at 37 °C for 24 h. Yield: 250 mg (23%). 1H NMR(400 MHz, 
d6-DMSO)  δ 9.77 (d, 2H), 8.46 (s, 2H), 8.31 (s, 2H), 7.59 (d, 2H), 7.31 (d, 2H), 6.92 (d,2H), 
2.61 (s, 6H), 2.33 (s, 6H). 13C NMR (150 MHz,) δ 156.9, 155.3, 154.9, 154.5, 147.5, 147.4, 




TLD1433 was synthesised according to a published procedure[278].  
L-7 (49 mg, 0.104 mmol)and L-8 (60 mg, 0.104 mmol) were dissolved  in ethanol (2 mL) 
in a microwave tube under nitrogen atmosphere before heating in a microwave reactor 
at 180 °C for 10 minutes. Aqueous saturated KPF6 was added drop-wise to the resultant 
solution to afford a precipitate. The precipitate was isolated by filtration and further 
purified via column chromatography (SiO2) eluting with water (containing 0.5% KNO3) 
and MeCN. The solvent was removed from the fractions containing TLD1433 and 
dissolved in water, filtered and aqueous saturated KPF6 was added to afford a precipitate 
which was isolated by centrifugation and washed with saturated KP6 (×3) then cold 
water (×3). The product (red-brown solid) was dried in a vacuum oven at 37 °C for 24 h. 
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Yield: 27 mg (22%). 1H NMR (400 MHz, d3-acetonitrile)  δ 8.87 (d, 2H, J= 6.60 Hz), 8.38 
(d, 4H, J= 10.1 Hz), 8.02 (m, 2H, J= 4.50 Hz), 7.84 (d, 2H, J= 4.02 Hz), 7.74 (br, 2H), 7.67 
(d, 2H, J=5.67Hz), 7.53 (d, 1H, J=6.42Hz), 7.42 (d, 2H, J=5.67Hz), 7.25-7.31 (m, 6H), 
7.07-7.14 (m, 3H). 13C NMR (150 MHz, d3-acetonitrile) δ 154.22, 154.18, 154.14, 154.10, 
151.06, 151.03, 151.00, 150.97, 147.71, 147.70, 147.17, 141.64, 140.73, 139.6, 138.6, 
136.9, 136.4, 136.1, 135.9, 135.4, 131.22, 131.20, 131.18, 131.16, 129.86, 129.49, 128.22, 
127.94, 127.28, 127.23, 127.19, 127.14, 125.46, 124.29, 124.18, 124.10, 123.11, 121.03, 
118.13, 21.1, 21.0. HRMS (+, ESI) m/z [M-PF6]2+ calcd: 468.557 found: 468.154 
 
5.4 Electrode cleaning and modification 
 
Gold electrodes 
Gold electrodes were immersed in the minimum volume of piranha solution (3:1 H2SO4 
(95%): H2O2 (30% w/v in H2O)) for 10 min in order to remove any organic matter from 
the gold surface, then the working electrode was successively polished on a polishing 
cloth using alumina slurries of 1, 0.3 and 0.05 μm particle size (Buehler, Germany). This 
electrode was then further cleaned by immersion in H2SO4 (95%) and then HNO3 (65%) 
at room temperature for 10 min. Finally, the working electrode was subjected to cyclic 
voltammetry with potential cycles between 0 and +1.6 V in 0.1 M H2SO4 at a scan rate of 
100 mV·s-1 until the characteristic voltammogram of clean polycrystalline gold was 
obtained. 
Glassy carbon electrodes 
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Glassy carbon electrodes were polished on a polishing cloth with alumina slurries of 1. 
0.3 and 0.05 µm particle size successively, three times. To ensure the electrode was clean, 
cyclic voltammetry analysis was carried out with potential cycles between 0 and +1.6 V, 
at a scan rate of 100 mV·s-1 in PBS.  
Methylene blue ternary self-assembled monolayer (MB-tSAM) functionalised electrode 
fabrication  
A clean gold macroelectrode was immersed in a solution composed of PEG-dithiol (600 
µM) and the probe MB-tSAM (40 µM) in ethanol (final volume of 500 µL) for 1 h at room 
temperature. After washing with fresh ethanol, the electrode was then immersed in 
mercaptohexanol (1 mM) in ethanol for a further 1 h. The electrode was then immersed 
in fresh ethanol (1 h) then immersed in PBS and stored at 4 °C.  
Successful tSAM formation was verified by cyclic voltammetry with potential cycles 
between 0 and -0.5 V at 100 mV·s-1 to confirm the presence of the characteristic 
methylene blue redox peaks. 
Polymethylene blue-functionalised electrode fabrication 
Clean glassy carbon electrodes were immersed in an aqueous solution of ammonium 
sulfate (0.1 M) and methylene blue (1 mM). The potential was cycled from -0.6 V to 1.2 
V at 50 mV.s-1 for 15 scans. The electrode surface was washed profusely with water and 
was immersed in PBS for 12 h. The polymethylene blue-modified electrodes were 
transferrd to a fresh solution of PBS and the electro-polymerisation was confirmed by 
analysing the methylene blue redox waves by cyclic voltammetry. 
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Nafion-encapsulated hexaammineruthenium functionalised modified electrode device 
(MED) fabrication  
A carbon ink screen-printed electrode was cleaned by washing with ethanol then water. 
Nafion perfluorinated resin solution (3 μL, 5% in a mixture of lower aliphatic alcohols 
and water) was drop casted onto the working electrode and air-dried at room 
temperature for 1 h. Once dried, the Nafion-coated electrodes were immersed into a 
solution of [Ru(NH3)6]Cl3 (3 mM) in deionised water for 2 h and transferred to a vial 
containing water and allowed to age overnight. Before use, the electrodes were washed 
with water and the redox properties of the Nafion-bound mediator were analysed by 
cyclic voltammetry. 
5.5 Fabrication of light sources 
 
For Plate A: LEDs (dominant wavelength: 470 nm; forward current: 20 mA; forward 
voltage: 4V) were soldered (using SnCu-alloy wire solder) in an 8×9 array with a 
common-row cathode arrangement to a copper-laminated matrixboard (100×160 mm; 
hole diameter: 1 mm). The barrel connector of a 48 V power supply was removed to 
expose the wiring. The cathode pins of the LEDs were then soldered to a DynaOhm LED 
driver that was wired to the 48 V power supply. The anode pins were connected to the 
negative polarity wire of the power supply.   
For Plate B: LED lighting strips (0.25 m) with an adhesive backing (Mouser Ltd., Cat. No. 
OVQ12S30B7) were arranged in a coil between 2 well plate covers and attached with 
even spacing between the turn of each coil. Contact pads were soldered to a 12 V power 
supply with a switch. For light irradiation studies, the light source allowed easy insertion 
of a well plate into the coil of the LEDs. Power measurements were made with a 
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THORLABS PM100D Power and Energy Meter console with photodiode (1 cm2 sensing 
area) to find average power of 0.582 mW.cm-1 throughout the coil. 
 
5.6 In vitro assays 
 
Chapter 3 
Cyclic voltammetric analysis of the pH dependence of the reduction wave of 6 
The pH of an aqueous solution of KCl (0.1 M) was modified by either addition of HCl (0.1 
M) or KOH (0.1 M). At each pH value analysed, 6 (2 mM) was dissolved and the potential 
swept between 0 and -1 V to identify the peak reduction potential of 6. CV analysis was 
done with a glassy carbon electrode, a Pt mesh counter electrode and potentials 
referenced to a Ag/AgCl reference electrode. 
Monitoring of pH during electro-activation of 6 
The pH of a solution of PBS was analysed before and after the addition of 6 (50 µM). This 
solution was then subjected to a potential of -0.4 V with a MED and the pH was measured 
at 2, 4, 8 and 24 h. 
Stability of [Ru(NH3)6]3+-modified electrodes towards biological milieu 
The redox waves of the immobilised [Ru(NH3)6]3+ were analysed by cyclic voltammetry 
before and after 24 h of immersion in either PBS, 10% FBS in PBS or HCT 116 cell lysate. 
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The potential was swept between 0 and -0.5 V with the MED, with Pt counter electrode 
and potentials referenced against a Ag pseudo-reference electrode. 
Quantification of the total Ru content in [Ru(NH3)6]3+-modified electrodes 
[Ru(NH3)6]3+-modified electrodes were fabricated as described above. The carbon ink 
and the layer of Nafion-bound [Ru(NH3)6]3+ was removed from the electrode surface by 
immersion in 1 mL of aqueous HNO3 (10%) in Eppendorf tubes. After 5 min of 
immersion, mechanical agitation with a glass stirring rod was employed to ensure the 
ink was completely removed. Resulting mixtures were sonicated and vortexed 
intermittently for 10 min before centrifugation at 7000 rpm for 5 min to remove the 
insoluble carbon ink components. The supernatant was decanted and further diluted to 
2% aqueous HNO3. The Ru content was then analysed by ICP-OES with calibration 
against Ru standard solutions. 
Quantification of the redox-active mediator in [Ru(NH3)6]3+-modified electrodes 
Redox-active Ru content was analysed by integration of total charge difference between 
[Ru(NH3)6]3+-modified electrodes and Nafion-coated carbon ink screen-printed 
electrodes without any mediator encapsulated after applying -0.4 V for 400 s. To quantify 
the mass (w) of Ru related to the charge (Q), Faraday’s law was applied: 




where MW is molecular weight, n is number of electrons involved in redox process and 
F is Faraday’s constant. 
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Quantification of leaching of [Ru(NH3)6]3+-modified electrodes 
[Ru(NH3)6]3+-modified electrodes were subjected to a potential of -0.4 V for 24 h in KCl 
(0.1 M). Following this, the solutions were analysed for their Ru content by ICP-OES with 
calibration against Ru standard solutions. 
Reaction monitoring of the electro-activation of 6 
A solution of 6 (100 µM) was made in PBS and a potential of -0.4 V was applied with 
either a [Ru(NH3)6]3+-modified electrode, an unmodified electrode or no potential was 
applied. The conversion was monitored by HPLC with detection at 254 nm. After 24 h of 
application of potential, GMP was added to make a final concentration of 1000 µM and 
were incubated at 37 °C for 4 h. The solutions were then again analysed by HPLC to 
quantify the level of Pt(II) species present in each.  
For monitoring of the electro-activation in 10% FBS or HCT 116 cell lysate, the same 
procedure as above was used with the solutions being filtered through centrifugal filters 
(Amicon Ultra-0.5, molecular weight cut-off of 3000 Da) prior to analysis by HPLC.  
Chapter 4 
Photocatalytic reduction of 6 with Ru(bpy)3Cl2 
A solution of 6 (250 µM) and Ru(bpy)3Cl2 (1 µM) in PBS was illuminated with an LED-
array lamp (with dominant wavelength of 470 nm) from a height of 10 cm. The reduction 
of 6 was monitored over time by HPLC. Control experiments were carried out with 
exclusion of light and/or photosensitiser. 
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Biological reductant assay with compounds 7-13 
Solutions were made with each of the compounds 7-13 (15 µM), sodium ascorbate (1500 
µM) and glutathione (reduced form, 1500 µM). The solutions were incubated at 37 °C 
and the reduction of each compound was monitored by HPLC over time. 
Stability of PS 16 in FBS 
The absorbance at 440 nm of PS 16 (100 µM) in 10% FBS/DMEM was monitored over 
time. 10% FBS in DMEM was used to calibrate the background absorbance. 
Quantum yield of singlet oxygen generation for PS 16 
Solutions of either 16 or Ru(bpy)3Cl2 (both at 1 µM) and the singlet oxygen sensor green 
(SOSG, 5 µM) were prepared in MeOH. The fluorescence of SOSG was measured (λex = 
504 nm, λem = 525 nm) over time while irradiating at 470 nm. The fold-increase of 
fluorescence was plotted for each photosensitiser and used to calculate the quantum 
yield of singlet oxygen generation (Φ): 




where ΦSTD is quantum yield of standard Ru(bpy)3Cl2 in MeOH; k(16) is the rate of increase 
in fluorescence of SOSG by 16 and kSTD is the rate of increase in fluorescence of SOSG by 
Ru(bpy)3Cl2. The quantum yield of Ru(bpy)3Cl2 was taken to be 0.86 and the calculated 
quantum yield of singlet oxygen generation for 16 was found to be 0.72[262]. 
Calibration line of OxPt-GMP adduct 
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Solutions of OxPt (10, 20, 50, 100 µM) and GMP (1000 µM) in PBS were incubated at 37 
°C for 4 h before analysis by HPLC at 254 nm. The peak corresponding to the Pt-GMP 
adduct for each concentration was integrated. 
Photocatalytic reduction of 9 in vitro 
In a 48-well plate, solutions of 9 (50 µM) and 16 (1 µM) in PBS were illuminated with the 
light source, Plate B, and analysed over time by HPLC at 254 nm. For Pt(II) quantification, 
GMP was added to give a final concentration of 1000 µM and the well plate was incubated 
at 37 °C for 4 h, before analysis by HPLC. 
For NMR reaction monitoring, the solution was comprised of 9 (100 µM) and 16 (1 µM) 
in D2O in an NMR tube. The solution was illuminated by placement of the tube into Plate 
B. The conversion was monitored over time by 1H NMR with water pre-saturation (pulse 
sequence: zgpr). 
Cyclic voltammetry analysis of the photocatalytic reduction of 9 
A solution of Ru(bpy)3Cl2 (500 µM) was made in DMF with tetrabutylammonium 
chloride (0.1 M) as organic electrolyte. Potential was swept between 0.2 and -2 V for 1 
scan, before the addition of 9 (1 mM). Another scan was then taken following the addition 
of 9. The solution was illuminated with an array-LED lamp for 5 min and the duration of 
the next CV scan. The solution was then left for 30 min in the absence of light before 
another CV scan was taken. Potential measurements were with a carbon ink screen-
printed working electrode with Pt counter electrode and referenced against a Ag pseudo-
reference electrode. 
Photocatalytic reduction of 9 with other photosensitisers 
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Solutions of 9 (50 µM) were incubated with either methylene blue, rose bengal, XD-Br, 
zinc phthalocyanine or TLD1433 (1 µM) in PBS. The solutions were illuminated with 
array-LED lamps with dominant wavelength near to the corresponding absorbance 
maxima of each of the photosensitisers (methylene blue: 630 nm; rose bengal: 545 nm; 
XD-Br: 630 nm; ZnPc: 630 nm; TLD1433: 470 nm) for 24 h, with HPLC analysis at 254 
nm to monitor conversion. 
5.7 Cell culture assays 
 
Note: Number of replicates quoted throughout this work refer to technical 
replicates and not biological replicates. 
Chapter 3 
Cell viability studies of 6 and OxPt 
HCT 116 cells grown in a 96-well plate (5,000 cells/well) were incubated with a solution 
of 6 or OxPt at the desired concentrations and the cells incubated at 37 °C, 5% CO2 for 72 
h. The media was then replaced with 100 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution (1 mg/mL) in PBS and the cells incubated 
for 3 h at 37 °C. After incubation, the resulting formazan crystals were dissolved by 
adding 100 µL of MTT solubilisation solution (10% Triton-X 100 in 0.1 N HCI in 
isopropanol). The absorbance was measured at a wavelength of 570 nm (BioTek HT 
Synergy multi-mode reader equipped with Gen5 microplate and imaging software 2.0) 
and the results compared to untreated cells. 
Cell viability analysis following electro-activation of 6 in 2D cell culture 
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HCT 116 cells grown in a 24-well plate (15,000 cells/well) for 24 h before the media was 
removed, the cells were washed with PBS (2×) and DMEM containing 6 (50 µM) was 
added to give a total volume of 1.7 mL. Modified electrodes or unmodified electrodes 
were added to the wells treated with 6 or with DMEM. A potential of -0.4 V was applied 
for 1 h in an atmosphere and temperature controlled chamber (37°C, 5% CO2), after 
which the electrodes were removed and the cells incubated at 37 °C for 3 days. The media 
was then replaced with 350 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) solution (1 mg/mL) in PBS and the cells incubated for 3 h at 37 °C. After 
incubation, the formazan crystals were dissolved by adding 350 µL of MTT solubilisation 
solution (10% Triton-X 100/0.1 M HCI/isopropanol). The absorbance was measured at 
a wavelength of 570 nm and the results compared to untreated cells.  
Cellular apoptosis analysis following electro-activation of 6 in 2D cell culture 
HCT 116 cells grown in a 24-well plate (15,000 cells/well) for 24 h before the media was 
removed, the cells were washed with PBS (2×) and DMEM containing 6 (50 µM) was 
added to give a total volume of 1.7 mL. Modified electrodes or unmodified electrodes 
were added to the wells treated with 6 or with DMEM. A potential of -0.4 V was applied 
for 1 h, after which the electrodes were removed and the cells incubated at 37 °C for 3 
days. After incubation, a fluorescein-conjugated Annexin-V (Annexin V-FITC) binding 
assay was performed.  
Labelling of cells with Annexin-V-FITC conjugate was performed using an Apoptosis 
Detection Kit (eBiosciences, San Diego, CA) with Annexin V-FITC and binding buffer 
included as controls. Flow cytometry (Becton Dickinson (BD) FACScan) was performed 
with excitation at 488 nm. FITC fluorescence was measured at 515–545 nm. Cell debris 
was excluded from analysis by appropriate forward light scatter threshold setting. For 
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fluorescence imaging, cells were washed with PBS after Annexin-V/FITC incubation, 
stained with Hoechst 33342 for 10 min and imaged with a Zeiss Axio Vert inverted 
fluorescence microscope. Microscope lasers settings were: excitation laser lines at 405 
nm and 488 nm with emission filters of 385–470 nm for Hoechst 33342 (nuclei stain) 
and 505–530 nm for Annexin-V/FITC. 
Quantification of whole-cell and nuclear DNA-platination by ICP-MS 
HCT 116 cells were grown in a 6 well-plate to confluence. The media was removed, cells 
washed with PBS (2×) then treated with 6 (50 µM). Modified or unmodified electrodes 
were immersed in the cell media and a potential of -0.4 V was applied for 1 h in an 
atmosphere and temperature controlled chamber (37°C, 5% CO2). The electrodes were 
then removed and the cells were incubated at 37 °C for 24 h. Then the media was 
removed, the cells washed with PBS (3×), detached with trypsin, and counted with a 
haemocytometer. The cells were centrifuged at 7000 rpm for 5 min and the resultant cell 
pellet was suspended in aqueous HNO3 (5%), sonicated for 1 h and analysed by ICP-MS 
with calibration against Pt standard solutions.  
For quantification of platinated DNA, the cell pellet obtained by centrifugation was 
resuspended in PBS (200 µL) and subjected the DNA content was isolated and purified 
by a Qiagen DNeasy blood and tissue kit. The DNA concentration was analysed by 
Nanodrop spectrophotometry. The samples were prepared by suspending the DNA 
solution in aqueous HNO3 (5%) and subjected to analysis by ICP-MS, as above. 
Generation of multi-cellular tumour spheroids 
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The hanging drop method was employed, using published procedures as a basis[212, 
213], for generation of multi-cellular tumour spheroids: from a cell suspension (50,000 
cells/mL) in DMEM, 20 µL was dispensed onto the covering of a petri dish (90 mm), 
inverted and incubated under standard conditions, with aliquots of DMEM added to the 
dish twice-daily to avoid evaporation and drying. The spheroids were incubated for 7 
days with the addition of fresh DMEM (5 µL) to the drops every 2 days. The size of the 
spheroids was monitored by inverted microscopy.  
Electro-activation of 6 in multi-cellular tumour spheroids 
Prior to the treatment with 6, the spheroids were transferred to a 24 well-plate coated 
with 1% agarose, with each well containing 350 µL of DMEM. The media was removed 
and the spheroids gently washed with PBS, before submerging in a solution of 6 (50 µM) 
in DMEM. Modified or unmodified electrodes were immersed in the media and a 
potential of -0.4 V applied for 1 h at 37 °C, 5% CO2. The media was then removed, the 
spheroids washed with PBS and incubated at 37 °C for 72 h. The viability of the spheroids 
were analysed with a Cell Titre Glo 3D assay. Apoptotic onset was monitored over time 
using a RealTime-Glo Annexin-V Assay. 
Chapter 4 
Generation of an oxaliplatin-resistant ovarian cancer cell line (SKOV-3-OxR) 
SKOV-3-wt cells were seeded in a T25 cell culture flasks and cultured until confluent. 
Cells were exposed to OxPt and cultured in OxPt-containing media over 3 months. Doses 
were delivered in two ways: an intermittent dose where cells are exposed to a higher 
dose before being replaced by fresh media containing no OxPt and continuous dose 
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where cells are split and cultured in low-dose OxPt-containing media. The intermittent 
doses of OxPt were for 1 h before replacing with fresh media free of OxPt, allowing the 
cells to recuperate overnight before sub-culturing in fresh media that did not contain 
OxPt. Once nearing confluency, cells were exposed to low continuous dose until the next 
intermittent dose with increasing concentration of dose over 3 months. Cells were 
cultured in OxPt-free media following the first three doses and escalated to 2 µM over 3 
months, at which point, doses were suspended and cells were grown in normal OxPt-free 
cell media. 
Week Number Intermittent Dose (µM) Continuous dose (µM) 
1 0.1 0 
2 0.1 0 
3 0.1 0 
4 1 0.1 
5 2 0.1 
6 2 0.5 
7 5 0.5 
8 5 0.5 
9 10 0.5 
10 10 1 
11 10 1 
12 20 1 







Live-cell imaging of HCT 116 cells with 16 
HCT 116 cells were seeded in an 8-well µ-slide (Ibidi) at a cell density of  7×104 cells/well 
and allowed to attach overnight at 37 °C. Hoechst nuclei stain was added to cells to a final 
concentration of 1 µg/mL and incubated for 30 min. Media was removed and replaced 
with media containing MitoTracker Green (50 nM) and 16 (1 µM) and incubated for 
further 30 min before removing them media, washing with PBS and replacing with fresh 
media. 
Cell viability studies of 9 and OxPt 
HCT 116, SKOV-3-wt or SKOV-3-OxR cells were grown in a 96-well plate (5,000 
cells/well) and were incubated with a solution of OxPt or 9 at the desired concentrations 
and the cells incubated for 48 h. To the media was added 10 µL of CCK-8 and incubated 
for a further 2 h. After incubation, the absorbance was measured at a wavelength of 450 
nm and the results compared to untreated cells. 
Photocatalytic reduction of 9 with PS 16 in cell culture 
Cells grown in a 96-well plate (5,000 cells/well) were incubated with a solution of 9 (20 
µM) and 16 (1 µM) in a total volume of 100 µL for 4 h. The well plates were irradiated 
for 30 min then incubated for 2 d. Cell Titre Glo 2.0 (100 µL) was added to each well at 
rt and the plates shaken on an orbital shaker for 5 minutes. Plates were then left at rt for 
10 minutes to allow equilibration before measuring luminescence signal (BioTek HT 
Synergy multi-mode reader using the Gen5 microplate and imaging software 2.0.) and 
the results compared to untreated cells. 
Quantification of platination of mitochondrial and whole-cell DNA 
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Cells were grown in a 6-well plate until confluent and then treated with Pt-c (20 µM) or 
16 (1 µM) incubated at 37 °C for 4 h. Media was removed and cells washed with PBS (3×) 
and fresh media (3 mL) was added. Cells were then irradiated with light for 30 min and 
incubated at 37 °C for 24 h. Cells were detached with trypsin and each cell suspension 
was split into 2 microcentrifuge vials. For mitochondrial DNA extraction, the 
Mitochondrial DNA extraction kit was used. For nuclear DNA extraction, DNEasy Blood 
and Tissue kit was used. ICP-MS analysis was carried out to quantify Pt content. 
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